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Tuberculosis has plagued humankind since prehistoric 
times. Coughing tuberculosis patients disperse the bacterium 
Mycobacterium tuberculosis through the air. Inhalation of 
this bacterium does not always lead to an infection, and only 
one in ten infected individuals becomes ill. In most cases, 
tuberculosis is contained to the lungs, but the infection 
can also spread to lymph nodes, bones and even the brain. 
Over the last century, higher standards of living and the 
development of antibiotics have significantly reduced 
the disease burden but still, each year, 1.7 million people die 
because of tuberculosis globally.
 
This thesis examines the role of the human immune system in 
tuberculosis. The first part assesses tuberculosis susceptibility 
and transmission by studying the interaction between white 
blood cells and various tuberculosis strains. The second part 
focuses on the high mortality rates associated with tuberculous 
meningitis by studying cells, proteins and metabolites in blood 
and cerebrospinal fluid of infected patients. The research in 
this thesis aims to advance a customized and more effective 
treatment for this ancient, but still highly relevant disease.
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Tuberculosis: an overview
Tuberculosis is caused by Mycobacterium tuberculosis, which is spread through 
the air by coughing tuberculosis patients. Some individual’s lung mucosa and 
alveolar macrophages can prevent a persistent infection after inhalation of 
bacteria. In others, macrophages digest the bacteria and present parts of it to 
helper T cells. These will stimulate the macrophages to kill the bacteria. T cells 
recruit more macrophages, which get infected by a proportion of bacteria that 
survive macrophage killing. Tuberculosis’ unique feature is the subsequent 
formation of a granuloma, which creates a niche for bacterial persistence. In 
most individuals, a standstill (‘latency’) eventually arises in the granuloma with 
bacteria contained in macrophages, surrounded by T cells. One-fourth of the 
world’s population is estimated to have a latent tuberculosis infection1. When 
immunity is weakened by advanced age, HIV co-infection, immunosuppressive 
therapies or other, yet unknown mechanisms, pulmonary disease can develop 
after which patients become contagious to others. Only one out of ten infected 
individuals develops pulmonary tuberculosis at some point during life, but 
given the estimated 1.7 billion latently infected individuals, this still leads to 
10.4 million new cases and 1.7 million deaths globally each year2. 
Although knowledge on immunology in response to M. tuberculosis has vastly 
expanded over the past decades, this has hardly translated to effective strategies 
to prevent or treat tuberculosis. One reason may be that we need to study the 
immunology of tuberculosis in its specific context, as much as possible linking 
epidemiology, clinical manifestations and laboratory sciences. That is what I 
aimed for in this thesis, focussing on specific aspects of the pathophysiology of 
tuberculosis: susceptibility, transmission and outcome.
Persistence of M. tuberculosis in hunter-gatherer times 
Some individuals are more susceptible to tuberculosis than others. To understand 
differences in susceptibility, the first topic of this thesis, it is important to realise 
that mankind and M. tuberculosis have had a long-lasting interaction. Tuberculosis 
is an endemic disease in most parts of the world, with very different epidemiology 
compared to present epidemics as Zika and Ebola, or pox and plague in the past. 
These other pathogens cause disease directly in a large proportion of the 
exposed population and across ages, in contrast to the long latency of M. 
tuberculosis. This unique pattern can be understood because of its co-existence 
with mankind since hunter-gatherer times. Humans then lived in small groups 
with infrequent encounters outside of the group. In these circumstances, bacteria 
are most likely to be selected when they combine a high rate of infection with 
late breakthrough-to-disease, preferably in individuals after the reproductive 
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age. M. tuberculosis uses the granuloma to persist3 during this period of ‘waiting’, 
called ‘latency’, before active disease occurs. Indeed during its evolution, M. 
tuberculosis conserved genes that encode for proteins that can be recognized by 
T cells4, suggesting this to be beneficial for the bacterium. Indeed, the T cells 
initiated granuloma formation does not only help containing M. tuberculosis, but 
also protects it from an effective host response3. 
It is now estimated that M. tuberculosis evolved around 70,0005 years ago from 
the genus Mycobacteria, whose members otherwise persist in soil and water and 
rarely infect humans. Humans are the primary host of M. tuberculosis, from 
which M. bovis diverged, which causes tuberculosis in cows and sporadically 
infects humans6. The other members of the M. tuberculosis complex are also 
found in humans but more frequently in animals: goats (M. caprae), rodents (M. 
microti), oryx (M. orygis) and even seals (M. pinnipidi)7. All are slow-growing 
bacteria that have the special feature of retaining their staining in an acid 
environment, which is why they are called ‘acid fast’. It is possible that the 
relationship between M. tuberculosis and early Homo sapiens was mutually 
beneficial, at least as long as the infection stayed latent. In this hypothesized 
symbiosis, the bacterium provided vitamins and essential amino acids that have 
allowed human brain development8. Although the exact driving mechanisms 
and consequences are not yet known, it is clear that M. tuberculosis and man 
have a relationship that dates back a long time and co-evolved to their present 
state.
Transmission of M. tuberculosis in modern times
Tuberculosis can only remain endemic if M. tuberculosis can spread from one 
individual to the next individual. When the first humans migrated from East to 
West Africa, M. tuberculosis migrated with them and established two genetically 
ancient M. africanum lineages that still exist and are part of the M. tuberculosis 
complex. M. africanum strains transmit equally well, but take a longer time to 
cause active disease compared to modern strains9. The two M. africanum and five 
M. tuberculosis lineages identified so far, are all still found in Africa. From 
East-Africa, M. tuberculosis also co-migrated with man to the Arabian Peninsula 
and further to Europe and Asia5. From an evolutionary perspective, all the 
lineages that evolved after migration out-of-Africa are considered ‘modern’ 
based on genetic markers. Most other continents are dominated by the lineage 
that was introduced by the founding human population, although later 
migration made the picture less homogenous10. In Asia, the founder lineage is 
the East-Asian lineage, of which the Beijing genotype family is especially 
successful. Within the Beijing family, some members are evolutionary more 
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‘modern’ than others and these outcompete the relatively more ‘ancient’ strains11. 
Possible explanations for this include better transmission of modern Beijing 
strains, and therefore more latent infections for each coughing patient, or faster 
progression to disease of an infected individual. Both are suitable strategies in 
these areas with a high population density. From a mycobacterial perspective, a 
different strategy may be needed in a country with high population density, but 
low prevalence of latent tuberculosis and low incidence of active tuberculosis, 
such as the Netherlands. In both high and low endemic countries it is likely that 
the interplay between M. tuberculosis and the human immune response is 
important in tuberculosis transmission. This interaction is the topic of one of the 
studies in this thesis. 
Tuberculosis phenotypes
Infection with M. tuberculosis can follow many different scenarios. This thesis 
investigates some of most extreme outcomes after exposure to M. tuberculosis 
resulting from mycobacterial-human interplay (figure 1.1). In an unknown 
proportion of exposed individuals, ‘early clearance’ occurs, i.e. the first lines of 
defence, mucosa and macrophages, eliminate the bacteria before a T-cell 
response occurs12. In others, a persistent infection develops called ‘latent 
tuberculosis infection’ or ‘latency’, which has a 5-15% life-time risk for 
progression to ‘active disease’2, highest in the first years after infection14. Risk 
factors for active disease are infection at a younger age, patients with HIV, and 
those who received anti-TNF-α treatment15. Active disease manifests in the 
majority of patients as a pulmonary infection: ‘pulmonary tuberculosis’, or 
Figure 1.1  The different tuberculosis immune phenotypes.
Latent tuberculosis 
infection 
Extrapulmonary  
tuberculosis 
Early clearance 
Pulmonary 
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‘consumption’ in layman terms. Extrapulmonary tuberculosis can manifest 
itself in most sides of the body, but most prevalent locations are brain (tuberculous 
meningitis), lymph nodes (tuberculous cervical lymphadenitis or ‘scrofula’), 
bones and especially the spine (spinal tuberculosis or ‘Pott’s disease’), and bowel 
(intestinal tuberculosis). In some cases the infection widely disseminates and 
mycobacteria can be found in the blood, liver and spleen. This is called ‘miliary 
tuberculosis’. Lastly, also without miliary tuberculosis, bacteria can spread to 
the brain through a disrupted blood-brain barrier, possibly in infected 
monocytes16. Then so-called Rich foci are established, which can give rise to 
meningitis later17. This tuberculous meningitis has a subacute course with 
symptoms developing over weeks, from headache and drowsiness to severe 
disease with cranial nerve palsies and paresis, eventually leading to coma18.
Host-pathogen interaction 
The delicate balance between mycobacterium and human host defence is 
governed by a complex interaction of cell types and receptors (figure 1.2). Many 
innate cell receptors recognize M. tuberculosis, including Toll-like receptors, 
C-type lectins  and NOD-like receptors19. Antigen-presenting cells such as 
macrophages load mycobacterial peptides on their Major Histocompatibility 
Complex class II molecules, which allows recognition by CD4+ T cells. 
Macrophages, possibly alveolar epithelial cells and certainly T cells then produce 
a wide range of messenger molecules called cytokines. Of these, IFN-γ stimulates 
macrophage killing and TNF-α is crucial to maintain granuloma integrity20. 
Granuloma disruption and subsequent development of active disease occurs 
when immunity is still immature as in small children, or when immunity wanes 
during life by age, malnutrition, or immune deficiencies caused by HIV 
co-infection or immune modulating agents such as corticosteroids and TNF-α 
inhibitory molecules. Naturally, at each disease stage, different host defence 
mechanisms and different M. tuberculosis virulence factors may be involved. For 
instance, susceptibility to initial infection might be caused by macrophage 
factors12, whereas breakthrough to pulmonary disease might be prevented by 
the CD4 T-cell response. When disease is established, the neutrophil 
inflammatory response can cause tissue damage when not adequately governed 
by T cells, and this in turn may facilitate bacterial spread20. Clear definition of 
the host phenotype is therefore paramount for successful study of the 
host-pathogen interaction.
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The extent to which there is human genetic variation in the risk of tuberculosis 
infection and progression to disease is unknown. An in-vitro study suggests 
that the M. tuberculosis-induced cytokine response is largely genetically 
determined21, but only few genetic loci potentially contributing to susceptibility 
have been reported22 and these have not yet been replicated. The genetic risk for 
active disease has been studied more extensively but still, only few loci have 
been reproduced, each locus only marginally contributing to increased risk23. 
Explanations for this limited success of genetic studies include differences in 
linkage disequilibrium across human populations for these loci, and different 
M. tuberculosis strains infecting these populations24. A confounding factor in the 
current studies are inadequate phenotyping of the healthy control populations, 
which often have unknown infection status. Moreover, lack of data on the 
degree of exposure of the controls leaves the possibility that some of them were 
simply not infected. When control populations are well chosen and clinical 
covariates are taken into account, a useful contribution of genetics is expected.
Figure 1.2   The different biological processes hypothesized to be important  
at different stages of disease.
• Mucosal defence 
• Recognition by 
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Host response in relation to outcome of tuberculous meningitis
The immune system is critical in tuberculosis, but its specific role, that may be 
beneficial or detrimental, depends on the stage or specific disease ‘phenotype’. 
Tuberculous meningitis is the most severe manifestation of tuberculosis, and its 
risk is increased with HIV-infection25 and young age14. This implies a malfunctioning 
or immature immune system to be important in tuberculous meningitis 
susceptibility. Tuberculous meningitis leaves 30-50% of patients disabled or 
dead25,26 and has a complex pathogenesis that is not well understood. Good 
outcome is dependent on a correct and swift diagnosis of the disease27, which 
often remains unrecognized at first presentation (Ganiem et al., unpublished 
data). Other important factors are adequate supportive nutrition, oxygenation 
and blood pressure28 and adequate antibiotic concentrations29,30. 
This thesis focuses on how the immune system is important for the outcome of 
tuberculous meningitis. Mortality of tuberculous meningitis, like susceptibility 
for tuberculous meningitis, is linked to HIV-infection25, which implies that 
adequate immunity, i.e. CD4+ T cells, is important to combat infection. On the 
other hand, uncontrolled inflammation is thought to cause damage16 and it is 
not yet known which cells cause this inflammation. Hektoen described ‘giant 
cells’ (fused epithelioid macrophages) in the brain of a previous tuberculous 
meningitis sufferer already in 189831 but it was not until 1972 that cerebrospinal 
fluid (CSF) leukocytes were systematically analysed microscopically32. Later, 
flow cytometry and ex-vivo expansion techniques have been used to acquire 
further knowledge on CSF leukocytes in tuberculous meningitis (summarised 
in text box 1.1). 
CSF is routinely obtained through lumbar puncture to test for the presence of 
mycobacteria and to determine the leukocyte count and glucose and protein 
concentration for diagnostic purposes. Inflammatory mediators such as 
cytokines and metabolites can be studied later in the remaining material from 
routine diagnostic tests. CSF contains waste products from the brain, leukocytes 
and bacteria. Studies of circulating cytokines show an increase in concentration 
compared to controls, with persistence up until a year after diagnosis. A positive 
correlation to severity is found in HIV-positive tuberculous meningitis patients, 
while in HIV-negative tuberculous meningitis patients this relationship is often 
absent (see text box 1.2). Only one study compared cytokine according to 
HIV-status and found higher levels of TNF-α, IL-1β, IL-2, IL-5, IL-6, IL-10 and 
IL-12p70 for HIV-positive patients43. The strong inflammatory response in 
tuberculous meningitis has led to the idea of adding treatment to modulate the 
host inflammatory response to antibiotic therapy. Examples of this so-called 
adjunctive host-directed therapy are the use of corticosteroids, which reduces 
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mortality especially in HIV-negative patients with milder disease44 and aspirin, 
which might show a survival benefit45 although this requires further study. One 
may hypothesize that host-directed therapy needs to be targeted. For instance, 
corticosteroids may be beneficial in one patient, but harmful in another. 
However, previous trials have not taken the immune response in individual 
patients into account. This thesis aims to provide a more detailed description of 
the immune response in tuberculous meningitis and to examine its relation to 
patient survival. I think that such insights are necessary to improve the design 
of future host-directed trials.
Text box 1.1  Cerebrospinal fluid (CSF) leukocytes
• T cells present in CSF consist of at least CD4+, CD8+ and γδT cells33 and are 
more vulnerable to mitogen-induced cell death compared to blood T cells33. 
They are antigen-specific as shown by clonal expansion in response to M. 
tuberculosis purified protein derivate34. Numbers of antigen-specific T cells 
have not been compared in CSF and blood, but incorporation of thymidine 
by antigen-specific lymphocytes is higher in CSF than blood35. Although 
specificity of IFN-γ produced ex vivo by antigen-specific T cells is higher for 
CSF than blood, sensitivity is lower36-38. Concluding, T cells compartmen-
talise to CSF, and an unknown proportion of those T cells are M. tuberculosis 
antigen specific.
• B cells are present in CSF and show antigen-specificity, as shown by an 
ex-vivo anti-purified protein derivate IgG antibody response39, but these 
have not been well studied.
• NK cells are present33 but have not been studied in detail.
• Monocytes and macrophages have been described in CSF of tuberculous 
meningitis patients, but not been studied in detail32. 
• Neutrophils commonly form 10-30% 26,40 and sometimes up to 50% 41 of 
CSF cells. In HIV-positive patients they are associated with tuberculous 
meningitis immune reconstitution inflammatory syndrome42.
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Text box 1.2  Circulating immune mediators in CSF of patients with 
tuberculous meningitis
• TNF-α levels approximate 43 pg/mL (geometric mean of four studies, 
including 204 patients42,46-49) and are comparable levels to patients with 
bacterial meningitis50, and persist up to 16 months51. Higher TNF-α 
correlates with severity in HIV-positive patients43,52 while in HIV-negative 
patients a positive49 or no association43,48 is seen.
• IFN-γ levels approximate 99 pg/mL (geometric mean of five studies 
including 287 patients42,46,49,53,54) are higher than in bacterial meningitis53 
and persist up to 8 months51. High IFN-γ after one month relate to 
intracranial granuloma at that moment54. Higher IFN-γ correlates with 
disease severity in HIV-positive43,52 and HIV-negative43,49 tuberculous 
meningitis patients.
• IL-1β levels are low and often below the limit of detection (geometric mean 
of three studies including 158 patients is 2 pg/mL42,48,49). Levels are 
comparable to viral and bacterial meningitis50. Higher IL-1β correlates 
with disease severity in HIV-positive43,52 patients, while in HIV-negative 
patients a positive49 or no association43,48 is seen.
• IL-2 levels approximate 2 pg/mL (geometric mean of two studies, including 
200 patients49,53) and are higher than in bacterial meningitis53. IL-2 relates 
correlates positively to disease severity in HIV-positive patients43, while in 
HIV-negative patients both a positive49 and no association43 is seen. 
• IL-4, IL-5, IL-12p70 and IL-13 were measured in only one study. The first 
three correlate with disease severity in HIV-positive tuberculous meningitis 
patients43.
• IL-6 levels approximate 249 pg/mL (geometric mean of three studies, 
including 174 patients42,48,49). IL-6 relates correlates with disease severity in 
HIV-positive patients43, while in HIV-negative patients both a positive49 or 
no association43 is seen. 
• IL-8 shows levels comparable to bacterial meningitis55 and higher than 
aseptic meningitis or control patients in whom meningitis was excluded56 
in children. Only one study in adults quantified levels of IL-8, averaging 
501 pg/mL (n = 16)48.
• IL-10 levels approximate 23.2 pg/mL (geometric mean of four studies, 
including 133 patients42,48,53,54) and persist up to months51. Studies 
comparing IL-10 levels used mixed control groups and IL-10 in tuberculous 
meningitis is lower than in bacterial meningitis and patients in whom 
meningitis was excluded53 and higher than in syphilitic meningitis and 
bacterial meningitis57.
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Aim and scope of the thesis
This thesis aims at better understanding of factors determining tuberculosis susceptibility, 
transmission and outcome. An integrative approach was used, combining patient 
studies with genetics and in-vitro experimental models (see text box 1.3 for a 
concise summary of materials). The thesis consists of two parts (graphically 
summarised in figure 1.3). The first part focuses on susceptibility to tuberculosis 
and on transmission of M. tuberculosis, combining mycobacterial genotyping 
with experimental models or host genetics. The second part of the thesis 
addresses factors that influence outcome of tuberculous meningitis, using a 
systematic analysis of clinical parameters, CSF metabolites and inflammatory 
markers. This may ultimately lead to rational design of immunomodulatory 
therapy for the individual patient.
Tuberculosis susceptibility and transmission
This part combines in-vitro studies with molecular epidemiological studies of 
human host and M. tuberculosis. As mentioned before, C-type lectin receptors 
are among the many human receptors that recognize M. tuberculosis. The 
recently described CLEC4D, present on human monocytes and neutrophils, 
recognizes the mycobacterial component trehalose 6,6-dimycolate (TDM). In 
chapter 2, we first used an experimental M. tuberculosis mouse infection model 
because it allowed investigating the role of clec4d in curtailing early infection, 
Text box 1.3  Materials and data sources used in this thesis
• Peripheral blood mononuclear cells and neutrophils of healthy, Dutch 
volunteers, collected by blood bank in Nijmegen, the Netherlands
• M. tuberculosis strains collected together with their clinical information by 
the National Institute for Public Health and the Environment, the 
Netherlands
• Patient clinical characteristics and materials collected in the Hasan Sadikin 
Hospital in Bandung, Indonesia. Established in 1923, this is the tertiary 
referral hospital for the province of West Java (43 million inhabitants), 
linked to the Medical Faculty of the Universitas Padjadjaran. Its joint 
 tuberculosis-HIV Working Group, together with Radboud university 
medical center, studied tuberculosis diagnostics25,58, pharmacology29,59 
and human60 and mycobacterial61 genetics, establishing a research infra-
structure that enabled much of the research in this thesis.
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but also later pathology. Then, in human studies, we examined whether 
tuberculosis infection and disease influence CLEC4D expression, and if genetic 
variation in CLEC4D is associated in human pulmonary tuberculosis. 
Besides genetic variation of the human host, genetic variation of M. tuberculosis 
may also be relevant to the outcome of infection. In the next two chapters, we 
examined if evolutionary more successful strains of M. tuberculosis evoke a 
different immune response that might explain their success. We stimulated 
leukocytes from healthy volunteers with M. tuberculosis lysate, which of course 
is different from natural infection with live mycobacteria that encounter lung 
epithelium and macrophages, but which has the advantage of a high level of 
standardisation. We used peripheral blood mononuclear cells that contain 
monocytes and lymphocytes, both of which are important in mycobacterial 
clearance. In chapter 3, we compared the response to modern versus ancient 
strain groups of the ‘Beijing’ family of the East Asian M. tuberculosis lineage. We 
investigated if the immune response helped explaining the success of the 
modern Beijing strains, which have a high and increasing prevalence. We 
compared different groups of strains within this rather specific branch of the 
Figure 1.3  A schematic overview of the topics addressed in this thesis.
Role of CLEC4D in tuberculosis 
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Tuberculous meningitis mortality related to:  
• Patient characteristics (chapter 5) 
• CSF and serum metabolites with genetic 
correlate (chapter 7) 
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• CSF immune mediators (chapter 8) 
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phylogenetic tree of M. tuberculosis, as they are in evolutionary ‘competition’ in 
high endemic settings in East Asia. In chapter 4 we first identified individual M. 
tuberculosis strains that had shown high or very low transmissibility in the 
Netherlands. We could then search for mycobacterial genetic factors explaining 
these differences in transmissibility, and examined whether strains with and 
without these genetic factors yielded different immune responses in leukocytes 
of healthy volunteers. 
Outcome in tuberculous meningitis
Most immunological studies in tuberculosis have addressed the question why 
some individuals are more susceptible than others, few have studied why some 
patients survive and others die from the disease. The second part of the thesis 
focuses on tuberculous meningitis, the most deadly manifestation of tuberculosis, 
linking patient studies and laboratory sciences. Mortality in tuberculous 
meningitis is known to be associated with HIV-infection and more advanced 
disease presentation. Systematically collected data on other patient characteristics 
predicting a worse outcome were lacking. In chapter 5 we therefore examined 
prospectively collected clinical parameters, blood and cerebrospinal fluid (CSF) 
measurements in a large number of tuberculous meningitis patients, and used 
sensitivity analyses restricted to culture positive patients as clinical diagnosis is 
not 100% specific.
The immune system clearly plays an important role in outcome of tuberculous 
meningitis. Therefore In the next chapter we examined the immune profile of 
tuberculous meningitis patients in more depth. It is thought that better 
host-directed therapy, adjunctive to antibiotics, can contribute to reducing 
mortality. A one-size-fits-all approach is not likely to be successful as patients 
may have very different immune responses. We therefore asked whether it is 
possible to distinguish ‘immune phenotypes’ in chapter 6. To add to routinely 
collected data as analysed in the previous chapter, we optimised flow cytometry 
to study innate leukocyte cell types and activation in blood and CSF, and used 
ex-vivo whole blood cytokine assays. The results were compared with pulmonary 
tuberculosis patients and healthy controls. 
It is generally thought that damaging inflammation contributes to mortality of 
tuberculous meningitis. Cellular metabolism is known to underlie inflammation, 
but it has not been studied systematically in tuberculous meningitis. In chapter 7, 
we examined which aminoacids and lipids differentiate tuberculous meningitis 
patients from control subjects, and surviving from non-surviving patients. We 
therefore measured more than 400 metabolites in blood and CSF of tuberculous 
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meningitis patients. We chose a platform that required only a small volume of 
sample to measure a large number of amino acids, sugars, vitamins and lipids, 
including relevant inflammatory lipid mediators. With this large number of 
metabolites relative to the number of patients, there is a high chance of false 
positive findings. We therefore confirmed the most promising result in an 
independent group of patients. We then searched for genetic determinants of 
the concentration of relevant metabolites, and examined if they could predict 
survival in an independent group of patients, as this would support a causal role 
for altered cerebral metabolism in outcome of tuberculous meningitis. In chapter 8, 
we used a similar approach, this time focusing on inflammatory proteins in the 
CSF. We used a very sensitive technique on a pre-defined panel of almost 100 
proteins and also tested which inflammatory proteins correlated with markers 
of CSF inflammation, brain damage or blood-CSF barrier disruption. We then 
searched for a genetic signature of prognostic proteins and tested whether this 
genetic signature predicted mortality in a different group of patients. 
In chapter 9 the findings of this thesis are summarised and discussed.
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Tuberculosis susceptibility 
and transmission
amor tussisque non celatur
(often attributed to Ovid, but most probably added to Desiderius Erasmus' 
Adagia by his secretary Gilbert Cousin. Source: Heinrich Bebel's Proverbia 
Germanica, ed. 1879)
Part 1

The C-Type lectin receptor  
CLECSF8/CLEC4D is a key component  
of anti-mycobacterial immunity
Gillian J Wilson*, Mohlopheni J. Marakalala*, Jennifer C. Hoving*, Arjan van Laarhoven*, 
Rebecca A. Drummond, Bernhard Kerscher, Roanne Keeton, Esther van de Vosse,  
Tom H.M. Ottenhoff, Theo S. Plantinga, Bachti Alisjahbana, Dhirendra Govender, 
Gurdyal S. Besra, Mihai G. Netea, Delyth M. Reid, Janet A. Willment, Muazzam Jacobs, 
Sho Yamasaki, Reinout van Crevel and Gordon D. Brown
* Equal contribution
Cell Host and Microbe. 2015;17(2):252–9.
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Abstract
Rationale
The interaction of microbes with pattern recognition receptors (PRRs) is essential 
for protective immunity. While many PRRs that recognize mycobacteria have 
been identified, none is essentially required for host defence in vivo. The recently 
discovered C-type lectin CLEC4D (CLECSF8, MCL) recognizes the important 
mycobacterial compound trehalose 6,6-dimycolate (TDM). This study explores 
its role in mouse and man. 
Methods
Wild-type and Clec4d-/- C57BL/6 mice were challenged intratracheally with 
M. bovis BCG, M. tuberculosis strain H37Rv and unrelated microorganisms after 
which mice were evaluated for weight loss, bacterial burden and survival. Flow 
cytometry was performed on blood and bronchio-alveolar lavage fluid from 
lungs. Cytokine levels were measured using the Bio-Plex Pro Mouse 23-Plex kit. 
In-vitro binding experiments were performed using green fluorescent protein 
(GPF)-expression BCG. Genotype assignation by Sequenom was performed on a 
cohort of pulmonary tuberculosis patients from Indonesia (n=1032) with age and 
gender-matched controls (n=952). 
Findings
Clec4d-/- mice exhibited higher bacterial burdens and increased mortality upon 
M. tuberculosis infection. Additionally, Clec4d deficiency was associated with 
exacerbated pulmonary inflammation, characterized by enhanced neutrophil 
recruitment. Clec4d-/- mice showed reduced mycobacterial uptake by pulmonary 
leukocytes, but infection with opsonized bacteria could restore this phagocytic 
defect as well as decrease bacterial burdens. Notably, a CLEC4D polymorphism 
identified in humans was associated with an increased susceptibility to pulmonary 
tuberculosis.
Interpretation
CLEC4D plays a non-redundant role in anti-mycobacterial immunity in mouse 
and in man.
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Introduction
Tuberculosis caused by M. tuberculosis is one of the leading causes of infectious 
disease-related death worldwide. Mycobacterial recognition by innate immune 
cells is mediated by several pattern recognition receptors (PRRs), including 
members of the Toll like receptor, NOD-like receptor, and the C-type lectin 
receptor family. These receptors activate inflammatory reactions that are 
essential for controlling the infection. Indeed, these early innate responses 
determine the outcome of disease and deficiencies in the major signalling 
adaptors downstream of these receptors, including MyD88 and Card9, render 
mice extremely susceptible to mycobacterial infection. Yet, despite convincing 
evidence from in-vitro studies, no single PRR has yet been found to play a 
non-redundant role in anti-mycobacterial immunity in vivo62. This has given rise 
to the assumption that recognition of M. tuberculosis involves multiple redundant 
interactions with numerous PRRs.
While the susceptibility of the MyD88-deficient mice to tuberculosis has been 
ascribed to defects in IL-1 receptor signalling63, the receptor(s) involved in the 
Card9-deficient phenotype have not been fully defined. Card9 is an essential 
component of the intracellular signalling pathway utilized by CLRs, and loss of 
this molecule leads to neutrophil-mediated pulmonary inflammation and rapid 
death in infected mice64. Three CLRs that utilize this pathway, Dectin-1, Mincle 
and Dectin-2, have been described to recognise M. tuberculosis or its components. 
Dectin-1 was found to play a role in dendritic cell IL-12 production in response 
to mycobacteria in vitro, however loss of this receptor did not alter susceptibility 
to infection in vivo62. Mincle recognises trehalose 6,6’-dimycolate (TDM or cord 
factor) and was found to mediate robust responses to this mycobacterial cell 
wall glycolipid both in vitro and in vivo65,66. However, the role of Mincle in vivo is 
controversial, with some studies describing no clear role for this receptor during 
mycobacterial infection67,68. Dectin-2 induces pro- and antiinflammatory 
cytokines in response to mannose-capped lipoarabinomannan and knockout 
mice infected with M. avium presented with altered lung pathology at early time 
points during infection69. However, the importance of Dectin-2 during infection 
with M. tuberculosis is still unknown.
We recently identified another CLR (CLEC4D or CLECSF8) and have shown that 
it also recognises TDM70,71. CLEC4D is a member of the “Dectin-2 cluster” of 
CLRs and consists of a single extracellular C-type lectin-like domain, a stalk and 
transmembrane region and a short cytoplasmic tail. The receptor is expressed 
by peripheral blood neutrophils, monocytes and various subsets of dendritic 
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cells70. CLEC4D can associate with FcRγ chain to trigger intracellular signalling, 
inducing phagocytosis, the respiratory burst and the release of proinflammatory 
cytokines70,71. Moreover, like Mincle, Clec4d can drive both innate and adaptive 
immunity in response to TDM71. In this study, we have explored the role of 
Clec4d in vivo and have discovered that this CLR plays a non-redundant role in 
anti-mycobacterial immunity.
Methods
Animals
10 to 12 week old C57BL/6, Clec4d-/- 70, and OT.II mice were obtained from 
specific pathogen free facilities at the University of Aberdeen (UoA) and 
University of Cape Town (UCT). Animal experiments were performed using age 
and sex matched mice and conformed to the animal care and welfare protocols 
approved by the UoA (project licence 60/4007) and UCT (011/027 and 012/031).
Strains, growth conditions and infections
M. tuberculosis strain H37Rv or Beijing and M. bovis Bacille Calmette-Guérin 
(BCG) strain Pasteur were grown on Middlebrook 7H10 agar plates containing 
10% ADC (BD), or Middlebrook 7H9 broth containing 10% ADC and 0.05% 
Tween 80 (Sigma). Green fluorescent protein (GFP)-expressing M. bovis BCG was 
cultured in the presence of 10 µg/mL Kanamycin (Sigma). 100 colony-forming 
units (CFU) of M. tuberculosis H37Rv were administered using an inhalation 
exposure system (Terre Haute, IN). For intratracheal inoculations, 5 x 105 CFU 
M. tuberculosis or M. bovis BCG were administered to the caudal oropharynx of 
anesthetized mice. In some experiments, M. bovis BCG was opsonized with 
anti-BCG antiserum (Alpha diagnostics) before intratracheal challenge. Organs 
were homogenised in PBS containing 0.05% Triton X-100 and complete 
mini-EDTA-free protease inhibitors (Roche). Bacterial burdens determined by 
plating onto Middlebrook 7H10 agar. 
Flow cytometric analysis of lung cells
Cells were obtained from the lung by bronchio-alveolar lavage with PBS 
containing 5 mM EDTA (Gibco), or by enzymatic digest with DNase (Sigma-
Aldrich) and liberase (Roche). Digested tissue was passed through 70 μm and 40 
μm nylon filters and erythrocytes lysed in Pharm lyse solution (BD). The 
following antibodies were used: CD45.2, Ly6G, CD11c, CD11b, Siglec F, CD3, 
CD4, CD8, CD19, Vα2, CD45.1, CD62L, CD44, CD69, CD25, IFN-γ, and F4/80 (BD 
or Abd Serotec). FACS was performed using an LSRII, Fortessa or FACSAria (BD) 
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and analysed using FlowJo 7.6.4. Alveolar macrophages were defined as CD11c+ 
SiglecF+, neutrophils as CD11b+ Ly6Ghigh, and macrophages as CD11bhigh F4/80+.
Cytokine assays
Tissue homogenates (above) were centrifuged to remove debris and supernatant 
stored at -80 °C. Cytokine levels were measured using the Bio-Plex Pro Mouse 
23-Plex kit (Bio-Rad) or by ELISA (BD OptEIA and R&D Systems). Cytokine 
levels of tissue homogenates were normalized to sample protein concentrations. 
Reporter cell analysis
Reporter cell analysis with NFAT-GFP expressing T hybridoma cells, co- 
transfected with mCLEC4D and Fcγ, was performed as described previously71. 
BCG binding experiments
For in-vivo binding experiments, 1.5 x 106 CFU GFP-expressing M. bovis BCG 
were administered intratracheally and bronchio-alveolar lavage cells isolated 
after 4 h and analysed by FACS. For in-vitro binding experiments, BCG-GFP was 
added to thioglycollate elicited macrophages (10:1) or neutrophils (1:1). In some 
experiments, TDM was added at 1 μg/mL. Cells were harvested, stained for 
CD45 and GFP-positivity (indicating bacterial association) ascertained by FACS. 
Human CLEC4D Expression Analyses
Publicly available micro-array data sets from the Gene Expression Omnibus 
(GEO) were analysed for the transcript of CLEC4D in six cohorts. Expression in 
whole blood of HIV-negative pulmonary tuberculosis cases was compared to 
expression in healthy controls or latently infected individuals from the same 
setting with a Mann-Whitney U test. In order to display the expression of the 
different cohorts in one graph, data were log-transformed and then normalised 
by subtracting each value with the mean value of the controls of the respective 
cohort, divided by the standard deviation of the controls. The United Kingdom 
cohort in the study of Berry et al., included data on follow-up, and on cell subsets 
(CD4+ cells, CD8+ cells, monocytes and neutrophils). The cohorts used were 
(country; patients; GEO accession number; assay; probe):
 
- United Kingdom and South-Africa72; adult pulmonary tuberculosis cases; 
GSE19491; Illumina Human HT-12 V3  BeadChip; ILMN_1808979.
- Germany73; adult pulmonary tuberculosis cases; GSE34608; Agilent 4 × 44-k 
human expression arrays; A_23_P25235.
- Indonesia74; adult pulmonary tuberculosis cases; GSE56153; Illumina 
HumanRef-8 V3 BeadChip; ILMN_1808979.
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- Malawi and Kenya75: paediatric tuberculosis cases; GSE39941; HumanHT-12 
v.4 Expression BeadChip; ILMN_1808979.
For quantitative trait locus (eQTL) analysis of CLEC4D expression in whole 
blood, we used data available from a meta-analysis of >5000 individuals (online 
available at http://genenetwork.nl/bloodeqtlbrowser76) and the Genotype- 
Tissue Expression (GTEx) consortium77,  which currently includes 168 individuals 
(online available at http://www.gtexportal.org/). 
Selection of SNPs investigated
Using Haploview version 4.278 we accessed the publicly available HapMap 
Version 3 Release 2 to select single nucleotide polymorphisms (SNPs) for testing. 
As no data are available for the Indonesian population specifically, we based our 
selection on the data for the Han-Chinese (CHB) and Japanese (JPT) population. 
For CLEC4D, three SNPs tagged all the predicted haplotypes with frequencies 
of > 0.05 (See supplementary figure 2.3 and table 2.1). In the current cohort, 
based on a disease prevalence of 262/100,000 (WHO Global tuberculosis report 
2012), the power of detecting an allele that has a relative risk of 1.5 to disease, is 
87% with a nominal significance of 0.05 (http://www.sph.umich.edu/csg/
abecasis/cats/tour1.html).
Subject recruitment and Ethics statement
We made use of cohort of pulmonary tuberculosis patients in Indonesia. We 
previously recruited 1135 consecutive pulmonary tuberculosis patients diagnosed 
in two outpatient clinics and two hospitals in Jakarta and Bandung (Indonesia) 
from January 2001 to December 2006, for a series of genetic studies examining 
host susceptibility to tuberculosis (79 and references therein). Diagnosis of 
pulmonary tuberculosis was done according to WHO criteria by clinical 
presentation and chest radiograph examination, followed by confirmation with 
microscopic detection of acid-fast bacilli in ZN-stained sputum smears and 
positive culture of M. tuberculosis on 3% Ogawa medium. Patients with confirmed 
diagnosis of extrapulmonary  tuberculosis (n=93) and HIV-positive subjects 
(n=10) were excluded. During the same period, 1000 age and gender matched 
genetically unrelated community control subjects were selected; those with 
symptoms or chest X-rays suggesting possible active tuberculosis (n=48) were 
excluded from further analysis. Sample collection and genotype analysis is 
described in the supplementary methods. All individuals recruited had signed 
a written informed consent. The study protocol was approved by the review 
boards of the University of Indonesia, the Eijkman Institute for Molecular 
Biology, and the Medical Ethical Committee Arnhem-Nijmegen.
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Statistical analysis
Data were analysed using GraphPad Prism 5.04. Unpaired t test or non-parametric 
Mann-Whitney was applied for comparison of groups, as appropriate, and the 
Wilcoxon sign rank test for paired follow-up data. For genotyping analysis the 
Hardy-Weinberg equilibrium was checked for each SNP using the program HWE 
Version 1.10 (Rockefeller University, New York). Significance was indicated by 
p<0.05. 
Results
Clec4d is required for resistance to mycobacterial infection in vivo
We previously characterized the effect of Clec4d deficiency but did not identify 
a role for this receptor in vivo despite extensive analysis70. However, during 
these experiments we noticed that subcutaneous immunisation with Complete 
Freund’s Adjuvant reproducibly led to ulceration at the injection site in more 
than 50% of the Clec4d-deficient mice, an effect which was not apparent in the 
wild-type mice (figure 2.1A and data not shown). Given that the major im-
mune-stimulating component of Complete Freund’s Adjuvant is M. tuberculosis, 
and that Clec4d can recognise TDM71, we investigated whether this receptor 
was required for anti-mycobacterial immunity in vivo. 
We first determined whether the loss of Clec4d would influence the survival of 
mice during infection with live mycobacteria. In order to explore this possibility, 
wild-type and Clec4d-/- mice were challenged intratracheally with the attenuated 
vaccine strain M. bovis BCG and survival of the animals was monitored over 
time. Notably, in contrast to the wild-type mice, the Clec4d-/- mice gained less 
weight (figure 2.1B) and more than 10% of these animals succumbed to infection 
between 6 and 14 weeks (figure 2.1C). Importantly, knockout mice aerosol 
infected with M. tuberculosis H37Rv also gained less weight and 20% of these 
animals succumbed to the infection within 6 weeks (figure 2.1D and data not 
shown). Longer-term experiments did not reveal any further reduction in 
survival of the Clec4d-deficient mice, compared to wild-type animals (data not 
shown).
Zhu and colleagues have recently suggested that Clec4d is also required for 
control of systemic infection with Candida albicans80, but only after low dose 
infection. These results are in contrast to previous observations from several 
laboratories including our own70, and repeated experiments using high and low 
doses of C. albicans failed to demonstrate any role for Clec4d in controlling this 
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fungal pathogen (supplementary figure 2.1A). Clec4d has also been implicated 
in immunity to Klebsiella pneumoniae81, but as with Candida, we observed no 
differences in mortality or weight loss in the knockout mice following 
intratracheal infection with this organism (supplementary figure 2.1B and data 
not shown). Importantly, K. pneumoniae and C. albicans both failed to stimulate 
GFP expression in Clec4d-expressing reporter cells71, whereas these cells 
robustly induced GFP in response to BCG (figure 1E). 
Thus, these data identify Clec4d as a pattern recognition receptor with a non- 
redundant role in anti-mycobacterial immunity in vivo.
Clec4d is not required for adaptive responses to mycobacteria
Purified ligands of many C-type lectins receptors, including Clec4d71, can act as 
adjuvants and direct the development of adaptive immunity, but the role of 
these receptors in driving responses to intact microorganisms is less clear. 
Notably, acquired immunity to mycobacteria was unaffected by the loss of 
the major CLR intracellular signalling adaptor Card9 64. Nevertheless, we 
investigated the possibility that this receptor may be capable of modulating 
adaptive immunity using Complete Freund’s Adjuvant. However, no differences 
were observed in the Clec4d-/- mice in terms of the number, division or activation 
of antigen-specific CD4+ T-cells in the draining lymph nodes at the two time 
points that were examined post immunization (supplementary figures 2.1C-F 
and data not shown). The knockout mice also developed normal antigen-specific 
immunoglobulin responses (supplementary figure 2.1G). There were no 
defects in CD4/CD8 T-cell ratios in the lungs during mycobacterial infection 
(supplementary figure 2.1H). Clec4d-/- mice also displayed normal delayed-type 
hypersensitivity (supplementary figure 2.1I) and mycobacterial-specific T-cell 
recall responses (supplementary figure 2.1J), following BCG vaccination. Thus, 
deficiency of Clec4d does not influence the development of acquired immunity 
to mycobacteria. 
Clec4d is involved in controlling bacterial burdens, cytokine 
production and granuloma formation in vivo
To examine how deficiency of Clec4d was affecting anti-mycobacterial immunity, 
we characterised the lungs of wild-type and Clec4d-/- mice following aerosol 
infection with M. tuberculosis H37Rv. At early time points after infection, we did 
not detect any difference in bacterial burdens, but by 4 months we observed 
moderately increased burdens in the infected knockout mice (~0.50 log; 
figure 2.2A). These increased bacterial burdens could be observed directly in 
Ziehl-Neelsen stained tissue sections (supplementary figure 2.2A), and analysis 
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Figure 2.1 Clec4d-/- is required for resistance to mycobacterial infection in vivo. 
(A) Ulceration in Clec4d-/- but not wild-type mice at the site of injection with Complete Freund’s 
Adjuvant. Change in weight (B; mean ± SEM) and survival curve (C) of Clec4d-/- and wild-type mice 
following intratracheal infection with 5x105 M. bovis BCG. (D) Survival of wild-type and Clec4d-/- 
mice following aerosol infection with 100 CFU M. tuberculosis H37Rv. (E; mean ± SD) Analysis of 
green fluorescent protein (GFP) expression in Clec4d-expressing reporter cells following stimulation 
with BCG (MOI: 1, 5, 15), C. albicans yeast (CaY; MOI: 5, 50) or hyphae (CaH; MOI: 5, 50), and K. 
pneumoniae (KPn, MOI: 5, 50), as indicated. Values in (B - D) are pooled data from at least two 
experiments, while the data in (E) is from one representative experiment. *, p<0.05. See also 
supplementary figure 2.1.
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of the lungs of mice infected with M. tuberculosis revealed larger inflammatory 
lesions in the Clec4d-/- mice at later time points (figure 2.2B and supplementary 
2.2B). Similarly, increased bacterial burdens were also observed in BCG-infected 
knockout mice at later time points (figure 2.2C), and cellular analysis of digested 
lung tissue at 3 months post infection revealed significantly more CD11b+Ly6Ghigh 
neutrophils and CD11b+F4/80+ macrophages in the Clec4d-/- mice (figure 2.2D). 
Strikingly, Clec4d-/- mice most affected by infection, as determined by less than 
10% weight gain, had the highest numbers of neutrophils in their lung, even 
when compared to wild-type mice with a similar phenotype (figure 2.2E). 
Consistent with the increased cellular infiltrates, there were significantly higher 
levels of inflammatory cytokines including TNF-α, IFN-γ and G-CSF, in the 
lungs of the knockout mice (figure 2.2F). There were no differences in IL-10 
levels in the Clec4d-/- mice.
 
To gain further insights, we next characterised pulmonary inflammation 48 
hour following the administration of a high dose of mycobacteria. Similar to the 
later time points, flow cytometry analysis and histology revealed a significant 
increase in neutrophils in the lungs of Clec4d-/- mice infected with either 
BCG, M. tuberculosis H37Rv or the more pathogenic M. tuberculosis Beijing 
(figure 2.2G and supplementary 2.2C). The cellular inflammatory response to 
M. tuberculosis H37Rv was accompanied by increased levels of many pro-
inflammatory cytokines and chemokines, but also increased levels of IL-10 
(figure 2.2H). There were no differences in CFU recovered from wild-type and 
knockout mice at this early time point (supplementary figure 2.2D). Therefore 
we conclude that deficiency of Clec4d results in higher mycobacterial burdens 
and increased pulmonary inflammation, which is predominantly neutrophilic. 
Clec4d is required for mycobacterial uptake
We have previously shown that intracellular signalling from Clec4d can trigger 
particle phagocytosis70,71, and therefore examined the possibility that the 
phenotype of the Clec4d-/- mice was stemming from a defect in mycobacterial 
uptake and clearance by leukocytes. For these experiments, we infected mice 
with a GFP-expressing strain of M. bovis BCG and then characterised bacterial 
association with pulmonary CD45+ myeloid cells four hours after challenge. 
Notably, while the total number of pulmonary leukocytes was similar in both 
groups of mice at this early time-point (supplementary figure 2.2E), we observed 
significantly less mycobacterial-association with leukocytes isolated from the 
Clec4d-/- mice, as determined by GFP-positivity (figure 2.3A). Characterisation 
of these cells demonstrated defective mycobacterial association with all major 
pulmonary leukocyte subsets, including CD11c+SiglecF+ alveolar macrophages, 
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Figure 2.2   Clec4d-/--deficiency results in exacerbated pulmonary  
inflammation with increased accumulation of neutrophils and 
higher bacterial burdens.
(A) Pulmonary bacterial burdens in wild-type or Clec4d-/- mice following aerosol infection with 100 
colony forming units (CFU) M. tuberculosis H37Rv. (B) Pulmonary inflammatory lesion size over time. 
Pulmonary bacterial burdens (C) and leukocyte composition (D) in wild-type or Clec4d-/- mice 3 
months following intratracheal infection with 5x105 M. bovis BCG. (E) Neutrophil levels in wild-type 
(n=3) and Clec4d-/- animals (n=8) that show the greatest change in body weight (<10%). (F) Pulmonary 
cytokine levels in 3 month M. bovis BCG infected animals. (G) Pulmonary leukocyte composition in 
wild-type or Clec4d-/- mice 48 h after intratracheal infection with M. bovis BCG, M. tuberculosis 
H37Rv or Beijing, as indicated. (H) Bronchio-alveolar lavage cytokine levels in mice at 48 h after 
infection with M. tuberculosis H37Rv. Shown are pooled data (mean ± SEM). *, p<0.05. ns =, not 
significant. See also supplementary figure 2.2.
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CD11b+Ly6Ghigh neutrophils and CD11b+F4/80+ macrophages (figure 2.3B). 
Consistent with this observation, there were increased levels of non-cell associated 
mycobacteria in the lungs of the Clec4d-/- mice (supplementary figure 2.2F).
To demonstrate that the defect was solely due to loss of recognition by Clec4d, 
we opsonized the bacteria with anti-BCG antibodies, prior to infection, and 
observed that association of the bacteria with leukocytes was fully restored in 
Clec4d-/- mice in vivo (figure 2.3C). Unlike with unopsonized bacteria (figure 
2.2G), there was no difference in cellular inflammation at 48 hour in the knockout 
mice when challenged with opsonized bacteria (figure 2.3D). Importantly, 
opsonisation rescued the phenotype of the knockout mice even out to 3 months, 
in terms of weight gain (supplementary figure 2.2G), survival (supplementary 
figure 2.2H), pulmonary neutrophil influx (figure 2.3E) and bacterial burdens 
(figure 2.3F). 
We could also demonstrate defective mycobacterial association with Clec4d-/- 
thioglycollate-elicited macrophages (figure 2.3G) and neutrophils (figure 2.3H) 
in vitro. Clec4d-deficiency specifically affected mycobacterial binding to 
leukocytes, but not phagocytosis, as the levels of ingestion of bacteria that were 
cell-bound was equivalent to wild-type cells (supplementary figure 2.2I). 
Importantly, bacterial binding to knockout macrophages could be restored 
following opsonisation, and was specific for mycobacteria as loss of Clec4d had 
no effect on association of the unrelated particle zymosan (figure 2.3G). 
Moreover, we could show that TDM inhibited the binding of unopsonized 
mycobacteria with wild-type thioglycollate-elicited macrophages in vitro, but 
had no effect on bacterial binding to cells isolated from the knockout mice 
(figure 2.3I). TDM had no effect on the association of zymosan with macrophages 
isolated from either strain of mice (supplementary figure 2.2J). Thus, we 
conclude that the phenotype of the Clec4d-/- mice stems from defective 
mycobacterial recognition by leukocytes. 
Figure 2.2  Continued.
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Figure 2.3  Clec4d-/- is required for mycobacterial binding.
Total green fluorescent protein (GFP)+ CD45+ cells (A) or particular cell types (B), as indicated, 
in the lungs of wild-type or Clec4d-/- mice 4 h after infection with GFP- expressing M. bovis BCG 
(n>14). Total GFP+ CD45+ cells (C) and numbers of neutrophils (D) in bronchio-alveolar lavage 
isolated from wild-type or Clec4d-/- mice after infection with opsonized M. bovis BCG at 4 and 48 h, 
respectively (n>10). Numbers of neutrophils (E) and bacterial burdens (F) in the lungs of wild-type or 
Clec4d-/- mice 3 months after infection with opsonized M. bovis BCG (n=12). In-vitro binding of 
unopsonized (unops) and opsonized (ops) GFP-expressing M. bovis BCG, or zymosan, to (G) thiogly-
collate-elicited macrophages or (H) neutrophils. (I) Effect of trehalose 6,6-dimycolate (TDM) on in 
vitro binding of GFP+BCG to thioglycollate-elicited macrophages isolated from wild-type or Clec4d-/- 
mice. Shown are pooled data (mean ± SEM) from at least two independent experiments. *, p<0.05. See 
also supplementary figure 2.2.
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Polymorphisms of human CLEC4D cause susceptibility to tuberculosis
To determine whether CLEC4D may also be important for human anti-mycobac-
terial immunity, we examined publicly available micro-array data sets for effects 
of tuberculosis on the expression of this CLR. Expression of CLEC4D in whole 
blood was strongly upregulated in HIV-negative patients with pulmonary 
tuberculosis compared to controls in five out of six cohorts from various 
geographic areas (supplementary figure 2.3A). In mice, we observed similar 
increases in Clec4d expression on leukocytes during pulmonary infection 
(supplementary figure 2.3B). In the United Kingdom tuberculosis cohort, 
expression data were also available for uninfected (tuberculin skin test negative) 
and latently infected (tuberculin skin test positive) controls; there was no 
difference in CLEC4D expression between these two groups (supplementary 
figure 2.3C). Initiation of treatment in pulmonary tuberculosis patients led to 
normalization of CLEC4D expression over time (supplementary figure 2.3D). 
The highest levels of expression of the receptor were observed in monocytes and 
neutrophils in peripheral blood, consistent with our earlier observations70, and 
pulmonary tuberculosis was associated with significantly increased levels of 
expression on circulating neutrophils compared to healthy controls (supplementary 
figure 2.3E). These differences cannot be explained by differences in leukocyte 
numbers, as absolute and relative neutrophil counts did not differ between 
active tuberculosis patients and controls72.
As the expression of CLEC4D correlated with pulmonary tuberculosis, and as 
we had identified a role for this receptor in anti-mycobacterial immunity in 
mice, we then determined whether polymorphisms of this CLR had an influence 
on susceptibility to tuberculosis in humans. We genotyped three CLEC4D SNPs 
in a total of 1032 confirmed pulmonary tuberculosis patients and 955 age- and 
gender-matched community controls from an Indonesian cohort collected in 
Jakarta and Bandung, West-Java. These SNPs were chosen as together they 
covered all haplotypes with a frequency of >5%, as described in the HapMap 
Figure 2.3  Continued.
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database for Japanese and Han-Chinese populations (table 2.1 and 
supplementary figure 2.3F). However, we found that the minor allele frequencies 
of the three CLEC4D SNPs were lower in the control Indonesian subjects (table 
2.2) than those described in the HapMap database. 
Of the three polymorphisms, the combined GA and GG genotypes of the 
non-synonymous SNP rs4304840, were significantly associated with disease 
with an odds ratio of 1.33 with a 95% confidence interval of 1.02–1.73 
(supplementary figure 2.3F and table 2.2). As the number of patients with the 
GG genotype was small, it seems likely that the G allele confers susceptibility in 
a dominant fashion. The functional relevance of the rs4304840 polymorphism is 
further demonstrated in available expression quantitative trait locus (eQTL) 
data, where we found the G allele to be significantly associated (p<10-4) with 
altered CLEC4D expression (data not shown). The intronic SNP rs4486677, which 
showed a high degree of linkage disequilibrium with rs4304840 in HapMap, 
had a similar odds ratio, which bordered significance (supplementary figure 
2.3F and table 2.2). Haplotype analyses showed that the haplotypes with 
GG/GA alleles for rs4304840 had similar odds ratio’s (OR), irrespective of the 
rs4486677 allele (data not shown). The SNP rs4883165, which is located 12 kb 
upstream of the CLEC4D gene, was not associated with disease. In conclusion, 
the GG and GA genotypes for CLEC4D rs4304840 are associated with 
susceptibility to pulmonary tuberculosis, irrespective of the genotype for the 
SNP rs4486677. 
The rs4304840 polymorphism causes a non-synonymous change (Ser32Gly) in 
the transmembrane region of the protein. This change could influence the 
association of this CLR with the Fcγ adaptor and affect the ability of this receptor 
to be transported to the cell surface62. To explore this, we generated constructs 
Table 2.1  The CLEC4D SNPs selected for analysis 
SNP alleles Minor allele frequency for the 
JPT & CHB population
Type
rs4883165 T / G 0.076 5’upstream of gene
rs4304840 A / G 0.129 nonsynonymous 
(Ser32Gly; transmembrane)
rs4486677 T / G 0.062 in intron 2
JPT = Japanese; CHB = Han-Chinese
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for both wild-type and mutated CLEC4D and transfected them into fibroblasts. 
These experiments revealed that while both wild-type and mutated proteins 
were expressed at equivalent levels in transfected cells, there was a significant 
reduction in the surface expression of the mutated protein (supplementary 
figure 2.3G). Thus the rs4304840 polymorphism reduces surface expression of 
CLEC4D.
Discussion
C-type lectin receptors (CLRs) have key functions in host defence and although 
they are best known as PRRs for fungi, there is growing evidence that CLRs are 
also involved in host responses to mycobacteria62. The most compelling data 
comes from analysis of mice deficient in a central CLR-signalling adaptor, Card9, 
which were extremely susceptible to mycobacterial infection64. Yet despite the 
identification of several CLRs capable of mycobacterial recognition, all have 
been found to be dispensable during infection with M. tuberculosis in vivo62. In 
this report, we identify the CLR Clec4d as the first PRR to have a non-redundant 
role in anti-mycobacterial immunity. 
Loss of Clec4d led to exacerbated pulmonary inflammation, characterised by 
enhanced neutrophil recruitment and increased mycobacterial burdens, but had 
no effect on the development of adaptive immunity. This phenotype resembles 
that of the Card9-/- mice, however, these animals presented with greater 
pathology and all of the animals died shortly after infection; a severity that was 
linked to defects in IL-10 production64. Similar profound phenotypes have also 
been observed in mice lacking other essential immune components, such as 
IFN-γ. In contrast, fewer Clec4d-/- mice succumbed to mycobacterial infection 
and there was no loss of IL-10. This suggests that the levels of IL-10 were 
protecting the majority of the infected Clec4d-/- mice from lethal pathology, 
despite the enhanced inflammation and bacterial burdens that was present in 
their lungs.
This difference in phenotype raises the question about the relationship between 
Clec4d and Card9. Card9 is downstream of several PRRs implicated in 
mycobacterial recognition, including C-type lectin receptors, NOD-like 
receptors and Toll like receptors and deficiency of this adaptor is likely to affect 
all of these pathways. Yet mouse models have not revealed a clear role for any of 
the PRRs so far identified82. Although Clec4d has not formally been shown to 
require Card9, it triggers intracellular signalling via the Fcγ chain and Syk 
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kinase, and therefore must utilize this pathway70,71. Clec4d also associates and 
functionally interacts with Dectin-280 and Mincle83, both of which have also 
been implicated in anti-mycobacterial immunity65,69. In fact, Clec4d stimulation 
is required for Mincle expression, at least in response to TDM71. However we 
detected expression of both Dectin-2 and Mincle during mycobacterial infection 
in the Clec4d-/- mice (data not shown). Interestingly, expression of Clec4d with 
Fcγ alone was insufficient to mediate mycobacterial binding in transfected 
fibroblasts, suggesting that its ability to associate with these other receptors is 
an important component of its function (data not shown). Thus, despite the fact 
that these and other receptors are involved in mycobacterial recognition 
(mediating the IL-10 response discussed above, for example), Clec4d deficiency 
recapitulates the major components of the Card9-/- phenotype. 
In both the Card9-/-64 and Clec4d-/- mice, pulmonary pathology was associated 
with an accumulation of neutrophils and higher levels of neutrophil-associated 
cytokines, such as G-CSF. Indeed, depletion of either neutrophils or G-CSF 
reduced inflammation and prolonged survival of the Card9-/- mice64. However, 
the involvement of neutrophils during tuberculosis is still controversial, with 
evidence for both protective and non-protective roles during infection. In 
humans, infected neutrophils were found to predominate in the lungs of patients 
with active pulmonary tuberculosis and a neutrophil-driven transcriptional 
signature in blood was shown to correlate with disease severity72. Interestingly, 
even though lessening the clinical disease, depletion of neutrophils in the 
Card9-/- mice did not affect bacterial burdens in the lung, demonstrating that 
these granulocytes were the major drivers of pathology and were not directly 
contributing to protective host responses64. Indeed, the ability of neutrophils to 
actually kill mycobacteria is also controversial84. 
In humans, we show that neutrophils have the highest levels of CLEC4D 
expression70. Importantly, we have identified the association of a polymorphism 
(rs4304840) in this receptor with increased susceptibility to pulmonary 
tuberculosis in an Indonesian cohort. This polymorphism causes a non- 
synonymous change (Ser32Gly) in the transmembrane region of the protein 
that substantially reduces its expression at the cell surface. Genetic variations in 
several PRRs have been shown to influence mycobacterial disease susceptibility, 
severity and/or outcome, but many of these observations have not been 
confirmed in other cohorts. Moreover, the effects of these PRR polymorphisms 
are also dependent on bacterial genotype85. However, the involvement of Clec4d 
does not appear to be strain specific, at least in our animal models (figure 2G). 
Moreover, based on M. tuberculosis spoligotyping, we did not find any difference 
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in allele frequency for rs4304840 (the non-synonymous SNP that showed an 
association with disease) between the cases infected by a Beijing strain (n=182) 
versus those infected by other strains (n=379) (p=.371, data not shown). It will be 
nevertheless important to validate our observations in additional patient cohorts 
and determine the effect, if any, of CLEC4D polymorphisms in other disease 
phenotypes, such as meningeal and paediatric tuberculosis. 
Interestingly, the few families with mutations in Card9 have not been associated 
with an increased susceptibility to tuberculosis62. While the underlying reasons 
for this are unclear, the intact adaptive responses64 may mediate protection due 
to successful vaccination of these patients in endemic areas. Another possible 
mitigating factor is the inability of human neutrophils to express IL-1086, one of 
the major defects causing the pathology in the Card9-/- mice64. This suggests 
that the cellular functions of Card9 may differ in humans and mice during 
mycobacterial infection.
Neutrophils can internalize mycobacteria84 and we found that Clec4d-deficiency 
resulted in defective mycobacterial association with these and several other 
leukocyte populations in the lung. Defective mycobacterial clearance in the 
 Clec4d-deficient mice led to increased levels of extracellular bacteria, 
exacerbating neutrophilic pulmonary inflammatory responses. In a small subset of 
infected knockout mice, these deregulated responses ultimately led to death. 
Restoring mycobacterial leukocyte association through antibody opsonisation 
completely rescued the Clec4d-deficient phenotype both in vitro and in vivo. 
In addition to mycobacteria, Clec4d has been implicated in immunity to Candida 
albicans80 and Klebsiella pneumoniae81. Yet we found no defect in resistance to 
infection with either of these pathogens. The role of Clec4d in immunity to C. 
albicans is arguably the most controversial, as previous experiments70,83 and the 
data shown here failed to show any role for this CLR in the control of this fungal 
pathogen. The underlying reasons for these disparate results remain to be 
determined. 
Overall, our data show that mycobacterial recognition is the primary function of 
CLEC4D. Importantly, a polymorphism of CLEC4D causing reduced surface 
expression associates with increased susceptibility to pulmonary tuberculosis 
in humans. In conclusion, CLEC4D is a non-redundant component of anti-myco-
bacterial immunity.
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Supplementary methods
Infections
Mice were challenged intratracheally with 600 CFU K. pneumonia strain 32. 
Intravenous infection with low (2x104 CFU) and high (2x105 CFU) doses of 
Candida albicans SC5314 was carried out as described previously (Vautier et al., 
2012). C. albicans hyphae were induced in 20% FCS in PBS for 3-5 h at 37°C.
Histology
Lungs were prepared for histology by fixing the large left lobe in 10% phos-
phate-buffered formalin and then embedding in paraffin. 5 µm-thick sections 
were stained with haematoxylin and eosin (H&E) for evaluation of pathologic 
changes and Ziehl-Neelsen for M. tuberculosis detection. The sizes of all 
inflammatory lesions per section in infected mouse lungs were determined by 
automated morphometric analysis using a Nikon microscope eclipse 90i and the 
software NIS-Elements BR 3.1 (Nikon), as described previously87.
Adoptive Transfer
OT.II donor mice were culled and the lymph nodes and spleens were removed, 
disaggregated through 70 µM filters and white cells counted by trypan blue 
exclusion. CD4+ cells were purified from single-cell suspensions by depleting 
irrelevant populations using biotin-antibody cocktail and anti-biotin 
micro-beads (Miltenyi Biotech). The purified CD4+ cells were stained with 5 µM 
CFSE for 5 to 8 min at room temperature with continual rotation, and CFSE 
labelling was subsequently quenched by washing 2-3 times in 10% FCS in PBS. 
CFSE+CD4+ OT.II cells were checked by FACS for labelling efficiency and purity, 
which was routinely >80%. CFSE+CD4+ OT.II cells were then injected 
intravenously into gender-matched recipient mice (3 to 5 x 106 cells per recipient) 
of the same background strain as the donors (C57BL/6). Mice were immunised 1 
h following the adoptive transfer, with 50 µg purified ovalbumin (Hyglos 
GmBH) emulsified in Complete Freund’s Adjuvant (Difco), delivered as 2 
subcutaneous injections in the hind legs. Mice were sacrificed 4 and 8 days 
post-immunisation for analysis by flow cytometry. Inguinal (draining) lymph 
nodes were removed, made into single cell suspensions and processed for FACS, 
as described above standard methods. OT.II cells were defined as 
CD4+Vα2+CD45.1+.
Immunoglobulin Assays
Mice were immunised with 100 µg NP-KLH (Biosearch Technologies) emulsified 
in Complete Freund’s Adjuvant (Difco) delivered as three sub-cutaneous 
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injections. Animals were sacrificed 10 days later, and anti-NP antibodies in the 
serum were measured by ELISA using specific secondary antibodies conjugated 
to HRP (Cambridge Biosciences).
BCG vaccination, DTH and recall responses
Mice were subcutaneously inoculated with 106 CFU M. bovis BCG strain Pasteur 
as previously described64. At 4 weeks after vaccination, BCG-vaccinated and 
control mice were intradermally challenged with 2 µg purified protein derivate 
into the footpad. Footpad swelling was recorded 48 h after challenge using 
a dial gauge caliper. For recall responses, mice were infected intratracheally 
with 5 x 105 CFU BCG. Draining lymph nodes were isolated after 2 weeks, 
disaggregated and plated at 5 x 105 cells per well in 96 well plates. Cells were 
then stimulated for 3 days with media only or with a French-pressed BCG lysate. 
Cytokines were measured in the supernatant by ELISA (BD OptEIA).
Phagocytosis assays
Phagocytosis was measured using our previously published methodology88. 
In brief, thioglycollate elicited macrophages were incubated with BCG-GFP 
(10:1) or zymosan at 4 °C for 1 h to allow binding, washed and incubated at 37°C 
5% for 3 h to allow uptake. Extracellular BCG-GFP was stained with primary 
anti-BCG rabbit antiserum (Alpha diagnostics) and secondary APC-conjugated 
goat anti-rabbit IgG (Life Technologies). Surface-bound FITC-labelled Zymosan 
was stained with biotinylated Fc-Dectin-189 and streptavidin-APC (Invitrogen). 
Phagocytosis was defined as the percentage of GFP+ or FITC+ cells with 
internalised (APC-) particles. Samples kept at 4⁰C to prevent internalization 
were used as controls.
Generation of Cell lines
Generation of the pFBneo retroviral vector containing the full length hCLEC4D 
open reading frame fused to an HA-tag was described previously70. The S32G 
SNP (rs4304840) was introduced by a two-step PCR protocol. Firstly, the 
sequences downstream and upstream of the S32G SNP were amplified separately 
from pFB_hCLEC4D using a vector specific and SNP-encoding primers (pFB-neo 
(5’-GCCAGGTTTCCGGGCCCTCAC-3’) and hCLEC4D_S32G_F (5’-TAGTTTTC- 
ATCTTACTTCTCGGTGTCTGTTTTATTGCAAG-3’); pFB-retro (5’-GGCTGC-
CGA-CCCCGGGGGTGG-3’) and hCLEC4D_S32G_R (5’- CTTGCAATAAAACA-
GACACCGAGAAGTAAGATGAAAACTA-3’). The original pFBneo_hCLEC4D 
template was digested with DpnI followed by fusion and amplification of the 
two PCR products using the vector specific primers. The PCR product was 
cloned into pFBneo_HA and the fidelity confirmed by sequencing. 
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NIH 3T3 cell lines stably co-expressing FcRγ with wild-type hCLEC4D-HA, 
hCLEC4D_S32G-HA or empty vector control were generated by retroviral 
transduction as described previously90. All cell lines were generated twice and 
used as non-clonal populations to reduce founder effects. 
Receptor expression was assessed by flow cytometry as described in the main 
text. Briefly, cells were blocked in FACS wash (PBS, 5 mM EDTA, 0.5% BSA, 2 
mM NaN3) containing 5% heat-inactivated rabbit serum, followed by staining 
with an anti-HA antibody (HA.11, clone 16B12, Covance) for 1 h at 4°C.  Cells 
were washed twice and stained with a goat-anti-mouse PE secondary antibody 
(Jackson) for 30 min at 4°C.  After three additional washes, cells were fixed in 1% 
paraformaldehyde and analysed on a BD LSRII flow cytometer.  To assess the 
total cellular CLEC4D content, cells were fixed in 1% paraformaldehyde followed 
by permeabilisation with 0.5% saponin prior to assessing receptor expression, as 
described above. To calculate relative expression, mean fluorescence intensities 
(MFI) of all samples were normalised by subtracting their respective control 
background MFI.  Subsequently, the MFI of each cell population was divided by 
the average MFI of wild-type hCLEC4D expressing cells and expressed as a 
percentage.  Data points plotted represent the means of independent experiments.
Sample collection and genotype analysis
Peripheral blood samples were obtained by venepuncture. Genotyping was 
performed as described previously79. In brief, genomic DNA was isolated from 
EDTA blood of patients and control subjects using standard methods. 5 ng of 
DNA was used for genotyping with multiplex assays designed using Mass 
ARRAY Designer Software (Sequenom) and genotypes were determined using 
Sequenom MALDI-TOF MS according to manufacturer’s instructions (Sequenom 
Inc., San Diego, CA, USA). Briefly, the SNP region was amplified by a locus-specific 
PCR reaction. After amplification a single base extension from a primer adjacent 
to the SNP was performed to introduce mass differences between alleles. This 
was followed by salt removal and product spotting onto a target chip with 384 
patches containing matrix. MALDI-TOF MS was then used to detect mass 
differences and genotypes were assigned real-time using Typer 4 software 
(Sequenom Inc. San Diego, CA, USA). As quality control, 5% of samples were 
genotyped in duplicate and each 384-well plate also contained at least 8 positive 
and 8 negative controls, no inconsistencies were observed. For quality control 
purposes the genotype of at least two samples for each homozygous genotype 
were confirmed by sequencing using Sanger method. 
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Supplementary figures
Supplementary figure 2.1  Clec4d-/- is required for resistance to mycobacterial 
infection but does not impair adaptive immunity. 
Related to Figure 2.1. (A) Survival of wild-type and Clec4d-/- following systemic  infection with a high 
(2x105, circles) and a low (2x104, squares) dose of Candida albicans SC5314. (B) Change in weight of 
wild-type versus Clec4d-/- mice following intratracheal infection with 600 CFU Klebsiella pneumoniae 
strain 32. Characterization of the frequency (C), division (D), activation (E) and differentiation (F) of 
adoptively transferred OT.II T-cells in the draining lymph nodes of wild-type and Clec4d-/- animals 
immunized with Ovalbumin and Complete Freund’s Adjuvant. (G) Immunoglobulin responses in 
the serum of wild-type and Clec4d-/- animals immunized with NP-KLH and Complete Freund’s 
Adjuvant. (H) CD4+ and CD8+ T-cell populations in the lungs of wild-type and Clec4d-/- mice 4 
months after infection with 5x105 M. bovis BCG. (I) DTH responses in the footpad of wild-type and 
Clec4d-/- mice 4 weeks after subcutaneous. BCG vaccination. (J) IFN-γ recall responses following a 
3-day BCG stimulation of lymph-node cells isolated from mice two weeks after infection. No cytokine 
response was obtained following stimulation of cells isolated from naïve animals (not shown). 
Values shown are from a representative experiment, except for (C, D, H - J) which are data from two 
pooled experiments. Each symbol (C to G) represents one mouse, and the data shown are the mean ± 
SD. *, p<0.05; ns, not significant.
A 
100 
days post infection 
75 
50 
n=9 
7 14 0 
%
 s
ur
vi
va
l 
ns 
21 
C. albicans 
25 
0 
ns B 5 
days post infection 
0 
-5 
n=10 
7 14 0 
%
 w
ei
gh
t c
ha
ng
e 
ns 
21 
K. pneumonia 
-10 
30 
20 
10 
0 
4 8 
day post transfer  
%
 O
TI
I c
el
ls
 ns 
ns 
C 
80 
40 
0 
4 8 
day post transfer  
%
 d
iv
id
ed
 O
TI
I c
el
ls
 
ns 
ns 
D 
1.5 
1.0 
0.5 
0 
A
B
S
45
0n
m
 
ns 
ns 
ns 
ns 
ns ns 
ns 
IgM IgG1 IgG2a IgG2b IgG2c IgG3 IgE 
G 
CD44 CD25 CD69 CD62L 
1500 
1000 
500 
200 
100 
0 
M
FI
 
ns 
ns ns ns day 8 
E F 
16 
12 
6 
3 
0 
day post transfer  
4 8 
%
IF
N
-γ
+ 
O
TI
I c
el
ls
 
ns ns 
wild type 
Clec4d-/-
/ 
/ 
30 
0 %
 C
D
45
+  
ce
lls
 
20 
10 
CD3+ CD4+ CD8+ 
ns 
ns ns 
H I 
ns 
vaccinated - + 
0.6 
0.4 
0.2 
0 f
oo
tp
ad
 s
w
el
lin
g 
(m
m
) 
1.8 
1.2 
0.6 
0 
IF
N
-γ
 n
g/
m
l 
BCG - + + 
naive 
J ns 
ns ns 
 CLEC4D in tuberculosis susceptibility | 49
Supplementary figure 2.1  Continued. 
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Supplementary figure 2.2 Clec4d-/--deficiency results in higher bacterial burdens 
and exacerbated pulmonary inflammation. 
Related to figure 2.2 and figure 2.3. (A) Ziehl-Neelsen stained lung sections from wild-type and 
Clec4d-/- mice after 4 months of infection with M. tuberculosis H37Rv. Mycobacteria are indicated 
with arrows. (B) Inflammatory lesion size 4 months after infection with M. tuberculosis H37Rv in H&E 
stained lung sections. (C) H&E stained lung sections at 48 hour showing accumulation of neutrophils 
(indicated with white arrows) after intratracheal infection with a high dose (5x105) M. tuberculosis 
H37Rv. (D) Mycobacterial burdens in mice 48 h after intratracheal infection with 5 x 105 CFU M. 
tuberculosis H37Rv or M. bovis BCG, as indicated. (E) Numbers of CD45+ cells 4 h after intratracheal 
inoculation of 1.5 x 106 CFU M. bovis BCG. (F) Gating strategy (control mouse shown for clarity) and 
percentage of non-cell associated mycobacteria (as detected in the green gate) in the lung 4 h after 
intratracheal inoculation of 1.5 x 106 CFU green fluorescent protein (GFP) + M. bovis BCG. (G) 
Percentage weight change in mice 12 weeks after infection with opsonised M. bovis BCG. (H) Survival 
curve mice following intratracheal infection with 5x105 CFU of opsonised M. bovis BCG. (I) Gating 
strategy for flow cytometric assessment of levels of internalization of unopsonized BCG or zymosan 
bound to thioglycollate-elicited macrophages. Percentage internalized was defined as the percentage 
of APC- (αBCG-) GFP+ or APC- (FcDectin-1-) FITC+ cells versus total GFP+ or FITC+ cells. (J) Effect of 
trehalose 6,6-dimycolate (TDM) on in vitro binding of FITC+ zymosan to isolated from wild-type or 
Clec4d-/- mice. Shown in (D - I) are pooled data (mean ± SEM) from two independent experiments. *, 
p<0.05.
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Supplementary figure 2.2 Continued.
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Supplementary figure 2.3  Expression and polymorphisms of CLEC4D. 
(A) Relative expression of CLEC4D in whole blood in patients with active pulmonary tuberculosis of 
six cohorts, compared to the controls from the respective cohorts. (B) Clec4d expression on mouse 
CD45+ leukocytes isolated from the lung 48 hour after BCG infection. (C) Expression of CLEC4D in 
whole blood in tuberculin skin test negative healthy control subjects (cont) from the United Kingdom 
(UK), individuals with latent tuberculosis infection (LTB), and patients with active pulmonary 
tuberculosis (PTB). Pulmonary tuberculosis and control data is the same as UK cohort data in (A). 
(D) Expression of CLEC4D over time in pulmonary tuberculosis patients following initiation of 
tuberculosis treatment. (E) Expression of CLEC4D in CD4+ and CD8+ cells, monocytes and neutrophils 
of patients and healthy controls in the UK. *, p<0.05. (F) Linkage disequilibrium plot of the CLEC4D 
gene region and 15kb upstream. SNPs with a prevalence of > 0.05 are shown with their linkage 
disequilibrium, based on data from the Han-Chinese (CHB) and Japanese (JPT) populations in 
HapMap. The figure was generated with Haploview and then redrawn. Bright red indicates high 
level of linkage. The three SNPs that were investigated in this study (shown in bold) collectively tag 
the haplotypes that occur with a frequency of > 0.05 in CHB + JPT populations. (G) Example flow 
cytometry plots (left) and pooled analysis (right) of total and surface expression of mutated CLEC4D, 
relative to the wild type receptor in NIH3T3 cells expressing the Fcγ chain. Each cell line was 
independently generated and tested twice. *, p<0.05; ns, not significant.
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Supplementary figure 2.3  Continued. 
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Abstract
Rationale
One of the most widespread clades of M. tuberculosis worldwide, the Beijing 
genotype family, consists of ancient (atypical) and modern (typical) strains. 
Modern Beijing strains outcompete ancient strains in terms of prevalence, while 
reserving a higher degree of genetic conservation. We hypothesize that their 
selective advantage lies in eliciting a different host immune response. 
Materials
Bead-disrupted lysates of different M. tuberculosis strains of the modern (n=7) or 
ancient (n=7) Beijing genotype, and the Euro-American lineage (n=6) were used 
for induction of ex-vivo cytokine production in peripheral blood mononuclear 
cells (PBMCs) from 10 healthy individuals. Hierarchical clustering and multi- 
variate regression analyses were used to study possible differences in production 
of nine cytokines. 
Findings
Modern and ancient M. tuberculosis Beijing genotypes induced different cytokine 
signatures. Overall induction of IL-1β, IFN-γ, and IL-22 was 38 to 40% lower 
after stimulation with modern Beijing strains (corrected p values of <0.0001, 
0.0288, and 0.0002, respectively). Euro-American reactivation strains induced 
2-fold more TNF-α  production than both types of Beijing strains. 
Interpretation
The reduction in proinflammatory cytokine response possibly contributes to the 
evolutionary success of modern Beijing strains. 
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Introduction
DNA fingerprinting has greatly facilitated the study of the molecular 
epidemiology of tuberculosis, while disclosing the phylogeny of the M. 
tuberculosis complex. The first genotype family described was the Beijing clade91, 
later recognized as the most important part of the East Asian lineage92. Strains 
of the widespread Beijing family are of particular interest due to their established 
association with drug-resistance, increased virulence in animal models, and 
association with infection of younger patients93, the last of which points to an 
increased relative reproductive fitness94. 
The vast majority of circulating Beijing strains is thought to belong to a conserved 
type genetically, as was first described based on insertion sequence 6110 
restriction fragment length polymorphism (IS6110-RFLP)95 and recently 
confirmed by whole genome sequencing96. These so-called ‘modern’ Beijing 
strains represent 65-95% of Beijing strains in most areas, including China97, 
Russia98, Taiwan99, South-Africa100, Europe97 and the United States101. Modern 
Beijing strains were first named ‘typical’ by the presence of a typical pattern of 
one or two copies of IS6110 in the NTF chromosomal region. In contrast, this 
insertion was found absent in the ‘atypical’ or ancient Beijing strains. These 
strains seem in fact to be representing a genetically diverse group96. It is only in 
Japan and South-Korea that the ancient strains are still highly prevalent, 
although they form a declining majority102,103.
The high prevalence and degree of genetic conservation of modern Beijing 
strains suggest they possess a selective advantage over ancient Beijing strains 
and other M. tuberculosis genotypes. Drug resistance has most likely occurred 
on several independent occasions104 and cannot be linked definitely to one of the 
strain subtypes105,106. One possible explanation for their success is that modern 
Beijing strains induce a different, less effective, host immune response compared 
to ancient Beijing strains. Although several studies have reported differences in 
immune responses after infection by Beijing genotype strains, none has 
performed an extensive comparison of immune responses induced by modern 
and ancient Beijing strains. The aim of our study therefore was to examine if the 
epidemiological success of modern M. tuberculosis Beijing strains is paralleled by 
a distinctive cytokine production profile. Our strain selection comprised a 
widespread geographic area and also included Euro-American strains isolated 
from endogenous reactivation cases in the Netherlands. We identified differences 
in innate immune response between modern and ancient M. tuberculosis Beijing 
strains that may help to explain their evolutionary success.
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Methods
M. tuberculosis strains
Twenty M. tuberculosis strains were selected from the reference database of 
clinical isolates of the Dutch National Institute for Public Health and the 
Environment (RIVM) in Bilthoven. Fourteen had been spoligotyped previously 
as Beijing strains. Using IS6110 PCR in NTF, these strains were further subdivided 
as modern (n=7) or ancient (n=7) Beijing strains107. A third group consisted of 
six strains isolated from elderly (>70 years of age) Dutch tuberculosis patients. 
On basis of IS6110 restriction fragment length polymorphism (RFLP) typing that 
has ben applied routinely to all tuberculosis cases in the Netherlands, all six 
had unique profiles and are assumed to represent endogenous reactivation 
from remote infections decades ago. Spoligotyping designated these strains to 
the Haarlem and T spoligotypes of the Euro-American lineage (figure 3.1). All 
strains were grown in Middlebrook 7H9 medium in one batch for three weeks. 
Ancient Beijing strains grew to a median OD of 0.47 (range 0.32-0.61), modern 
Beijing strains to a median OD of 0.43 (0.32-0.57) while the Euro-American 
reactivation strains grew less efficient and reached a median OD of 0.27 
(0.15-0.55). Then strains were washed two times in PBS, heat-killed and then 
disrupted using a bead beater, after which concentration was measured using a 
bicinchoninic acid (BCA) protein assay to standardise the concentration used in 
the immunological experiments.
Stimulation experiment with human peripheral blood  
mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats 
purchased from the Sanquin Blood bank Nijmegen. The healthy volunteers gave 
their written informed consent for the use of their blood for scientific purposes, 
as approved by the Ethics Committee of Radboud University Medical Centre, 
Nijmegen, The Netherlands. Donations occurred anonymously and therefore no 
tuberculosis skin test or interferon-gamma release assay could be performed, 
but the present incidence of tuberculosis in the indigenous Dutch population is 
extremely low (4/100,000/year) and BCG-vaccination is not part of the routine 
vaccination program. Isolation was performed using Ficoll-Paque, involving 
separation by density gradient followed by three wash steps in PBS and 
resuspension in RPMI 1640 supplemented with Glutamax, pyruvate and 
gentamicin. Subsequently, 100 µL of 5x106/mL PBMC’s and 50µL of stimulus at 
4 times the designated final concentrations were added in duplicate to a 96-well 
round-bottom plate, together with 50 µL of RPMI, or human pooled serum in 
case of a 7-day stimulation. Heat-killed Candida hyphae were used as a positive 
 M. tuberculosis modern Beijing sublineage cytokine profiles | 59
Fi
g
u
re
 3
.1
  T
he
 se
lec
tio
n 
of
 M
. t
ub
er
cu
lo
sis
 st
ra
in
s w
ith
 ge
ne
tic
 m
ar
ke
rs
 an
d 
co
un
try
 of
 or
ig
in
. 
IS
61
10
 R
es
tri
cte
d 
Fr
ag
m
en
t L
en
gt
h 
Pa
tte
rn
s (
RF
LP
) i
s s
ho
w
n 
w
ith
 cl
us
te
rin
g,
 as
 w
ell
 as
 ty
pi
ng
 by
 sp
ol
ig
ot
yp
in
g a
nd
 d
et
er
m
in
at
io
n 
of
 th
e p
re
se
nc
e o
f I
S6
11
0 
in
 N
TF
. N
ot
e: 
al
l r
ea
ct
iv
at
io
n 
str
ai
ns
 w
er
e i
so
lat
ed
 fr
om
 D
ut
ch
 p
at
ien
ts 
ov
er
 70
 ye
ar
s o
f a
ge
.
IS
61
10
 R
FL
P 
pr
oﬁ
le
 a
nd
 c
lu
st
er
in
g
S
tr
ai
n 
ID
S
po
lig
ot
yp
e
IS
61
10
in
 N
TF
C
ou
nt
ry
 o
f 
or
ig
in
NL
A0
0 
· 1
10
07
82
Be
ijin
g
on
e
Be
lgi
um
NL
A0
0 
· 1
10
08
86
Be
ijin
g
on
e
Ire
lan
d
NL
A0
0 
· 0
70
08
73
Be
ijin
g
on
e
Ch
ina
NL
A0
0 
· 9
40
17
09
Be
ijin
g
on
e
So
ut
h-
Af
ric
a
NL
A0
0 
· 9
40
20
19
Be
ijin
g
on
e
Th
ail
an
d
NL
A0
0 
· 9
40
17
07
Be
ijin
g
on
e
Ru
ss
ia
NL
A0
0 
· 0
80
01
62
Be
ijin
g
on
e
Vi
et
na
m
NL
A0
0 
· 0
30
07
00
Be
ijin
g
ab
se
nt
Th
e 
Ne
th
er
lan
ds
NL
A0
0 
· 9
40
20
08
Be
ijin
g
ab
se
nt
So
ut
h-
Ko
re
a
NL
A0
0 
· 0
20
02
30
Be
ijin
g
ab
se
nt
US
A
NL
A0
0 
· 0
70
16
04
Be
ijin
g
ab
se
nt
Th
e 
Ne
th
er
lan
ds
NL
A0
0 
· 9
80
12
52
Be
ijin
g
ab
se
nt
In
do
ne
sia
NL
A0
0 
· 0
50
18
14
Be
ijin
g
ab
se
nt
Th
ail
an
d
NL
A0
0 
· 0
01
75
83
Be
ijin
g
ab
se
nt
Th
e 
Ne
th
er
lan
ds
NL
A0
0 
· 0
00
02
88
Ha
ar
lem
-3
n/
a
Th
e 
Ne
th
er
lan
ds
NL
A0
0 
· 0
00
15
37
Ha
ar
lem
-1
n/
a
Th
e 
Ne
th
er
lan
ds
NL
A0
0 
· 0
00
03
70
T1
n/
a
Th
e 
Ne
th
er
lan
ds
NL
A0
0 
· 0
00
04
70
T1
n/
a
Th
e 
Ne
th
er
lan
ds
NL
A0
0 
· 0
00
05
25
T1
n/
a
Th
e 
Ne
th
er
lan
ds
NL
A0
0 
· 0
00
09
28
T1
n/
a
Th
e 
Ne
th
er
lan
ds
m
od
er
n 
B
ei
jin
g
Ea
st-
As
ian
 
lin
ea
ge
Ea
st-
As
ian
 
lin
ea
ge
an
ci
en
t B
ei
jin
g
re
ac
tiv
at
io
n
Eu
ro
-A
m
er
ica
n 
lin
ea
ge
60 | Chapter 3
control. The plates were incubated for 24 h, 48 h or seven days at 37°C in a 5% 
CO2 environment, after which they were spun at 700 g for 8 minutes. Supernatants 
were collected and stored at -20°C. Preliminary studies were performed using 
two modern and two ancient strains grown in a different batch, to define a 
dose-response and select the most appropriate stimulatory concentration of 
bead-disrupted M. tuberculosis, based on signatures of all cytokines tested. 
Afterwards, five experiments, involving two healthy volunteers each, were 
performed with the selection of twenty strains. Enzyme-linked Immuno- 
absorbence Assays (ELISA’s) were performed batch-wise, following the 
manufacturer’s protocols to measure cytokines in supernatants. The length of 
stimulation for the different cytokines was based on previous experiments: IL-1β, 
IL-1Ra, TGF-β and TNF-α (R&D Systems, Minneapolis, after 24h stimulation); 
IL-6 (Sanquin, Amsterdam, 24h); IFN-γ and IL-10 (Sanquin, 48 h); and IL-17 and 
IL-22 (R&D Systems, 7 days). 
Data analysis and statistics
Hierarchical clustering analysis was performed to investigate whether modern 
and ancient Beijing strains induced a different cytokine signature. Data points 
for 20 strains times 10 donors per cytokine were ln transformed and then 
normalized by subtracting each value from the mean response per cytokine per 
donor and dividing this value by the standard deviation. This resulted in a table 
with standardised donor-response per cytokine in rows and different strains in 
columns. Using Pearson correlation a distance measure was calculated on which 
clustering was performed with weighted-pair group method using average 
linkages (WPGMA) as the linkage method, using the freeware program J 
Express 2012 108.
Multivariate regression on the ln-transformed cytokine data was used to 
determine the contribution of the individual cytokines to the difference between 
the strain groups. In the multivariate regression, groups were compared based 
on their genetic classification, unbiased for results of the clustering hierarchy, to 
test the hypothesis that modern Beijing strains, on average, induced a different 
immune response. Fixed factors were strain type (modern Beijing, ancient 
Beijing or Euro-American reactivation) and donor, the latter to correct for donor 
variability. For the nine cytokines, predicted means of strain types and difference 
between those means with the respective confidence intervals were calculated 
with Stata MP, version 12.1. Differences with confidence intervals were plotted 
in a radar graph on a logarithmic axis. Reported p values and confidence 
intervals were Bonferroni-adjusted to correct for multiple comparisons. For 
clarification, relative percentages of differences were added to the radar graph 
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and for the reported table values were transformed as an exponent of e to obtain 
the prediction of the mean in pg/mL.
Results
Strains
All strains were fully susceptible to all first-line antituberculosis drugs. See 
figure 3.1 for other characteristics. Using a standardized stimulation model 
with bead-disrupted M. tuberculosis and isolated PBMCs, we first explored 
concentrations of 0.1, 1.0 en 10 μg/mL M. tuberculosis looking for a single 
concentration associated with reasonable induction of all cytokines evaluated. 
We chose a final concentration of 5 µg/mL as this was expected to most clearly 
show differences between groups for all cytokines of interest. Production of 
TNF-α, IL-1β, IL-6, IL-10, IL-17 and IFN-γ using PBMCs from 4 donors was 
almost identical when different concentrations of a H37Rv control strain that 
was grown in two different laboratories (the Dutch National Tuberculosis 
Reference Centre and Leiden University Medical Centre, supplementary figure 3.1) 
were used. 
Cytokine signature
The hierarchical clustering of cytokine signatures revealed different clusters of 
strains that grossly followed the distinction in modern versus ancient Beijing 
strains and the Euro-American reactivation strains. This study aimed explicitly 
to explore differences between groups of strains that have shown important 
 epidemiological differences in terms of recent spread and genetic heterogeneity. 
Indeed, the ancient Beijing strains clustered separately from the epidemiologi-
cally more successful and genetically more conserved modern Beijing strains. In 
the hierarchical clustering, this group of modern Beijing strains was divided in 
two groups, one of which also harboured one Euro-American reactivation 
strains, while the other Euro-American strains clustered as a fourth cluster 
(figure 3.2). Multivariate regression was applied on the groups of strains as they 
were defined based on their genetics and statistically significant differences in 
cytokine responses were found between modern Beijing strains and the other 
two groups for IL-1β, IL-1 receptor antagonist (IL-1Ra), IFN-γ and IL-22. 
Individual cytokines
The most striking difference in cytokine production was observed for induction 
of IL-1β, which is essential in protective host defence against M. tuberculosis 
(figure 3.3A and table 3.1). Overall, modern Beijing strains induced significantly 
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lower IL-1β concentrations after 24h compared to ancient Beijing strains 
(estimated mean 3,115 versus 5,184 pg/mL, p<0.0001), and reactivation strains 
(4,250 pg/mL) (figure 3.3B). Moreover, compared to ancient Beijing strains, 
modern Beijing strains induced significantly more IL-1Ra (5,094 versus 4,501, 
p=0.0001). Because IL-1Ra antagonizes the effect of IL-1β, this will further 
deplete the biologically active fraction of IL-1β after stimulation with modern 
Beijing strains. Production of all cytokines, including IL-1β and IL-1Ra, showed 
considerable in-between-strain and in-between-donor variability (figure 3.4A 
and supplementary figure 3.2). However, at the level of the individual donors, 
the amount of IL-1β was consistently lower and that of IL-1Ra consistently larger 
for modern compared to ancient Beijing strains in cells from all 10 donors (figure 
3.4B and supplementary figure 3.3). 
Modern Beijing strains also induced lower production of IFN-γ (48 hour) 
compared to the more ancient Beijing strains (48 versus 80 pg/mL, p=0.002). 
TNF-α production (24 hour) was slightly lower for modern compared to ancient 
Beijing strains (300 and 365 pg/mL, not significant) and interestingly, both 
groups induced much less TNF-α than the Euro-American reactivation strains 
(623 pg/mL, non-significant for ancient Beijing strains after Bonferroni 
correction, p<0.0001 for modern Beijing strains). IL-22 (7 days) was significantly 
lower in modern Beijing strains compared to ancient Beijing strains (662 versus 
1061 pg/mL, p=0.0002). Conversely, induction of IL-17 (7 days) was higher in 
modern Beijing strains compared to ancient Beijing strains (160 pg/mL versus 
106 pg/mL, not significant) and the reactivation strains (103 pg/mL, p<0.0001) 
(figure 3.3B). No significant differences were found for production of IL-6 
(24 hour), TGF-β (24 hour) and IL-10 (48 hour). 
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Discussion
In our in-vitro model, heat-killed and bead-disrupted lysates of modern 
(“typical”) M. tuberculosis Beijing strains induced a clearly different cytokine 
signature in freshly isolated PBMCs compared to ancient (“atypical”) Beijing 
strains. Overall, modern Beijing strains induced considerably lower production 
of IL-1β, IFN-γ and IL-22, and moderately higher production of IL-1Ra and IL-17. 
Interestingly, stimulation with Euro-American reactivation strains from elderly 
patients resembled stimulation with ancient Beijing strains, except for TNF-α. 
Euro-American reactivation strains induced twofold higher TNF-α than both 
type of Beijing strains, which may represent a possible explanation why 
infections with these strains only appear in these patients under circumstances 
of waning immunity.
Table 3.1  Cytokine induction in modern and ancient Beijing strains  
and Euro-American reactivation strains
Predicted mean (95% CI) (pg/mL)
Cytokine Length of 
stimulation
Modern  
Beijing strains
Ancient  
Beijing strains
Euro-American 
reactivation strains
% Difference for 
modern Beijing vs 
ancient Beijing strains 
p % Difference for 
modern Beijing vs 
Euro- American 
reactivation strains
% Difference for 
ancient Beijing vs 
Euro- American 
reactivation strains
IFN-γ 48 h 48 (40–57) 80 (67–95) 90 (76–107) - 40% 0.0288 - 47% < 0.0001 - 12% 1
TNF-α 24 h 300 (252–357) 365 (272–490) 623 (535–725) - 18% 1 - 52% < 0.0001 - 41% 0.3136
IL-1β 24 h 3,115 (2,954–3,285) 5,184 (4,823–5,572) 4,250 (4,082–4,424) - 40% < 0.0001 - 27% < 0.0001 + 22% 0.0036
IL-1Ra 24 h 5,094 (4,971–5,220) 4,501 (4,329–4,681) 4,531 (4,333–4,738) + 13% 0.0001 + 12% 0.0010 - 1% 1
TGF-β 24 h 2,175 (2,067–2,289) 2,264 (2,080–2,465) 2,219 (2,062–2,388) - 4% 1 - 2% 1 + 2% 1
IL-10 48 h 193 (180–207) 181 (166–198) 201 (181–224) + 6% 1 - 4% 1 - 10% 1
IL-6 24 h 6,590 (5,962–7,284) 5,610 (4,641–6,782) 5,283 (4,373–6,383) + 17% 1 + 25% 0.7859 + 6% 1
IL-17 7 days 160 (137–186) 106 (83–136) 103 (88–122) + 51% 0.7123 + 54% < 0.0001 + 2% 1
IL-22 7 days 662 (618–711) 1,061 (914–1,231) 963 (860–1,079) - 38% 0.0002 - 31% < 0.0001 + 10% 1
Data were calculated by multivariate regression on ln-transformed data. The outcomes were transformed 
back from ln-transformed data to show predicted means in pg/mL. The Bonferroni correction was 
applied to the P values to account for the multiple comparisons made. CI = confidence interval.
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We hypothesize that the lower induction of proinflammatory cytokines may 
help explain the increased spread of modern Beijing strains across the globe. 
The presence of an IS6110 in the NTF chromosomal region is used traditionally 
to distinguish modern from ancient Beijing strains. Deletions that occurred 
after the insertion of IS6110 are used to further type the group of modern Beijing 
strains, but so far, there are insufficient epidemiological data to define a genetic 
subgroup within the modern Beijing strains that is driving its success. For this 
reason we decided to compare the group of modern Beijing strains as a whole to 
the other groups. 
A striking observation in the present data is that the ancient Beijing strains, 
which are considered as genetically heterogeneous96, showed a rather uniform 
cytokine response, and also that only four out of seven genetically modern 
Beijing genotype strains showed the distinctive low-inflammatory response. 
The modern strains that showed the lowest induction of proinflammatory 
cytokines may share specific properties that enable them to counteract or subvert 
effective host responses, and one could thus hypothesize that an even narrower 
Table 3.1  Cytokine induction in modern and ancient Beijing strains  
and Euro-American reactivation strains
Predicted mean (95% CI) (pg/mL)
Cytokine Length of 
stimulation
Modern  
Beijing strains
Ancient  
Beijing strains
Euro-American 
reactivation strains
% Difference for 
modern Beijing vs 
ancient Beijing strains 
p % Difference for 
modern Beijing vs 
Euro- American 
reactivation strains
% Difference for 
ancient Beijing vs 
Euro- American 
reactivation strains
IFN-γ 48 h 48 (40–57) 80 (67–95) 90 (76–107) - 40% 0.0288 - 47% < 0.0001 - 12% 1
TNF-α 24 h 300 (252–357) 365 (272–490) 623 (535–725) - 18% 1 - 52% < 0.0001 - 41% 0.3136
IL-1β 24 h 3,115 (2,954–3,285) 5,184 (4,823–5,572) 4,250 (4,082–4,424) - 40% < 0.0001 - 27% < 0.0001 + 22% 0.0036
IL-1Ra 24 h 5,094 (4,971–5,220) 4,501 (4,329–4,681) 4,531 (4,333–4,738) + 13% 0.0001 + 12% 0.0010 - 1% 1
TGF-β 24 h 2,175 (2,067–2,289) 2,264 (2,080–2,465) 2,219 (2,062–2,388) - 4% 1 - 2% 1 + 2% 1
IL-10 48 h 193 (180–207) 181 (166–198) 201 (181–224) + 6% 1 - 4% 1 - 10% 1
IL-6 24 h 6,590 (5,962–7,284) 5,610 (4,641–6,782) 5,283 (4,373–6,383) + 17% 1 + 25% 0.7859 + 6% 1
IL-17 7 days 160 (137–186) 106 (83–136) 103 (88–122) + 51% 0.7123 + 54% < 0.0001 + 2% 1
IL-22 7 days 662 (618–711) 1,061 (914–1,231) 963 (860–1,079) - 38% 0.0002 - 31% < 0.0001 + 10% 1
Data were calculated by multivariate regression on ln-transformed data. The outcomes were transformed 
back from ln-transformed data to show predicted means in pg/mL. The Bonferroni correction was 
applied to the P values to account for the multiple comparisons made. CI = confidence interval.
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subgroup within the modern Beijing strains is in fact responsible for its global 
emergence. In future epidemiological and experimental studies, mutations and 
deletions that occurred subsequently to the insertion of IS6110 in NTF in the 
evolution of modern Beijing strains will have to be assessed to define this group 
more specifically. 
The most striking difference in our study was the almost two-fold lower IL-1β 
production induced in PBMCs by modern compared to ancient Beijing strains. 
For IL-1Ra the opposite was found, further limiting the activity of IL-1β after 
stimulation with modern Beijing strains. IL-1β is increasingly recognized as an 
important cytokine involved in host defence against M. tuberculosis. IL-1β 
restricts mycobacterial growth in murine models, and IL-1β knockout mice are 
highly susceptible to mycobacteria. In humans, polymorphisms in IL-1β or IL-1R 
are associated with increased tuberculosis susceptibility and progression109. 
Modern M. tuberculosis Beijing strains also induced lower production of IFN-γ, 
which has a well-established role in protection against mycobacterial infections, 
including tuberculosis110,111. Apart from lymphocytes, innate immune cells (NK, 
NKT cells and γδT cells) also contribute to the production of IFN-γ in response 
to mycobacteria109,112. TNF-α production was strikingly lower in response to 
both types of Beijing strains compared to the Euro-American strains isolated 
from patients with reactivation tuberculosis. This is of specific interest because 
of the swift reactivation of tuberculosis after TNF-α blocking therapy113. TNF-α 
has a paramount role in granuloma formation and maintenance114 and 
contributes importantly to the balance of pro- and anti-inflammatory cytokines 
that determines the success of mycobacterial control115. 
IL-17, which was induced in higher amounts by modern Beijing strains, especially 
when compared to Euro-American reactivation strains, may act as a double 
edged sword: it facilitates the formation of mature granuloma, but in excess 
leads to enhanced neutrophil recruitment and concurrent lung tissue damage116. 
Interestingly, a zebrafish model shows that in the early phase granuloma 
formation IL-17 also facilitates bacterial spread117, which makes a high IL-17 
concentration possibly favourable to the bacteria112. In contrast, IL-22 production 
was lower in modern Beijing strains. IL-22 is produced in the lung and has been 
found in bronchoalveolar lavage fluid118. In general, it provides the crosstalk 
between immune cells that produce IL-22 but lack the receptor and nonimmune 
cells – e.g. lung epithelium cells – that do express the IL-22 receptor. Activation 
of the IL-22 receptor on these cells leads to upregulation of several chemokines 
in the lung119. Lower production of IL-22 as found in modern Beijing strains 
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might thus lead to lower expression of chemokines, possibly favouring 
outgrowth of M. tuberculosis. However, a definitive role of IL-22 in human 
tuberculosis still has to be confirmed: in a mouse model of tuberculosis the 
neutralisation of IL-22 did not increase the bacterial burden in the lungs116. 
In recent years a number of studies have examined whether M. tuberculosis from 
different genetic backgrounds induce strain-specific differences in cytokine 
production. In the global phylogeny of M. tuberculosis, evolutionary modern 
strains – bearing the TbD1 deletion, as all Euro-American and Beijing strains do 
– generally have a tendency towards inducing a lower cytokine response, as 
recently comprehensively shown in a macrophage infection model by Portevin 
et al.120. Other studies, using small numbers of strains from a wide range of 
lineages, show the existence of clear but ill-reproducible differences (extensively 
reviewed by Coscolla et al.121). However, it is likely that most of the evolution of 
M. tuberculosis occurs within its main lineages and our study is the first with a 
comprehensive assessment of immune stimulatory capacity of intralineage 
strains. These lineages show a distinctive geographical pattern10 and may adapt 
to and shape the specific host population they encounter.
Few studies have examined cytokine production in multiple strains within one 
of the most successful lineages of M. tuberculosis, the Beijing genotype. Wang et 
al. found lower a TNF-α induction for Beijing strains compared to H37Rv and a 
trend towards lower TNF-α concentration after stimulation with two ancient 
Beijing strains122. In two macrophage infection models, one Beijing isolate 
appeared more immunogenic than H37Rv, with higher mRNA expression for 
IL-1β, TNF-α123 and IFN-γ124. Krishnan et al. found less TNF-α induction with 
the Beijing outbreak strain HN878 but variable results for other Beijing strains125. 
Kato-Maeda et al. compared Beijing strains with different ability to cause 
secondary disease in humans on their pathogenicity in guinea pigs. Strains 
were characterized using genetic Regions of Difference. Interestingly, guinea 
pigs appeared to be most susceptible to ancient Beijing strains (RD207-). In line 
with our study, the authors of this study found that strains in modern sublineages 
RD142- and RD150- induced less TNF-α mRNA. Expression of IFN-γ mRNA 
varied among the modern sublineages and IL-1β was not measured126.
To our knowledge, the present study is the first that specifically examines the 
successful sub-branch of modern strains within M. tuberculosis Beijing strains. 
There are, however, a few limitations to this study. To maximise standardisa-
tion, we used a model in which freshly isolated PBMCs were stimulated with 
heat-killed bead-disrupted lysates. Although these lysates, stored in many 
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similar aliquots, produce highly reproducible cytokine patterns, they of course 
lack some of the lipid structures present in the M. tuberculosis cell wall. In 
addition, the use of PBMCs may not fully reflect the response of resident tissue 
macrophages, although it is not logical to expect that the differences in cytokine 
profiles we have found would be reversed in macrophages, which are related to 
circulating monocytes. An alternative approach would have been to infect 
macrophages with live mycobacteria. This interesting model has the disadvantage 
of less reproducibility and absence of lymphocytes. Also, differences in growth 
kinetics or mycobacterial gene-expression under specific conditions may by 
itself lead to differences in cytokine induction. Yet another model would be to 
measure circulating cytokines in patients infected with different genotype 
strains, though possibilities are limited by differences in disease status, the high 
variety of genotype groups that hinder sound statistical analysis as well as the 
fact that plasma cytokine concentrations are generally low in tuberculosis 
patients. An Ethiopian study designed this way hinted at a lower induction of 
IL-4 in patients infected with Euro-American strains compared to East-African 
Indian strains127.
As a strong point, our study design and approach to analyse the results are 
thorough and innovative. We used 10 donors and 20 different strains belonging 
to three subgroups (modern and ancient Beijing strains as well as tuberculosis 
reactivation strains). This approach provided enough statistical power to detect 
meaningful differences despite variation between donors and different strains 
within one subgroup, as was clearly the case for modern Beijing strains. 
Hierarchical clustering, which so far is mostly used for gene expression datasets, 
was used to analyse cytokine signatures. Radar graphs were used to graphically 
represent cytokine-specific differences between groups of the three groups of 
M. tuberculosis strains. 
We conclude that modern Beijing strains show lower induction of IL-1β, IFN-γ 
and IL-22 and higher IL-1Ra in vitro compared to ancient Beijing strains and 
Euro-American reactivation strains. This differential immune induction might 
contribute to the epidemiological success of the modern M. tuberculosis Beijing 
strains. 
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Supplementary figures
Supplementary figure 3.1 
For quality control, M. tuberculosis H37Rv was grown in two different laboratories. Heat-killed, 
bead-disrupted lysates of the two stocks were used to stimulate peripheral blood mononuclear cells 
(PBMCs) of four donors. RPMI and heat- killed Candida hyphae ware used as controls. Below the 
mean and standard deviation are shown for IL-1β (after 24 h stimulation), TNF-α (24 h), IL-6 (24 h), 
IFN-γ (48 h), IL-10 (48 h) and IL-17 (7 days). The results are comparable for the stock from the Dutch 
National Tuberculosis Reference Centre (RIVM, shown in red) and Leiden University Medical Centre 
(LUMC, blue).
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Supplementary figure 3.2  Strain-associated differences in cytokine production 
of ten healthy donors to 7 modern Beijing (red), 7 ancient Beijing (blue) and 6 
Euro-American reactivation strains.
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Supplementary figure 3.3  Donor-associated differences in cytokine production 
to modern (red) and ancient Beijing (blue) strains.
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Abstract
Rationale
Successful transmission of tuberculosis depends on the interplay of human 
behaviour, host immune responses, and M. tuberculosis virulence factors. 
Previous studies have focused on identifying host risk factors associated with 
increased transmission, but the contribution of specific genetic variations in 
mycobacterial strains themselves are still unknown. The objective of this study 
is to identify mycobacterial genetic markers associated with increased transmis-
sibility and to examine whether these markers lead to altered in-vitro immune 
responses. 
Methods
From the comprehensive Dutch tuberculosis registry (n=10,389), a set of 100 M. 
tuberculosis strains either least or most likely to be transmitted after controlling 
for host factors was identified. These were subjected to whole-genome sequencing 
and evolutionary convergence analysis, and this analysis was repeated in an 
independent validation cohort (n=143). Immunological experiments were 
performed to measure in-vitro cytokine production and neutrophil responses to 
a subset of the original strains with or without the identified mutations 
associated with increased transmissibility. 
Findings
The mycobacterial loci espE, PE-PGRS56, Rv0197, Rv2813–2814c, and Rv2815–2816c 
were identified as targets of convergent evolution among transmissible strains. 
Four of these regions could be validated in an independent set of strains, and 
mutations in three targets affected in-vitro monocyte and T-cell cytokine 
production, neutrophil reactive oxygen species release, and apoptosis. 
Interpretation
The convergent evolution of M. tuberculosis toward enhanced transmissibility is 
paralleled by specific genetic markers, which are associated with altered 
immune responses in vitro. 
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Introduction
Transmission of pulmonary tuberculosis occurs through inhalation of small 
droplet nuclei containing M. tuberculosis bacilli that enter the lungs, evade 
killing by the innate immune system, and replicate intracellularly. If a series of 
transmission events occurs over a relatively short time, one can identify a group 
of patients with M. tuberculosis strains that are genotypically highly similar. Ep-
idemiologists often use molecular fingerprinting to characterize the genetic 
similarity among a group of strains; strains that share a molecular fingerprint 
are described as ‘clustered’128 and are inferred to be the result of recent 
transmission rather than the reactivation of a previous infection. 
Host factors can affect tuberculosis transmission and disease progression129, but 
recent molecular epidemiologic studies have shown that M. tuberculosis strains 
also differ in their ability to cause pulmonary disease130, their proclivity to 
infect contacts131 or cause secondary cases9,101. This variability may reflect the 
strains’ ability to subvert innate122,132 and/or adaptive133,134 immunity, or their 
ability to exploit the host immune system by inducing a detrimental inflammatory 
response135 leading to tissue damage126,136 and formation of cavities that enable 
disease spread137. Cytokines play a pivotal role in these events; insufficient 
production of proinflammatory cytokines may lead to uncontrolled 
mycobacterial growth, while overproduction may lead to tissue damage20. 
Phylogenetic differences in cytokine response (chapter 3 and 120) suggest that 
specific microbial genetic determinants may underlie transmission related 
phenotypes. Several studies have used M. tuberculosis mutants in vitro and 
experimental models to identify the role of a few individual genes on transmis-
sion-associated phenotypes138. However, further elucidation of the full spectrum 
of genes affecting transmission could improve our understanding of the 
host-pathogen relationship in tuberculosis. 
We aimed to identify loci under positive selection for clustering by analysing 
whole M. tuberculosis genomes from clustered and unclustered isolates for 
evidence of convergence. Following the hypothesis that clustered strains have 
consistent genetic differences compared to unclustered ones, and that the genes 
or intergenic regions implicated in these differences affect the host immune 
response, we performed a functional validation of the newly identified targets 
of independent mutation (TIMs) by measuring in-vitro cytokine production and 
neutrophil responses.
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Methods
Clinical isolates
We selected 100 mycobacterial strains with extreme phenotypes at both ends of 
a transmissibility spectrum. We considered strains to be highly transmissible if 
they came from clusters of active tuberculosis cases lacking known risk factors 
for being part of a cluster. Similarly, we considered strains to be minimally 
transmissible if they were unique (unclustered) and isolated from patients (e.g. 
homeless individuals with grade 3 sputum smear-positive pulmonary tuberculosis) 
with increased risk for clustering. To classify strains as such, we used data on 
host risk factors for clustering to estimate the cluster propensity to propagate 
(CPP), a summary measure of risk for transmission of patients belonging to a 
particular tuberculosis cluster139 (supplementary table 4.1). This CPP was calculated 
for 10,389 patient isolates, with clusters defined by DNA fingerprinting140,141. 
CPP was significantly higher in clustered versus unclustered strains, although 
the CPP rapidly plateaus with increasing cluster size (figure 4.1). Because there 
is no basis for sample size calculation in studies associating genomic variants 
with transmissibility142,143, we arbitrarily chose 100 strains for whole genome 
sequencing: 66 unclustered strains and 34 clustered strains. Strains for the 
clustered phenotype were picked at random from 56 unique cluster fingerprints 
(5 pairs of strains came from within the same cluster). The 100 selected strains 
were all drug sensitive and belonged to patients originating from 44 different 
countries. At least one strain from both phenotypes (clustered and unclustered) 
and from each the four major M. tuberculosis lineages was represented. In an 
independent dataset (n=143), we contrasted clustered and unclustered strains 
collected from patients of different geographical backgrounds. Most of these 
strains were drug resistant (supplementary table 4.2).
Phylogeny construction
Strains underwent whole genome sequencing and variants were called (see 
Supplementary methods). We then constructed a phylogeny on the basis of 
multiple-sequence alignment of the sequences, excluding single nucleotide 
polymorphisms (SNPs) that occurred in repetitive elements, including Pro-Glu 
(PE), Pro-Pro-Glu (PPE) and polymorphic GC-rich sequence (PGRS) genes.
Phylogenetic convergence test for selection 
We used our previously developed method, the phylogenetic convergence test 
for selection, to identify genetic loci associated with clustering. For each 
nucleotide position in the genome, we counted the number of convergent SNPs 
and insertions/deletions (“Indels”) in clustered and unclustered branches 
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respectively, counting only one strain per cluster. We therefore assessed the 
significance of each convergent SNP or Indel compared to the empirical 
background distribution using a permutation test142.
Protein prediction
We used two protein prediction algorithms, I-Mutant v2.0 (http://folding.biofold.
org/i-mutant/i-mutant2.0.html) and PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/), to predict the functional impact of the significant SNPs on protein 
structure and function.
Immunological experiments
Nineteen strains from the initial study were recultured, heat-killed and 
bead-beaten. Peripheral blood mononuclear cells (PBMCs) from 12 healthy 
donors were stimulated with 3 μg/mL of lysate for production of TNF-α (4 and 
24 h), IL-1β, IL-1RA, IL-6 and IL-10 (24 h) and T-cell cytokines IL-17, IL-22 and 
IFN-γ (7 days) (see chapter 3 for the methods. We also stimulated isolated poly-
morphonuclear cells (PMNs, largely consisting of neutrophils) for one hour and 
measured the production of reactive oxygen species (six donors) after six hours 
using luminal-enhanced chemiluminescence, and neutrophil apoptosis and cell 
death with flow cytometry (eight donors). We constructed multivariate mixed 
models to exploit the covariance between assays and to control for lineage effect 
and inter-donor variability and compared null models without assay-specific 
TIM indicators to full models with these indicators using Likelihood Ratio tests.
Results 
Targets of independent mutations (TIMs)
The primary set of 100 selected strains included 66 clustered isolates with a low 
predicted CPP (mean CPP 0.75; sd=0.01) and 34 unclustered isolates with a high 
predicted CPP (mean CPP 1.02; sd=0.30) (figure 4.1). We conducted two parallel 
phylogenetic evolutionary convergence tests to identify either individual 
nucleotide positions, or genes and intergenic regions where cluster-associated 
mutations occur frequently along disparate locations in the phylogenetic tree 
(figure 4.2). Region-level phylogenetic evolutionary convergence tests detected 
three genes and two intergenic regions as statistically significant TIMs (p<0.05) 
(table 4.1). A total of 12 SNPs, 2 insertions and 31 deletions were found in these 
TIMs, including 1 SNP and 2 deletions that were also significant by the site-level 
phylogenetic evolutionary convergence test (supplementary table 4.3). TIMs in 
the PE-PGRS56 gene occurred solely in clustered branches, while those in espE, 
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Rv0197, Rv2813-2814c and Rv2815-2816c were also found in unclustered branches, 
but at a lower rate than in clustered branches (depicted for espE in supplementary 
figure 4.1). 
Analysis of the validation set of 143 strains confirmed four out of five genes or 
intergenic regions (table 4.1) including Rv0197, in which the phylogenetic 
convergence test detected the same nonsynonymous coding site (234,477TG). 
The TIMs occurring in the PE-PGRS56 gene could not be validated, because 
their occurrence in the original dataset was mostly restricted to lineage 1, which 
made up only 3.4% of the validation dataset.
Figure 4.2  Consensus Bayesian phylogenetic tree. 
Clustered strains and M. tuberculosis lineages are highlighted. CAS = Central Asian; EAI = East African- 
Indian; LAM = Latin American-Mediterranean.
Clustered strain
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Deleterious effect of SNP TIMs on proteins
All 12 SNPs in genes Rv0197 and espE are predicted to adversely affect the 
respective proteins (supplementary table 4.4), including two TIMs in Rv0197 
(234,265GT and 234,477TG) that result in a STOP codon and truncation of the 
protein. 
Association between TIMs and induction of cytokine responses 
Reasoning that genetic variation associated with transmissibility might be 
mediated through host response we next examined in-vitro cytokine responses 
in strains with and without convergent changes. The distribution of TIMs across 
the strains is depicted in supplementary figure 4.2 and supplementary table 4.5.
Mutations in two of the targets we identified, espE and Rv2813-2814, were 
associated with alterations in monocyte cytokine production (p<10-4, table 4.2, 
figure 4.3) in the multivariate mixed model. In the secondary analysis (see 
online supplement), mutations in espE were associated with decreased 
production of IL-10 (p=1.7 x 10-8, figure 4.4A) and TNF-α (at 4 hours, p=8.0 x 
10-3), and mutations in Rv2813-2814c were associated with increased production 
of TNF-α (p=2.5 x 10-3), IL-1β (p=7.7 x 10-3) and IL-10 (p=1.9 x 10-3). Of the five 
genes or intergenic regions, only PE-PGRS56 affected T-cell cytokine responses 
(p=5.4 x 10-3), and in our secondary analysis, this was associated with lower 
IFN-γ production (p=1.6 x 10-3, figure 4.4B). 
Association between TIMs and response of neutrophils 
We next examined the effects of TIMs on in-vitro responses of neutrophils, given 
their putative role in transmission and clinical manifestation of tuberculosis in 
the same 19 strains. In the multivariate mixed effects model, we found that 
Rv2813-2814c affected PMN responses (p<10-4) with lower reactive oxygen 
species production (p=4.8 x 10-4, Figure 4.4C) and higher early apoptosis (p=3.6 
x 10-3) in secondary analysis.
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Figure 4.3   Response to M. tuberculosis strains with or without mutations in 
the three targets of independent mutation that showed an effect  
in the primary analysis. 
Relative differences for individual assays in the secondary analysis are indicated by the difference 
between the thick black line (mutation present) and the thin reference line (no mutation) for each of 
the following targets of independent mutation that significantly influenced at least one assay group: 
(A) espE, (B) PE-PGRS56, or (C) Rv2813–2814c. Shaded area represents the 95% confidence interval, 
corrected for the fact that five genes or intergenic regions were tested for each assay. *p<0.05/5 = 0.01. 
**Significant after further correcting for number of assays per group (i.e., p<0.05/[5 x 6] for monocyte 
cytokines and p<0.05/[5 x 3] for T-cell cytokines and polymorphonuclear neutrophil [PMN] assays). 
Significance in the primary analysis is indicated by a coloured confidence interval for monocyte 
cytokines (blue), T-cell cytokines (red), and PMN assays (green).
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Figure 4.4   In-vitro responses of selected assays for targets of  
independent mutation. 
Stimulation was performed with lysate of M. tuberculosis strains from lineage 1 (filled circles) and 
lineage 4 (open circles) that did not harbour (blue) or harboured (red) a mutation in (A) espE, (B) 
PE-PGRS56, or (C) Rv2813–2814c. Peripheral blood mononuclear cells (PBMCs) of 12 healthy donors 
(A–L) were stimulated. (A) IL-10 was measured after 24 hours. (B) IFN-γ was measured after 7 days. 
(C) Polymorphonuclear cells (PMNs) of six healthy donors (1–6) and reactive oxygen species were 
measured by luminol-enhanced chemiluminescence and plotted in arbitrary units of the area under 
the curve (AUC) of the measurement over the first hour after stimulation. Circles in A show overlap 
because of limited variation; only lineage 1 strain results are shown in B, because no mutations 
occurred in PE-PGRS56 genes in strains from lineage 4.
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Discussion 
We identified five genes and intergenic regions (espE, PE-PGRS56, Rv0197, 
Rv2813-14c and Rv2815-16c) as targets of independent mutation (TIMs) in 
clustered M. tuberculosis strains. We confirmed four out of five genes and 
intergenic regions in a second dataset despite differences in lineages and drug 
resistance profiles between the original and validation datasets. The TIMs we 
identified are predicted to alter the function of their respective proteins, and 
three of five identified genes or intergenic regions were associated with altered 
cytokine production or PMN responses, supporting the hypothesis that they 
confer a selective advantage for tuberculosis transmission. 
Previous experimental studies have established the importance of three of the 
identified genes or intergenic regions, including espE which proved essential for 
M. tuberculosis virulence in a number of animal studies144-146 (supplementary 
table 4.6). Further support for our findings stems from other genomic epidemi-
ological studies. Non-synonymous SNPs – albeit different from the ones 
identified in this study – and a frameshift mutation in espE were found to be 
more common in M. africanum strains relative to H37Rv147, and to be implied in 
their reduced ability to induce a CD4 T-cell ESAT-6 induced IFN-γ host 
response148,149. Similarly, a previous study identified a Large Sequence 
Polymorphism associated with clustering in a gene (MT1801) encoding 
molybdopterin oxidoreductase, which is also encoded by Rv0197150. In another 
study researchers reported that an M. tuberculosis strain responsible for a large 
outbreak in the United Kingdom harboured an insertion in position 3,121,877 of 
intergenic region Rv2815-2816c151, adjacent to the 2-bp deletion in 3,121,879 
Table 2   Cytokine profiles and PMN responses to M. tuberculosis according to 
the presence or absence of mutations in the five TIMs.
Gene or  
intergenic region
monocyte cytokines
(df=6)
T-cell cytokines
(df=3)
PMN responses
(df=3)
espE 1.33 x 10-6 0.961 0.077
PE-PGRS56 0.039 5.35 x 10-3 0.021
Rv0197 0.017 0.224 0.343
Rv2813-2814c 7.47 x 10-6 0.309 5.79 x 10-8
Rv2815-2816c 0.025 0.027 0.151
Significance (in bold) is determined at α = 0.05/5 = 0.01, corrected for the five genes or intergenic 
regions tested. df = degrees of freedom. PMN = polymorphonuclear cell.
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observed in our own study. 
Three of five genes or intergenic regions with TIMs associated with clustering of 
tuberculosis showed a clear and statistically significant effect on monocyte or 
T-cell cytokine production or PMN responses. M. tuberculosis strains with TIMs 
in PE-PGRS56 induced lower production of IFN-γ, which is unequivocally seen 
as a key factor in protection against tuberculosis20,110. Two other TIMs were 
associated with altered production of the monocyte cytokines IL-10 and TNF-α 
which are involved in M. tuberculosis killing as well as damaging immunopa-
thology, both of which may affect tuberculosis transmission20. In line with our 
previous comparison of in-vitro cytokine responses to different M. tuberculosis 
lineage strains in chapter 3, TNF-α and IL-6 induction in this study was higher 
in lineage 4 (ancient) compared to lineage 1 (modern) strains. These lineage 
effects may depend on strain selection, as shown by another study by Reiling et 
al.152 that found opposite results. The aim of our study was not to discern lineage 
effects; therefore we corrected for these lineage effects in our statistical model. 
With regard to neutrophils, strains harbouring cluster-associated mutations in 
Rv2813-2814c induced significantly lower reactive oxygen species production 
and early apoptosis. Neutrophils are considered protective during early 
infection, when they are recruited to the site of infection, phagocytose 
mycobacteria84 or mycobacteria-infected macrophages153, and resist 
mycobacterial growth using reactive oxygen species153. Children with chronic 
granulomatous disease have a reduced oxidative burst and are more susceptible 
to tuberculosis154. Neutrophil reactive oxygen species also correlates with 
apoptosis132. Although speculative, lower induction of reactive oxygen species 
production might as such contribute to disease progression and higher 
transmission of certain strains. 
This study has several limitations. First, phenotype misclassification, most 
notably that of highly transmissible strains as unclustered, is a possibility among 
“imported” strains (those belonging to patients born outside the Netherlands: 
53% versus 88% in unclustered and clustered strains, respectively). Average 
follow-up time however, as indicated by proxy data on ‘days resided within the 
Netherlands’ at the time of diagnosis, amongst ‘imported’ cases within the 
unclustered cohort was 3,607 days (ranging from 321 to 10,874 days). In other 
words, it is reassuring that, with the exception of one case (where days resided 
within the Netherlands was 321 days), all the remaining ‘imported’ cases 
classified as unclustered had been in the Netherlands for at least 4 years. Second 
the difference in drug resistance profiles and related parameters such as 
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treatment efficacy between the original and validation cohort of strains for 
the phylogenetic convergence test, could have introduced bias in measurement 
of the transmissibility phenotype (supplementary table 4.2). The fact that 
transmission of drug resistant strains has been widely documented155,156 and 
that mathematical models have estimated the transmission cost of drug 
resistance to be as low as 10% 157 suggests that the overall fitness for transmission 
of drug resistant strains is comparable to that of sensitive strains. The possibility 
for epistasis indeed exists – earlier this year for example, MDR strains in China 
with rpoC compensatory mutations were found to be more likely to be clustered 
than their drug sensitive counterparts158. Future phylogenetic convergence test 
tests stratified by drug resistance would identify such potential (positive or 
negative) epistatic mutations, as has already been attempted using epidemio-
logical tools159. In this study however, confirmation of four out of the five genetic 
markers associated with transmission in the validation dataset reduces the risk 
of false positive findings. Finally, the inclusion of additional key host factors that 
may influence disease transmissibility, such as the level of tuberculosis exposure 
(i.e. via prospective household contact data) and pulmonary cavitation, could 
improve our ability to isolate bacterial factors influencing transmissibility in 
the future.
Validating our findings on longitudinally collected strains from other low 
burden settings and at a nationwide level could further increase the significance 
of our results. An adequately sized and publicly available whole genome 
sequence dataset as described was not available at the time of our analysis. In 
high-burden tuberculosis settings we would expect crowding, treatment delays 
and host risk factors (i.e. malnutrition, uncontrolled diabetes) to be more 
important for transmission. These factors could be controlled for using the CPP 
measure. Whether the sum of all these factors acting in synergy to facilitate 
transmission in high burden settings translates into a reduced selective pressure 
for genomic adaptations in M. tuberculosis itself remains an interesting question. 
Of note, we performed in-vitro cellular stimulations aiming to find biological 
support for the epidemiological associations identified through convergent 
evolutionary analysis, and not to identify specific effects of individual TIMs on 
in-vitro cellular responses. Such effects cannot be identified in this study, as 
multiple TIMs were present in single strains in this dataset (supplementary 
table 4.5). For this purpose, additional studies using mutagenesis or recombina-
tion-mediated genetic engineering to isolate the mutational effects should be 
performed. It is no surprise that no single pattern of cytokine production or 
PMN response was found for the five genes or intergenic regions, as M. 
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tuberculosis has different strategies to subvert or resist the host immune system 
or use it to its advantage.
In summary, we present evidence from an evolutionary convergence analysis 
that five M. tuberculosis genes or intergenic regions confer a selective advantage 
promoting the transmission of M. tuberculosis and/or tuberculosis disease 
progression, and that these genetic elements influence the response of the host 
to the mycobacteria. These findings serve as an important step forward in the 
quest for an improved understanding of the microbial genetic determinants of 
tuberculosis transmission. 
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Supplementary methods
Background of strains
The National Institute for Public Health and the Environment (RIVM) in 
Bilthoven serves as a tuberculosis reference laboratory for The Netherlands. 
Since 1993 all clinical isolates are genotyped, using IS6110 and polymorphic 
GC-rich sequence (PGRS) restriction fragment length polymorphism (RFLP) 
until 2009, and variable number of tandem repeat (VNTR) typing from 2004 
onwards. Clusters were defined as groups of patients who shared M. tuberculosis 
strains with identical RFLP or VNTR patterns or, if strains had fewer than five 
IS6110 copies, identical PGRS RFLP patterns160. DNA fingerprints of all 
nationwide M. tuberculosis complex strains and their cluster status have been 
stored in a database since 1993. Phylogenetic lineages were ascertained based on 
a combination of spoligotyping, MIRU-typing and Restriction Fragment Length 
Polymorphisms (RFLP)-pattern similarity, as previously described139. 
Demographic and clinical information, provided by the Netherlands 
Tuberculosis Register (NTR), were linked to the strains on the basis of gender, 
date of birth, year of diagnosis and postal code. 
Validation dataset
The validation dataset contained no information on host risk factors, for which 
reason we compared clustered (belonging to a cluster of unique footprint and 
minimum size of 3, n=96) and unclustered (having a unique fingerprint and no 
epidemiologic links reported from contact investigation, n=47) strains. For 19 
clustered strains, single end 36bp read sequencing was previously performed 
which made calling Indels unreliable.
Sequencing, alignment and variant calling
DNA was extracted from all strains using standard methods and was sequenced 
on an Illumina HiSeq 2500 instrument using reads of 50bp in length in the 
paired-end modus. The average genome coverage was approximately 100x. 
FASTQ sequence reads were generated using the Illumina Casava pipeline 
version 1.8.3. Initial quality assessment was based on data passing the Illumina 
Chastity filtering. Subsequently, reads containing adapters and/or PhiX control 
signal were removed using an in-house filtering protocol. A second quality 
assessment was based on the remaining reads using the FASTQC quality control 
tool version 0.10.0. The quality of the FASTQ sequences was enhanced by 
trimming off low-quality bases using the ‘Trim sequences’ option of the CLC 
Genomics Workbench version 6.5. The quality-filtered sequence reads were then 
reassembled into a number of contig sequences using the previously mentioned 
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software. SNPs were called against reference strain H37Rv using Breseq software 
(version 0.23) using a minimum threshold of 15x coverage161. Breseq derives a 
consensus score from the read Phred scores by calculating the Bayesian posterior 
probability of possible sample bases given the observed read bases. Specifically, 
it uses a haploid model with five possible base states (A,T,C,G and a gap), 
assuming a uniform prior probability of each state and using an empirical error 
model derived from the based Phred score to update the prior with each read 
base observation. Consensus scores averaged over the genomes assayed for the 
SNPs and small insertions/deletions found to be associated to transmissibility 
are listed in supplementary table 4.3. Mutations with low-quality evidence (i.e. 
possible mixed read alignment) or within 5 bp of an Indel (insertion or deletion) 
were not included. Breseq has strict criteria for calling variants and although it 
did call variants that occurred in repetitive regions, such as the two site-specific 
deletions in PE-PGRS56 significantly associated to transmissibility, we manually 
inspected all of these to confirm that they were indeed high quality variants that 
did not fall within repetitive regions. It is worth mentioning that not every base 
within the Pro-Glu (PE), Pro-Pro-Glu (PPE) and polymorphic GC-rich sequence 
(PGRS) falls in a repetitive region and that high quality variant calls within 
these regions, if done carefully, is possible. All sequences have been rendered 
publically available through NCBI. The complete genome sequence for reference 
strain H37Rv was accessed from GenBank accession NC_000962.3. Raw 
sequences for the 200 strains from Bryant et al. are available at the European 
Nucleotide Archive (ENA) under accession ERP000111.
Phylogeny construction
The phylogeny was constructed on the basis of multiple-sequence alignment of 
the M. tuberculosis whole-genome sequences. The final concatenate of SNPs was 
used to construct phylogenetic trees using three different methods: parsimony 
(PHYLIP dnapars algorithm v3.68), Bayesian Markov chain Monte Carlo 
(MCMC) (MrBayes v3.2) and maximum-likelihood (PhyML v3.0) using the GTR 
model with eight categories for the gamma model. One hundred bootstrap 
re-samplings were performed for each tree, except for the Bayesian tree, where 
posterior probabilities on the branches were used as a measure of confidence. 
The three methods of constructing a phylogenetic tree showed fully consistent 
results, and the Bayesian tree was used for all subsequent analyses.
Phylogenetic convergence test for selection 
The phylogenetic convergence test for selection can identify positive natural 
selection based on homoplasy or parallel evolution. The phylogenetic 
convergence test is well suited for the study of clonal pathogens such as M. 
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tuberculosis143,162, having a higher sensitivity (and likely also specificity) than the 
dN/dS method163. The phylogenetic convergence test was conducted here as 
previously described163 with two modifications: we used Carmin-sokal 
parsimony for reconstruction of the phenotypic states as we thought this better 
mirrors our assumption that transmissibility evolves unidirectionally (i.e. from 
less to more transmissible); we also performed ancestral reconstruction of Indels 
using FASTML and maximum-likelihood criteria164. We controlled for the 
occurrence of SNPs or INDELs in strains belonging to the same cluster (as 
defined by MIRU- or RFLP-typing) by counting only one strain per cluster. Some 
background convergence is expected owing to neutral mutation and sequence 
error, even without positive selection. Sites are expected to be more significant 
with the phylogenetic convergence test if they occur in more branches than 
expected (based on the pattern of distribution of mutations at other sites) or if 
they occur in more clustered branches than unclustered branches. As this was a 
permutation test based on the observed frequency distribution for all variants 
across the genome, a 0.05 p-value threshold was used. In parallel we ran the 
convergence test grouping SNPs and Indels by the gene or intergenic region in 
which they occurred, using the same empirical resampling strategy to assess 
significance.
Protein expression of genes
Publically available proteomic data from Schubert et al. confirmed the expression 
of Rv0197 and espE under logarithmic growth conditions in liquid medium165. 
Mawuenyega et al. separated lysates into cell wall, membrane and cytosolic 
fractions and detected PE-PGRS56 in the membrane fraction166. 
Selection of clinical isolates 
Mycobacterial lineage is known to influence host immune response167. We 
therefore only selected strains from the whole genome sequence dataset 
belonging to lineages 1 and 4, both of which had five TIMs represented, so that 
lineage could be included as a factor in the statistical model. Nineteen out of 
twenty-one strains could be re-cultured, fifteen of lineage 1 and four of lineage 
4. Fifteen of the strains were of the clustered phenotype, four unclustered. The 
unclustered strains had a maximum of one mutation in the genes or intergenic 
regions associated to increased transmissibility, whilst all clustered strains had 
at least one TIM in the genes of interest (range 1–5), with the exception of strain 
F6 which had zero. H37Rv, the most well characterized strain of M. tuberculosis, 
was added for quality control of the experiments, but not included in the 
analysis. 
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Optimal timing of harvesting mycobacterial strains and different methods for 
lysate preparation were compared prior to the actual experiments (supplementary 
figure 4.3). Clinical strains were cultured in Tween-albumin medium on a 
shaking platform to determine the growth curve, and then recultured to harvest 
mid-log (OD600 0.6-0.8 for all strains) after a total of 5-7 passages from the clinical 
isolate. Strains were heat-killed, washed in phosphate buffered saline, lysed 
mechanically by bead-beating and divided in two aliquots. One aliquot was 
used for stimulation experiments and for measurement of protein concentration 
by the bicinchoninic acid protein assay. A second aliquot was freeze-dried to 
determine dry weight, and was used after resuspension for measurement of 
reactive oxygen species production. Protein-to-dry weight ratio did not differ 
substantially between isolates (supplementary figure 4.3). 
PBMC cytokine stimulation experiments 
Cytokine stimulations were done using strains with and without convergent 
changes using a previously established method. As described in chapter 3 (the 
results of which were confirmed by others168), buffy coats from 12 healthy 
volunteers (Sanquin Blood bank, Nijmegen, the Netherlands) were used for 
PBMC isolation. PBMCs were stimulated in duplicate in 96-well round-bottom 
plates with 3 uGu/mL of selected strains in a total volume of 200 μL. Previous 
studies identified 24h stimulation as the optimal period for monocyte-derived 
cytokines169,170. TNF-α at 4h was added because of its early release169 and its key 
role in protection from tuberculosis infection20. For IL-17 and IL-22, we 
performed dose (0.001-32 μg/mL) and time (3-10 days) response experiments to 
determine conditions.
After incubation at 37°C at 5% CO2 (in the presence of 10% human pooled serum 
for 7 day stimulation), cytokines were measured batch-wise in supernatants 
using ELISA after 4h (TNF-α, using R&D Systems, Minneapolis, Minnesota, 
USA), 24h (TNF-α, IL-1β and IL-1Ra, R&D; IL-6 and IL-10 using Sanquin, 
Amsterdam, the Netherlands) or 7 days (IL-17 and IL-22, R&D; IFN-γ, Sanquin) 
stimulation. Stimulation of PBMCs from six donors with three batches of H37Rv 
showed a mean standard deviation of 0.33 for TNF-α (coefficient of variation 
[CV] 5.5%) and 0.45 for IL-1β (CV 6.1%).
PMN reactive oxygen species and apoptosis experiments
Polymorphonuclear cells (PMNs) were isolated from EDTA blood using 
Ficoll-Paque, cleared from erythrocytes by hypotonic lysis buffer (two times) 
and washed two times in cold PBS. Reactive oxygen species were measured for 
six volunteers in white 96-well flat-bottom plates using luminol-enhanced 
chemiluminescence (5-amino-2,3,dihydro-1,4-phtalazinedione, Sigma-Aldrich, 
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St. Louis, Missouri, USA). PMNs were stimulated in 240 μL at 106 cells/mL in 
0.5% BSA HBSS with culture medium alone, zymosan (final concentration: 833 
μg/mL) or the 20 different M. tuberculosis strains (10 µg/mL). Chemiluminescence 
was measured at 37°C for the next 60 min, after which the area under the curve 
for luminescence was calculated. 
For apoptosis, PMNs of eight volunteers were stimulated for six hours with the 
different strains (10 µg/mL). We used IL-1β as anti-apoptotic control and 
cyclohexamide as positive control. Annexin V-FITC conjugate (Av, BioVision, 
Milpitas, California, USA) and propium iodide (PI) were added after stimulation. 
Annexin V stains phosphatidylserine translocating from the inner to the outer 
leaflet of the membrane, marking early apoptosis. PI stains nuclei from cells that 
are permeable, reflecting cell death, either from advanced apoptosis or 
necrosis171. Flow cytometric analysis using Cytomics FC50 was performed to 
distinguish Av-/PI- (alive) Av+/PI- (early apoptotic) and Av+/PI+ (advanced 
apoptotic / necrotic) populations. Optimal conditions for reactive oxygen 
species and apoptosis assays were defined prior to the actual experiments 
(supplementary figure 4.3). 
Data analysis for immunological experiments
In the immunological experiments, the effects of 5 genetic loci (or TIM = target 
of independent mutation) on the immunological readout were measured in 
multiple experiments performed with 19 different M. tuberculosis strains from 
two mycobacterial linages (lineage 1 and 4). The experiments involved 12 
different measurements and were performed with isolated 12 donors (PBMC 
experiments) and 6-8 other donors (PMN experiments). The experiments 
involved three groups of assays based on cell type and time-point: 6 early (4h 
and 24h) monocyte cytokines, 3 later (day 7) T-cell cytokines and 3 PMN 
responses.
Cytokine concentrations and reactive oxygen species area under the curve 
(AUCs) were Ln-transformed. Several of the outcomes were correlated and 
therefore a linear mixed model was appropriate for data analysis. Because the 12 
assays fall into three biological groups, our primary analysis involved three 
separate mixed models, which were run for each of the five TIMs separately, 
according to this formula:
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Yi,j = assay*lineagei,j + assay*donori,j + assay*TIMi,j + random effect for straini
Y = assay outcome measure
assay * lineage = indicator for the combination of assay (6,3,3) and lineage (2)
assay * donor = indicator for the combination of assay (6,3,3) and donor (12 for 
PBMC, 6-8 for PMN experiments)
assay * TIM = indicator for the combination of assay (6,3,3) and TIM (1)
i = M. tuberculosis, j = donor observation
We took a two-step approach to conserve statistical power inspired by the 
inheritance procedure172. First, for each assay group and each TIM, we tested 
whether the presence of a TIM was associated with differential response by 
comparing null models without assay-specific TIM indicators to full models 
with these indicators using Likelihood Ratio tests (table 4.2). Second, in case a 
TIM gene or intergenic region was associated with differential response for a 
particular set of assays, we examined and discuss assay-specific effects of a TIM. 
Note that we reported all assay-specific results for future reference, also if the 
likelihood ratio test was not significant (online supplement). In both analyses, 
significance was determined at α=0.05/5, Bonferroni corrected for the five TIM. 
All analyses were performed using Stata MP, version 12.1. Radar graphs show 
the percentage change for each of the assays, plotted on a logarithmic axis.
Ethics statement
The Registration Committee of the Netherlands Tuberculosis Register approved 
the retrospective access to strains and provided demographic and clinical 
information for patients. Because the data are de-identified by name, DNA 
fingerprinting results from the RIVM were linked on the basis of sex, date of 
birth, year of diagnosis and postal code. PBMCs and PMNs were isolated from 
volunteers with written informed consent and approval from the Ethics 
Committee of Radboud University Medical Center, Nijmegen, the Netherlands.
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Supplementary figures
Supplementary figure 4.1  Pairwise convergence for SNPs in gene espE (Rv3864). 
Branches in red represent clustered isolates, stars denote locations in the tree where TIMs associated 
with increased clustering occurred.
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Supplementary figure 4.2  Distribution of TIMs in the five genes or  
intergenic regions associated to clustering across the 15 lineage 1 strains 
selected for functional validation studies. 
Phylogenetic relationship between strains taken from the lineage 1 portion of the original Bayesian 
tree in Figure 4.2.
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Supplementary tables
Supplementary table 4.1   Summary of host risk factors taken into consideration
to calculate the Patient Propensity to Propagate (PPP)*.
Category Odds ratio Case group  Reference
Sex 1
0.87
males 
females
173-175
Age at diagnosis 1.05
1
0.86
0.77
0.49
0.19
0.12
0-15
16-30
31-45 
46-60 
61-75
76-90
 >90 years
129,173,174
Disease classification 1
0.76
0.90
pulmonary
extrapulmonary
pulmonary + 
extrapulmonary
129,173,176
Smear-positivity 1
1.17
no
yes
173,174,177
Alcohol consumption 1
1.29
no
yes
173,174,176,178
Drug-use 1
2.75
no
yes
173,174,176,178
Homelessness 1
1.58
no
yes
173,174,178
Traveller to endemic areas 1
0.58
no
yes
179-181
Origin 1
0.28
0.76
1.06
0.43
native Dutch
foreign-born (Asia)
foreign-born (Africa)
foreign-born (America)
foreign-born (Europe)
129,173,174,176,177
* The geometric mean of the PPPs across the cluster was used to calculate the Cluster Propensity to 
Propagate (CPP). Of note: it can be argued that some of these host risk factors, such as smear positivity, 
may be controlled by bacterial genetic factors. Because of the likelihood of an interplay between host 
and bacterial factors we took the more conservative approach of including the risk factor through our 
CPP measure, thus decreasing the likelihood of finding a difference between the “transmissible 
strains” and “non transmissible strains” explained by smear positivity.
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Supplementary table 4.2  Description of validation set of strains including 
host risk factors.
Original dataset Validation dataset
Clustered 
strains 
(n=66) 
Unclustered 
strains 
(n=34)
Clustered 
strains 
(n=96)
Unclustered 
strains 
(n=47)
Publication source
Farhat et al.142 - - 50 (52%) 47 (100%)
Bryant et al.182 - - 46 (48%) -
Mutations called
SNPs & Indels 66 (100%) 34 (100%) 77 (80%) 47 (100%)
SNPs only - - 19 (20%) -
Lineage
1 (EAI) 22 (34%) 6 (18%) 4 (4%) 1 (2%)
2 (Beijing) 8 (12%) 1 (3%) 21 (22%) 12 (26%)
3 (CAS) 10 (15%) 8 (23%) 3 (3%) 11 (23%)
4 (EAM) 26 (39%) 19 (56%) 62 (65%) 18 (38%)
M. bovis - - 1 (1%) -
Unclassified/T - - 5 (5%) 5 (11%)
Patient origin
Europe 10 (15%) 16 (47%) 12 (13%) 12 (26%)
Africa 13 (20%) 8 (23.5%) 22 (23%) 12 (26%)
Asia 40 (61%) 2 (6%) 4 (4%) 18 (38%)
The Americas 3 (4%) 8 (23.5%) 9 (9%) 1 (2%)
Unknown - 49 (51%) 4 (8%)
Drug resistance profile
Susceptible 66 (100%) 34 (100%) 35 (36%) -
Mono-resistant - - 5 (5%) -
MDR - - 36 (38%) 37 (79%)
XDR - - 4 (4%) -
Unknown - - 16 (17%) 10 (21%)
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Supplementary table 4.2  Continued.
Original dataset Validation dataset
Clustered 
strains 
(n=66) 
Unclustered 
strains 
(n=34)
Clustered 
strains 
(n=96)
Unclustered 
strains 
(n=47)
Gender
Male 35 (53%) 23 (68%)
NA
Female 31 (47%) 11 (32%)
Age at diagnosis
0-15 - 1 (3%)
NA
16-30 25 (38%) 13 (38%)
31-45 12 (18%) 15 (44%)
46-60 15 (23%) 5 (15%)
61-75 10 (15%) -
76-90 4 (6%) -
>90 years -- - -
Disease classification
Pulmonary      36 (54.5%) 27 (79%)
NAExtrapulmonary                   20 (30%) 1 (3%)
Pulmonary + 
Extrapulmonary         
10 (15.5%) 6 (18%)
Smear positivity
No 38 (58%) 6 (18%)
NA
Yes        28 (42%) 28 (82%)
Alcohol consumption
No 66 (100%) 32 (94%)
NA
Yes - 2 (6%)
Drug-use
No 65 (98%) 29 (85%)
NA
Yes 1 (2%) 5 (15%)
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Supplementary table 4.2  Continued.
Original dataset Validation dataset
Clustered 
strains 
(n=66) 
Unclustered 
strains 
(n=34)
Clustered 
strains 
(n=96)
Unclustered 
strains 
(n=47)
Homelessness
No 66 (100%) 33 (97%)
NA
Yes 1 (3%)
Traveller to endemic areas
No 63 (95%) 34 (100%) NA
Yes 3 (5%) -
NA: not available
Supplementary table 4.3  Genomic positions of SNPs and Indels associated 
with the clustering phenotype.
    Mutations, deletions and 
insertions (N)
 
Genomic position: polymorphism Average 
Score*
In  
clustering 
strains
In  
non-clustering 
strains
p-value
espE 
4341369: T=>G 291.3 1 0 1
4341402: C=>T 35.1 1 0 1
4341402: T=>aC 32.7 5 0 0.8
4340408: A=>G 244.7 1 0 1
4340330: G=>T 908.2 1 0 1
4341224: G=>C 266.4 1 0 1
PE-PGRS56 
3943650: Δ3bp, Δ1bp 80.9 12 0 0.0027
3944270: Δ9 bp - 1 0 1
3943311: Δ9 bp - 1 0 1
3941910: Δ9 bp - 1 0 1
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Supplementary table 4.3  Continued.
    Mutations, deletions and 
insertions (N)
 
Genomic position: polymorphism Average 
Score*
In  
clustering 
strains
In  
non-clustering 
strains
p-value
Rv0197
234082: G=>A 314.2 1 0 1
234242: C=>T 250.3 1 0 1
234265: G=>T 502.7 1 0 1
234477: T=>G 335.9 1 1 1
234477: G=>T 301.8 16 8 0.0179
Rv2813-2814c
3119737: Δ512 bp - 1 0 1
3120432: +AGC, +AGCA 49.2 4 0 0.9998
3120031: Δ438 bp, Δ218 bp - 12 3 0.2542
3120395: Δ2 bp 54.6 1 0 1
3119592: Δ292 bp - 1 0 1
3120321: Δ74 bp - 5 1 1
3119913: Δ1 bp 19.75 2 1 1
3119663: Δ221 bp, Δ74 bp - 2 1 1
3119957: Δ438 bp - 1 0 1
3120469: Δ1,725 bp - 1 0 1
Rv2815-2816c
3122774: Δ144bp - 1 0 1
3122549: Δ72bp - 2 1 1
3122847: Δ144bp - 3 0 1
3123209: Δ75bp - 1 1 1
3122122: Δ72bp, Δ350bp - 4 0 0.9998
3121879: Δ2bp 247.6 1 1 1
3123284: Δ70bp, Δ142bp - 8 1 0.4468
Δ = deletion; + = insertion; p-values in bold denote mutations significant at the site-specific level. * 
For SNPs and small Indels in clustering strains.
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Supplementary table 4.4  Protein prediction for TIMs associated to an 
increased clustering phenotype.
Protein Prediction
Genomic 
position
Nucleotide 
change
Amino acid 
change
I-Mutant # PolyPhen &
espE
4,340,330 T=>G L21V Large Decrease of Stability NA
4,340,308 A=>G M47V Large Decrease of Stability NA
4,341,224 G=>C V319L Large Decrease of Stability NA
4,341,369 T=>G L367R Large Decrease of Stability NA
4,341,402 T=>C V378A Large Decrease of Stability NA
Rv0197
232,574 G=>T G115V No effect Probably damaging
233,564 G=>T R445L No effect Probably damaging
234,082 G=>A V618M Large Decrease of Stability Probably damaging
234,242 C=>T A671V No effect Probably damaging
234,265 G=>T E679 (STOP) Prediction not possible Prediction not possible
234,268 G=>T V680F Large Decrease of Stability No effect
234,477 T=>G Y749 (STOP) Prediction not possible Prediction not possible
NA: No homologs of espE were found therefore protein prediction was not possible.
Entries in bold denote that backwards mutations of these polymorphisms also occurred.
# I-mutant predicts free energy changes of protein stability upon a point mutation under different 
conditions
& PolyPhen predicts the possible impact of an amino acid substitution on the structure and function 
of a human protein using straightforward physical and comparative considerations.
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Supplementary table 4.6  Summary of relevant experimental findings on  
the functions of the five TIMs.
Gene Experimental findings
espE 
codes for an ESX-1 secretion-
associated protein.
Essential for survival of M. tuberculosis in C57BL/6J mouse 
macrophage144. 
Rv3616c, a homologue of espE is essential for in vivo 
survival of M. tuberculosis in C57BL/6J mice145.
Homologue of Rv3864 (espE) is an Esx-1 substrate required 
for virulence of M. tuberculosis in C57BL/6J and BALB/C-SCID 
mice146.
PE-PGRS56 
no data on function
One of the 10 most dominant M. tuberculosis H37Rv proteins 
found within both 30- and 90-day infected guinea pig lung 
samples183.
Rv0197  
codes for a possible 
oxidoreductase.
Contains the binding motif for molybdenum cofactor, a key 
component in tuberculosis pathogenesis184.
Upregulated during higB expression in M. tuberculosis 
H37Rv (important for bacterial survival under stress 
conditions encountered during infection)185.
Rv2813-14c 
not coding, intergenic region.
No published data.
Rv2815-2816c
contains promotor to both 
Rv2814c and Rv2815c
No published data.
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Abstract
Rationale
Damaging inflammation is thought to contribute to the high morbidity and 
mortality of tuberculous meningitis, but the link between inflammation and 
outcome remains unclear. 
Methods
We performed prospective clinical and routine laboratory analyses of a cohort of 
adult patients with tuberculous meningitis in Indonesia. We also examined the 
Leukotriene A4 Hydrolase (LTA4H) promoter polymorphism, which predicted 
CSF leukocyte count and survival of Vietnamese patients with tuberculous 
meningitis. Patients were followed for >1 year. 
Findings
We included 608 patients with tuberculous meningitis whom 67.1% had bacteri-
ological confirmation of disease and 88.2% had severe (i.e., grade II or III) disease. 
One-year mortality was 43.7% and strongly associated with decreased 
consciousness, fever, and focal neurological signs. HIV-infection, present in 
15.3% of patients, was associated with higher mortality and different CSF char-
acteristics, compared with absence of HIV infection. Among HIV-uninfected 
patients, mortality was associated with higher CSF neutrophil counts (hazard 
ratio [HR] 1.10 per 10% increase; 95% confidence interval [CI], 1.04–1.16), low CSF 
to blood glucose ratio (HR 1.16 per 0.10 decrease; 95% CI, 1.04–1.30), CSF culture 
positivity (HR 1.37; 95% CI, 1.02–1.84), and blood neutrophilia (HR 1.06 per 109 
neutrophils/L increase; 95% CI, 1.03–1.10). The LTA4H promoter polymorphism 
correlated with CSF mononuclear cell count but not with mortality (p=.915). 
Interpretation
A strong neutrophil response and fever may contribute to or be a result of 
(immuno)pathology in tuberculous meningitis. Aggressive fever control might 
improve outcome, and more-precise characterization of CSF leukocytes could 
guide possible host-directed therapeutic strategies in tuberculous meningitis. 
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Introduction
Meningitis is the most severe manifestation of tuberculosis, resulting in death 
or neurological disability of more than 30% of adult patients25,26. Previously 
identified factors associated with mortality of tuberculous meningitis include 
disease severity at time of presentation, drug resistance, HIV infection, low CD4 
cell counts among those HIV-infected, and low cerebrospinal fluid (CSF) cells 
and glucose level25,26,186-188. In addition, it has long been suggested that 
inflammation contributes to poor outcome of tuberculous meningitis, and adjuvant 
corticosteroids have shown to reduce mortality of tuberculous meningitis44.
The exact nature of the detrimental inflammatory response in tuberculous 
meningitis however remains unclear. A lower CSF cell count was associated 
with increased mortality among tuberculous meningitis patients in Vietnam186, 
but not in China189, nor South Africa190. The type of CSF cells may be important. 
On average, 70-90% of cells in the CSF are mononuclear cells26,40, mainly 
lymphocytes32, but up to a third of patients show a predominance of neutrophils41. 
Interestingly, among HIV-infected patients in South Africa, CSF neutrophils 
predicted the occurrence of tuberculous meningitis immune reconstitution 
inflammatory syndrome (IRIS)42. However, in HIV-negative tuberculous 
meningitis patients there are no published data relating CSF neutrophils with 
immunopathology or mortality.
A recent study linked Leukotriene A4 Hydrolase (LTA4H) rs17525495 genotype 
to CSF leukocyte count and patient survival. LTA4H converts instable 
Leukotriene A4 (LTA4) to the stable proinflammatory LTB4, and Vietnamese 
tuberculous meningitis patients with the gain-of-function TT LTA4H genotype 
showed a higher CSF leukocyte count and better survival with adjuvant corti-
costeroids, while patients bearing the hypo-inflammatory CC variant showed 
lower CSF cell numbers and no, or even a negative effect of corticosteroids191. To 
date, no other study has examined the effect of this LTA4H genotype on CSF 
inflammatory profile and survival of tuberculous meningitis.
Adjunctive therapy is topic of intensive research in tuberculosis192. Corticosteroids 
have a proven role in tuberculous meningitis44, while a range of other immuno-
modulatory drugs like thalidomide193, anti-TNF and recombinant inter feron-
gamma have been used sporadically194. Better understanding of immune-mediate 
pathogenesis of tuberculous meningitis is crucial to development of more effective 
adjunctive therapy. Therefore, we examined clinical parameters, routine CSF and 
blood haematology markers, and LTA4H genotype in relation to patient survival. 
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Methods
Setting and patients
In this prospective cohort study we included all patients more than 14 years of 
age who presented with suspected tuberculous meningitis between October 
2006 and June 2016 in a referral hospital in Bandung, Indonesia. Patients were 
considered suspect for tuberculous meningitis when they presented with 
subacute illness including headache, fever or focal neurological symptoms, 
irrespective of the presence or absence of pulmonary or other extrapulmonary 
tuberculosis. Patients underwent standardised screening that included CSF 
examination and chest radiography. Neurological status of tuberculous 
meningitis patients was classified according to modification of the British 
Medical Research Council (BMRC) definition as follows: grade I, normal 
consciousness, no neurological signs; grade II, Glasgow Coma Scale score of 
11-14 or 15 with neurological signs, and grade III, Glasgow Coma Scale score 
≤10 195. All patients were tested for HIV, retrospective HIV testing was done 
anonymously for those patients who died before consent was obtained or who 
were admitted before routine HIV testing was implemented in 2009. The study 
was part of the project “Optimization of diagnosis of meningitis”, approved by 
the Ethical Committee of Hasan Sadikin Hospital/Faculty of Medicine of 
Universitas Padjadjaran, Bandung, Indonesia. A subset of patients in this study 
was included in one of three randomised clinical trials evaluating intensified 
antibiotic treatment, for which separate ethical approval was obtained29,196 
(clinical trials registration NCT02169882).
Microbiological testing
Microbiological diagnosis of tuberculous meningitis was done using microscopy, 
solid Ogawa culture and liquid commercial culture, as well as using microscopic 
observation drug susceptibility assay (MODS, a liquid culture)197 after 2010. 
Four to 10 mL of CSF is concentrated by centrifugation at 3000 x g for 15 minutes, 
and CSF sediment is used for microscopy and culture. IS6110 PCR was performed 
retrospectively for a subset of 230 samples58, and Gene Xpert MTB/RIF has been 
used since 2015. Drug resistance testing is otherwise not routinely available in 
our setting, but genotypic drug resistance was measured through whole genome 
sequencing in 102 patients. Further microbiological testing included CSF 
microscopy and culture for bacteria and fungi, and cryptococcal antigen testing 
for those HIV-infected. CSF real-time PCR and serological testing for Toxoplasma 
gondii was performed retrospectively for HIV-infected patients198.
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Treatment and follow-up
Tuberculous meningitis was treated with a combination of rifampicin (450 mg, 
corresponding to approximately 10 mg/kg), isoniazid (300 mg), ethambutol (750 
mg) and pyrazinamide (1500 mg) for six months. For unconscious patients, 
drugs were given by nasogastric tube. As part of two published pharmaco-
kinetic studies29,199 and one ongoing RCT (NCT02169882), 47 patients received 
high-dose rifampicin, and 25 patients received moxifloxacin instead of 
ethambutol. Patients were given adjunctive dexamethasone, following the inter-
nationally accepted six-week tapering regimen starting at 0.3 mg/kg for grade I 
and 0.4 mg/kg for grade II/III tuberculous meningitis186, and switching to an 
equivalent dose of oral prednisolone in case of early discharge. Patients with 
newly diagnosed HIV infection were started on efavirenz-based antiretroviral 
treatment 4–8 weeks after the start of tuberculosis treatment200. Patients were 
followed prospectively for at least one year. Field doctors or nurses made phone 
calls, and a social worker conducted home visits for patients not returning after 
hospital discharge. Death after hospital discharge was assessed by interview of 
family members and retrieval of patients’ death certificates from local authorities.
LTA4H genotyping
Genotyping for rs17525495 LTA4H single nucleotide polymorphism (SNP) was 
performed using the TaqMan C__25593629_10 assay on the 7300 ABI real-time 
PCR system (Applied Biosystems, Foster City, CA). Samples with an 
indeterminate allele call could be assigned in a second run except for one, 
resulting in a final 99.8% call rate.
Case definitions 
Most meningitis patients in this setting present with subacute disease, and 
tuberculosis is the commonest cause25. Tuberculous meningitis was classified as 
“definite” if either CSF microscopy for acid-fast bacilli, M. tuberculosis culture or 
PCR was positive. Diagnosis of cerebral toxoplasmosis was based on toxoplasma 
PCR or neuroimaging198; cryptococcal meningitis on India Ink or CrAg 
testing201; and acute bacterial meningitis on Gram-staining. Based on prior 
evaluation of CSF characteristics of definite and clinically suspected cases in 
this cohort, patients were classified as having probable tuberculous meningitis 
if they had a CSF to blood glucose ratio <0.5 combined with a CSF cell count ≥5 
/μL. Patients for whom no alternative diagnosis was made and who presented 
with a CSF leukocyte count <5 /μL were classified as no meningitis. All 
remaining patients were classified as unknown diagnosis. Not all information 
listed in the recent consensus-based research definition for tuberculous 
meningitis202 was available, and a positive score according to this definition 
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suggesting “probable meningitis” (≥ 10 points in the absence of neuroimaging) 
was found in 36% of patients without meningitis, and 41.2% of those without a 
diagnosis according to our classification. For the purpose of this study, we 
therefore chose our own, somewhat more specific case definition for probable 
tuberculous meningitis.
Data analysis and statistics
Patient characteristics, presented as medians (with interquartile ranges) or 
proportions as indicated, were compared between HIV-infected and non-infected 
patients, and subsequent analyses were restricted to HIV-negative patients. 
Only patients with complete data for the respective variables were included for 
each analysis, as indicated in the legends of figures and tables. Kaplan-Meier 
curves were used to illustrate survival over time, with continuous predictors 
divided in three groups, with cut-offs allowed to deviate slightly from exact 
tertiles to improve interpretability of results. Glasgow Coma Scale score was 
treated as a continuous variable to avoid loss of power by stratification. All 
analyses were performed with RStudio in R 3.3.1. using the R packages ggplot2, 
reshape2, dplyr, openxlsx, tableone, survminer and Hmisc. Univariate and 
multivariate Cox regression was performed using the R package survival and 
hazard ratios as well as the result of log-likelihood ratio tests were reported. CSF 
cell counts and protein were positively skewed and therefore log-transformed, 
using a log10[x+1]-transformation to avoid having to exclude patients from 
regression analysis in whom either CSF cells or CSF protein were zero. Sensitivity 
analyses were performed excluding culture-negative cases, patients who did not 
start on corticosteroids, patients who participated in a trial or with known 
drug-resistant M. tuberculosis. Secondary analysis was done to distinguish early 
and delayed mortality, with early and late definitions based on the median time 
to death, to assure equal power for both groups. Secondary analysis for the 
genetic analysis involved a recessive model comparing the LTA4H TT genotype 
against the CC/CT genotypes combined. A correlation matrix was made using 
the R package corrplot with Spearman ranking, on pairwise-complete 
observations of all continuous variables. Multivariate analysis was performed 
as secondary analysis to explore dependence of predictors for clinical, CSF and 
blood variables separately, entering variables with p values < .1 in univariate 
analysis in the model. 
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Results
Clinical presentation and patient mortality
From 1186 patients with clinically suspected meningitis, we excluded 156 
patients with incomplete baseline data, 171 with no meningitis or an alternative 
diagnosis, and 251 with no final diagnosis. This left 608 tuberculous meningitis 
patients for further analysis, including 55.3% with culture-confirmed 
tuberculous meningitis and another 11.0% confirmed by in-house PCR or Gene 
Xpert. Patients generally presented with British Medical Research Counsil 
tuberculous meningitis Grade II (73.7%) or Grade III (14.5%) tuberculous 
meningitis; 52.0% had motor abnormalities, and 59.7% cranial nerve palsy. 
Ninety-three patients (15.3%) were HIV-infected, presenting with severe disease, 
with available median CD4 counts of 62 per blood (IQR 43-186) in 2014-2016. CSF 
examination showed typical abnormalities with elevated cell count and protein, 
and low glucose, especially among HIV-negative patients (table 5.1). Follow-up 
data were complete for 91.5% of patients at one month and 73.2% at one year. 
One-year mortality of patients with tuberculous meningitis was very high, with 
values of 60.0% (95% CI 47.8–69.9) for HIV-infected and 40.7% (95% CI 36.1–45.1) 
for HIV-uninfected patients (HR 1.99, 95% CI: 1.46–2.72, figure 5.1A), with a 
median time to death of 4 and 6 days after start of treatment respectively. As 
expected, those with the lowest Glasgow Coma Scale had the highest mortality 
(shown for 447 HIV-negative patients in figure 5.1B). We could not analyse an 
effect of adjuvant corticosteroids, as virtually all patients received corticoster-
oids (95.1% verified in individual case records). Isoniazid and/or rifampicin 
resistance (detected in 9 patients) was too infrequent to be analysed separately. 
The same was true for the use of high dose rifampicin (n=47), or moxifloxacin 
instead of ethambutol (n=25).
Baseline clinical and laboratory parameters as predictors for death
We restricted further analysis to the 515 HIV-negative patients because of large 
differences between HIV-infected and noninfected patients in terms of survival 
and laboratory parameters, and the relatively small number (n=93) of 
HIV-infected patients. Like Glasgow Coma Scale score, BMRC tuberculous 
meningitis grade was a very strong predictor of survival (table 5.2). Motor 
abnormalities and increased body temperature (figure 5.2A) also predicted 
mortality; risk estimates for these clinical markers were higher for early (0 - 6 
days) compared to late (7 - 365 days) mortality (supplementary table 5.1). 
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A focus on CSF characteristics revealed that low CSF to blood glucose ratio 
(figure 5.2B) and elevated protein were associated with death in univariate Cox 
regression, while the total CSF leukocyte count was not. However, a 10% increase 
in CSF neutrophil proportion, was associated with a 10% increase in the hazard 
for mortality. The sensitivity analysis in culture-confirmed cases showed that 
both neutrophil percentage and count increased risk of mortality. This indicates 
that neutrophils, rather than a decrease of mononuclear cells are responsible for 
this effect. Patients with more than 50% CSF neutrophils had a particularly high 
risk of dying (figure 5.2C). Interestingly, a low glucose ratio was more strongly 
associated with delayed than with early mortality, while CSF neutrophil 
proportion similarly predicted early and late mortality (supplementary table 
5.1). Similar or slightly higher risk estimates were found when the analysis was 
restricted to patients with a positive CSF M. tuberculosis culture (table 5.2). 
By itself, a positive CSF M. tuberculosis culture, reflecting a higher bacillary load, 
was associated with an estimated 1-year mortality of 44.4% (95% CI 35.5–47.3) 
Figure 5.1  Predictors for 365-day mortality due to tuberculous meningitis. 
(A) HIV-status in all patients and (B) Glasgow Coma Scale score in HIV-negative patients with 
survival tables for numbers at risk are shown below the Kaplan-Meier curves.
A
14
15
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compared with 34.8% (95% CI 27.7–41.2) for a CSF culture negative for M. 
tuberculosis. 
Blood neutrophilia (figure 5.2D) and corresponding leucocytosis were associated 
with higher 365-day mortality. In this analysis –still restricted to HIV-uninfected 
patients– patients with less than 1.3 x 109/L lymphocytes, and those with low (< 
0.30) or high (≥ 0.60 x 109/L) monocytes, showed a higher risk of dying. In 
secondary analysis, monocyte-lymphocyte ratio (ML-ratio), which has been 
linked to tuberculosis susceptibility203, was associated with mortality as well 
(HR 1.24, 95% CI 1.03–1.51, supplementary figure 5.1). Risk estimates for blood 
markers were similar for early and delayed mortality (supplementary table 5.1).
LTA4H genotype
Among 427 HIV-uninfected patients, 56.2% had a CC, 35.6% a CT, and 8.2% a TT 
rs17525495 LTA4H genotype (table 5.3). Clinical characteristics were not 
associated with genotype except for sex, but CSF mononuclear cells were 
different (median 91 cells/μL in TT vs. 65 cells/μL in TC and 109 cells/μL in CC). 
Total CSF leukocyte count, neutrophils, protein and CSF to blood glucose ratio 
were not associated with genotype. The percentage culture positivity decreased 
as a function of the presence of the T allele (p=.013), which is considered to be 
proinflammatory. LTA4H genotype was not associated with a difference in 
patient survival (table 5.2), also in sensitivity analyses excluding 177 patients 
with negative CSF culture (p=.585), 6 who had not received corticosteroids 
(p=.845), 9 who had isoniazid and/or rifampicin drug resistant tuberculous 
meningitis (p=.805) or 85 who participated in a trial  (p=.740). In a secondary 
analysis applying a recessive model, we increased power by combining CC/CT 
genotypes and compared against the TT genotype: the TT genotype showed a 
non-significant protective effect (HR 0.91, 95% CI 0.52–1.60), with a similar effect 
after adjustment for sex and age (HR 0.86, 95% CI 0.49–1.52) and an increased but 
still not significant effect after adjustment for Glasgow Coma Scale score (HR 
0.71, 95% CI 0.38–1.36). Indeed, among 175 patients with milder disease (Glasgow 
Coma Scale score 14-15) those with the TT genotype showed a trend towards 
better survival compared to the combined group with the CC or CT genotype 
(supplementary figure 5.2). 
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Prognostic markers - correlation and multivariate Cox regression 
analysis
We next examined the correlation of clinical, CSF and blood parameters linked 
with death. Age, fever, Glasgow Coma Scale score and motor abnormalities showed 
no correlation with one another, and were independently associated with 
mortality in Cox regression (figure 5.3, table 5.4). CSF neutrophil percentage, 
protein and glucose showed moderate correlation, and independently predicted 
death in multivariate analysis, while culture positivity did not. CSF markers 
showed only a weak correlation with blood leukocytes. Blood neutrophil count 
Figure 5.2   Inflammatory markers as predictors for 365-day mortality in  
HIV– negative patients with tuberculous meningitis. 
Kaplan-Meier curves are divided in tertiles with cut-offs rounded to meaningful numbers for (A) body 
temperature in °C, (B) CSF to blood glucose ratio, (C) CSF neutrophil levels as a percentage of the total 
CSF leukocyte count, and (D) blood neutrophil counts in 109 cells/L.
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was the sole blood inflammatory marker independently associated with death 
in a Cox regression model (neutrophil count correlates strongly with blood total 
leukocyte count and is the product of total leukocyte count and blood neutrophil 
percentage, both of which were not included in the model). Correlation matrices 
were similar for patients who died and those who survived the first year (not 
shown). 
Table 5.4   Multivariate Cox regression for clinical, cerebrospinal fluid  
and blood variables separately
    365-day mortality
  HR (95% CI) p
A Clinical
Age, per 10 years increase 1.16 (1.02–1.31) .015
Body temperature, per 1 °C increase 1.24 (1.06–1.46) .009
Glasgow Coma Scale score, per point higher 0.80 (0.75–0.86) <.001
Motor abnormalities present 1.50 (1.06–2.12) .020
B Cerebrospinal fluid
Neutrophils, per 10% increase a 1.10 (1.04–1.16) .012
Protein, per 10-fold increase 1.42 (1.06–1.90) .018
CSF to blood glucose ratio, per 0.10 increase 0.90 (0.80–1.01) .079
M. tuberculosis culture positive 1.13 (0.81–1.58) .455
C Blood
Neutrophils, per 1x109/L increase b 1.06 (1.03–1.10) <.001
Monocyte to lymphocyte ratio, per 0.10 increase 1.20 (0.97–1.47) .089
         
Multivariate Cox regression for survival including variables with a p value of < .1 in univariate 
analysis for 365-day mortality. Three separate models were run: for analysis of clinical variables, 412 
patients had complete data; for analysis of CSF inflammatory markers, 464 had complete data; and 
for analysis of blood inflammatory markers, 327 had complete data available.
a CSF neutrophil percentage was used because of its more common use in clinical practice and its 
stronger association as compared to count. 
b Blood neutrophil count was used being the multiplication of neutrophil concentration and total 
leukocyte count (both univariate predictors of mortality) together with the monocyte to lymphocyte 
ratio (resulting from secondary analysis).  CI = confidence interval; HR = hazard ratio.
Clinical parameters predicting tuberculous meningitis mortality | 133
Discussion
In a prospectively followed cohort of 608 tuberculous meningitis patients in 
Indonesia, one-year mortality was 43.7%. Mortality was linked with previously 
reported risk factors (HIV-infection, disease severity, neurological complications, 
and low CSF glucose) and several newly identified factors including fever, CSF 
culture-positivity, a predominance of neutrophils in CSF, and a high blood 
monocyte to lymphocyte ratio. Unlike a previous study in Vietnam we found no 
relation between the leukotriene A4 Hydrolase (LTA4H) promoter polymorphism 
rs17525495 and outcome.
Tuberculous meningitis is relatively rare, but responsible for a disproportionate 
number of tuberculosis deaths. Most studies are either relatively small, or 
compromised by low rates of bacteriological confirmation. Two large clinical 
trials conducted in Vietnam reported a nine-month mortality of 31.8% 186 and 
27.9% 26 for patients who received dexamethasone and standard dose rifampicin. 
Mortality in our cohort is higher (42.6% at nine months), possibly because 83% of 
our patients were not included in a clinical trial, or because our patients present 
with more advanced disease; the proportion of patients with grade I disease is 
12.0% in our cohort versus 32.3% and 39.1% in Vietnam. HIV was associated 
with a two-fold higher risk of death in this study, underlining the importance of 
early HIV diagnosis and treatment25.   
Because HIV strongly influences inflammatory phenotype and mortality, we 
concentrated further analysis on HIV-uninfected cases, making it the largest 
study on predictors of death in this group, with 67% of cases bacteriologically 
confirmed, and extensive follow-up. Our data clearly show that neurological 
complications, especially motor abnormalities, are strongly predictive of a poor 
outcome of tuberculous meningitis. Not unexpectedly, these risk factors weighed 
strongest for early mortality. Half of deaths in our cohort occurred in the first six 
days after start of treatment, mostly among those with the most-advanced stage 
of disease, again reflecting the importance of earlier diagnosis and treatment. 
We are the first to report that febrile patients have a higher risk of dying. Fever 
may reflect damaging inflammation or increased metabolism of a damaged 
brain, as has been suggested by increased mortality of stroke patients with 
fever204. Further study should determine if aggressive reduction of fever, as 
advocated in an excellent review on acute care management of tuberculous 
meningitis28, can improve outcome of tuberculous meningitis. Of note, mild 
hypothermia showed no benefit and even seemed harmful in an randomised 
controlled trial in acute bacterial meningitis patients205.
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Evaluation of CSF markers revealed that high neutrophil numbers strongly 
predicted mortality, while we did not find a higher fraction of neutrophils in 
patients with a short duration of disease (data not shown), unlike one earlier 
case series32. Neutrophils are capable of killing M. tuberculosis but may also play 
a detrimental role in tuberculosis84. Like in the lung206, M. tuberculosis can also 
infect neutrophils in the CSF207. Interestingly, a higher proportion of CSF 
neutrophils was associated with CSF culture positivity in studies from 
Vietnam208 and Brazil209, and with the occurrence of IRIS in South Africa42. 
High blood neutrophil counts, which did not correlate with CSF neutrophil 
counts, also predicted death. The association of a high monocyte to lymphocyte 
ratio to death provides further support for a possible detrimental role of a 
disregulated innate immune response in tuberculous meningitis. Of course, we 
should be careful about inferring a causal role for neutrophils in tuberculous 
meningitis-associated death, as higher CSF neutrophil counts might also be an 
epiphenomenon of unfavourable biological processes taking place in tuberculous 
meningitis. Clearly, the possible detrimental role of neutrophils in tuberculous 
meningitis needs more study. 
We confirmed that a low CSF to blood glucose ratio was associated with 
mortality, in line with sepsis studies linking cellular metabolism and death210. 
Our study also supports intensified antibiotic treatment as a beneficial strategy, 
as patients with a CSF culture positive for M. tuberculosis had a 37% increased 
hazard for mortality. In a recent randomized controlled trial, we found that high 
dose rifampicin administered intravenously, to compensate for poor CSF 
penetration of rifampicin, was associated with reduced mortality (HR 0.42; 95% 
CI 0.20–0.91)29. A larger randomized controlled trial in Vietnam failed to see an 
effect of a higher dose oral rifampicin26, but this may have been due to the 
modest dose increase in that study211.
It was recently shown that a polymorphism in LTA4H correlated with CSF 
leukocyte count and survival among 182 Vietnamese tuberculous meningitis 
patients191. This same LTA4H genotype was not associated with CSF leukocyte 
count or with survival in our genotyped cohort of 427 patients, also after 
correction for possible confounding factors such as disease severity as measured 
by Glasgow Coma Scale score. Late presentation, which increases mortality, 
might confound a possible effect of the LTA4H genotype and we therefore 
separately analysed patients with milder disease. Those with the TT genotype 
showed a trend towards better survival, so an effect in this subgroup cannot be 
excluded. Unlike the Vietnam study, we could not stratify the effect of LTA4H 
genotype for corticosteroid treatment, as all patients received adjuvant cortico-
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steroids according to international guidelines. Our findings suggest that more 
study is needed to understand the effect of host genetic background on 
tuberculous meningitis treatment response and outcome, although it will be 
difficult to examine this specific association outside East-Asia, due to a lower 
prevalence of the rs17525495 TT LTA4H genotype (1000 Genomes Project; 
available at http://www.internationalgenome.org/).
Our study has several strengths, including its size, high rate of bacteriological 
confirmation, and complete data and follow-up. We used a somewhat more strict 
case definition than a consensus definition202, which still needs evaluation in 
different settings. Unfortunately, neuroimaging and neurosurgical interventions 
were not available in this cohort. Also we have no verified treatment adherence. 
Finally, since our data are observational it is difficult to distinguish causation 
from association. 
In conclusion, this study strengthens the concept that damaging inflammation 
contributes to the presentation and poor outcome of tuberculous meningitis, 
and suggests that neutrophils play an important role in this effect. Further 
immunological, gene expression, metabolic and genetic studies could increase 
our understanding of immunopathology and help identify targets or genetic 
markers to guide host-directed therapy in patients with tuberculous meningitis.
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Supplementary figures
Supplementary figure 5.1  Blood inflammatory markers as predictors for 
365-day mortality in HIV-negative tuberculous meningitis patients. 
Kaplan Meier curves divided in tertiles with cut-offs rounded to meaningful numbers for blood 
lymphocytes (A) and monocytes (B) in 109 cells/L. C) Blood neutrophils versus blood monocyte- 
lymphocyte ratio. Individual survivors are indicated by grey open circles and nonsurvivors by red 
closed circles. Mortality was calculated for each of the four squares, which are divided by the overall 
medians. Patients with complete follow-up till day 365 are included only, which causes slight 
overestimation of proportion of nonsurvivors. One outlier (36.9 x 109/L neutrophils and ML-ratio of 
1) was removed from the graph to improve visibility of the other data points. 
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Supplementary figure 5.2  LTA4H rs17525495 genotype as predictor for 
365-day mortality in HIV-negative tuberculous meningitis patients stratified 
for disease severity. 
Kaplan Meier curves and risk tables for LTA4H genotypes CC (blue), CT (green) and TT (red) for 
patients with (A) severe (Glasgow Coma Scale score ≤ 13) or (B) milder (Glasgow Coma Scale score 
14-15) disease. In a recessive model in secondary analysis, TT genotype versus CT/TT combined had 
a HR 0.81 (95% CI 0.41–1.62, p=.550) in severe and HR 0.31 (95% CI 0.04–2.25, p=.156) in milder disease.
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Abstract
Rationale
Immunopathology contributes to high mortality in tuberculous meningitis  but 
little is known about the blood and cerebrospinal fluid (CSF) immune response. 
Methods
We performed the first in-depth immunophenotyping study combining blood 
and CSF flow cytometry and ex-vivo cytokine production in tuberculous 
meningitis patients. We prospectively characterised the immune response of 
160 tuberculous meningitis suspects in an Indonesian cohort, including 67 
HIV-negative probable or definite tuberculous meningitis cases. Pulmonary 
tuberculosis patients (n = 26) and healthy controls (n = 27) were recruited from 
the same site.
Findings
Tuberculous meningitis patients presented with severe disease and 38% died in 
6 months. Blood from tuberculous meningitis patients showed lower αβT and 
γδT cells, NK cells and MAIT cells compared to pulmonary tuberculosis patients 
(2.4-4-fold, all p<0.05) and healthy controls (2.7-7.6-fold, p<0.001), but higher 
neutrophils and classical monocytes (2.3-3.0-fold, p<0.001). CSF of tuberculous 
meningitis patients showed a predominance of αβT cells and NK with higher 
leukocyte activation compared to blood (1.8-9-fold, p<0.001), and CSF αβT and 
NK cell counts were both associated with better survival (p<0.05). Cytokine 
production in tuberculous meningitis showed a much broader range compared 
to both control groups (p<0.001). Among tuberculous meningitis patients, high 
ex-vivo production of TNF-α, IL-6 and IL-10 correlated with fever, lymphocyte 
count and monocyte HLA-DR expression (all p<0.05). 
Interpretation
Tuberculous meningitis patients show a strong myeloid blood response, with a 
broad variation in immune function. This may influence the response to adjuvant 
treatment and should be taken into account in future trials of host-directed 
therapy.
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Introduction
Meningitis is the most severe manifestation of tuberculosis, leaving 30-50% of 
patients deceased or disabled. Immune pathology is thought to play an important 
role in the poor outcome of tuberculous meningitis16. Adjuvant corticosteroids 
have shown an overall beneficial effect on survival in HIV-uninfected patients, 
especially in those with milder disease44 and are therefore part of routine care. 
It is conceivable, however, that a hypo-inflammatory subgroup of patients191 
would benefit from withholding corticosteroids as currently examined in 
HIV-negative patients (NCT02588196), while hyper-inflammatory patients may 
need additional anti-inflammatory treatment (trial completed, NCT02237365). 
More detailed information on the local and systemic immune response is needed 
to rationally select adjuvant agents and patient subgroups for improving 
host-direct therapy for tuberculous meningitis.
Routine cerebrospinal fluid (CSF) assessment only distinguishes mononuclear 
from polymorphonuclear cells. The latter, mostly neutrophils, make up on 
average one third of CSF cells, with higher proportions associated with a worse 
prognosis (chapter 5). Microscopic study of the remaining, mononuclear cells 
has shown wide variability of cell types and counts32. Analysis by flow 
cytometry has confirmed the presence of αβT and γδT cells, B cells and Natural 
Killer (NK) cells in CSF of tuberculous meningitis patients33,212, but these cells 
have not yet been quantified. NK cells can kill extracellular M. tuberculosis and 
trigger effector mechanisms in macrophages213. Other innate lymphocyte 
populations might also be of importance. Mucosal associated invariant T (MAIT) 
cells recognize M. tuberculosis and are found in the lung in pulmonary 
tuberculosis214. NKT cell number and function are reduced in the blood of 
tuberculosis patients215. Monocytes (myeloid mononuclear cells) recognise M. 
tuberculosis, steer immunity and mature into macrophages with killing 
capacity20. Only one study has examined ex-vivo monocyte responsiveness in 
tuberculous meningitis33.
In this study we first characterised and quantified leukocytes in a prospective 
cohort of tuberculous meningitis patients in blood and CSF. We then established 
immune phenotype based on ex-vivo whole blood cytokine assays, using pulmonary 
tuberculosis patients and healthy controls for comparison. We investigated 
whether separate ‘high-responding’ and a ‘low-responding’ immune phenotypes 
exist and possibly correlate with disease phenotype and outcome. 
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Methods
Setting and Patients 
We prospectively included all patients >14 years of age who presented with 
suspected tuberculous meningitis (subacute illness including headache, fever or 
focal neurological symptoms) between December 2014 and July 2016 in the 
Hasan Sadikin hospital in Bandung, Indonesia. This is a tertiary referral hospital 
with 966 beds, serving the population of West-Java (43 million). Standardized 
screening and diagnosis as ‘definite tuberculous meningitis’ (CSF culture or 
Gene Xpert positive) or ‘probable tuberculous meningitis’ (CSF to blood glucose 
ratio was <0.5 combined with a CSF cell count ≥5 cells/μL), followed the protocols 
established in chapter 5. Follow-up samples (day 2 and 10 for CSF and day 10, 60 
and 180 for blood) were done for a subset of patients included in a clinical trial 
on high-dose rifampicin with inclusion up until November 2016 (NCT02169882). 
After hospital discharge, patients were followed-up clinically at day 90 and 180. 
Patients not returning to the hospital were phoned by a social worker. Cause of 
death, obtained from hospital records or verbal autopsy for those who died after 
discharge, was classified as: primarily tuberculous meningitis-related (i.e. brain 
herniation or otherwise increased intracranial pressure); pneumonia or sepsis; 
other, including non-infection related causes, such as injury, pulmonary embolism 
and aspiration pneumonia. 
Pulmonary tuberculosis patients from the same hospital had chest X-ray 
abnormalities consistent with pulmonary tuberculosis and 25/26 patients were 
confirmed by positive sputum culture or smear. Asymptomatic pulmonary 
tuberculosis household contacts linked to the same study, who had no tuber-
culosis-suggestive symptoms or X-ray abnormalities and who were Interferon-γ 
Release Assay (IGRA)-negative were used as controls. HIV-infected patients or 
controls were excluded from final analysis. 
Ethics Statement
Samples for this study were collected as part of three ongoing studies approved 
by the Ethical Committee of Hasan Sadikin Hospital/Faculty of Medicine of 
Universitas Padjadjaran, Bandung, Indonesia. Tuberculous meningitis patients 
were included under the project “Optimization of Diagnosis of Meningitis” 
(449/UN6.C1.3.3/KEPK/PN/2015). This study sampled only at regular vene -
punctures and lumbar punctures moments that are part of routine care. Patients, 
or close relatives of patients who were unconscious therefore gave consent 
orally. Tuberculous meningitis patients who were part of the high-dose rifampicin 
study (NCT02169882), gave separate written consent for that study (299/UN6.
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C2.1.2/KEPK/PN/2014). Pulmonary tuberculosis patients were part of the TANDEM 
study216 (42/UN6.C1.3.2/KEPK/PN/2015) and healthy controls were part of 
the INFECT study (14/UN6.C2.1.2/KEPK/PN/2014). Pulmonary tuberculosis 
patients and healthy controls gave written consent for sampling. All samples 
were handled anonymized.
Flow cytometry
CSF was spun slowly (300 g) for 3 minutes to avoid cell activation, the sediment 
was resuspended immediately (median 0.8 hours, IQR 0.7-1.0) in 2.5 mL RPMI 
(ThermoFisher, 22409031) and stored at 4 °C prior to flow cytometry (median 8.7 
hours, IQR 4.0-16.2) later. Cell fixation interferes with measurement of activation 
markers and was therefore not performed. Blood was collected in lithium-heparin 
tubes and stored at 20-23°C. Blood and CSF samples were processed within 
24 hours of collection. Samples were divided in four equal parts, to which a fixed 
amount (5 μL for CSF, 30 μL for blood) of microparticles (Invitrogen 123count 
eBeads, 01-1234) was added for quantification, together with fluorochrome-labeled 
antibodies in four panels: A monocyte/neutrophil panel: CD14 (AF488), CD 16 
(PE), HLA-DR (PerCP) and CXCR4 (APC); a NK cell panel: CD3 (AF488), CD16 (PE), 
CD56 (PerCP) and CD69 (APC); a γδT / NKT cell panel: CD3 (AF488), Va24-Ja18 
(PE), Vδ2 (PerCP) and γδ-TCR (APC) and a MAIT cell panel: CD3 (AF488), Vα7.2 
(PE), HLA-DR (PerCP) and CD161 (APC). Data were acquired till 1,000,000 events 
(blood) or a maximum of two minutes (CSF), and were analysed using Kaluza 1.3 
(Beckman Coulter) using gating strategies depicted in supplementary figure 6.1A. 
Flow cytometry was started in the seventh month of the study. Routine counts 
were measured with the Sysmex XN-1000 throughout the study.
Ex-vivo whole blood stimulation assay
Stimuli were prepared in batches at 10 times the final concentration: M. 
tuberculosis H37Rv lysate (final concentration 5 μg/mL), Streptococcus pneumoniae 
lysate (106 colony forming units per millilitre, CFU/mL), Escherichia coli lysate 
(106 CFU/mL) and Candida albicans lysate (106 CFU/mL). Live Bacillus Cal-
mette-Guérin (BCG) was resuspended weekly from the vaccine bottle and used 
at 105 CFU/mL. Blood obtained in lithium-heparin tubes (Greiner) was stored at 
20-23°C and processed within 24h. Blood was diluted 1:4 with RPMI in a 24-well 
flat-bottom culture plate and incubated in the presence of the above mentioned 
stimuli, or left unstimulated, for 24h after which supernatant was stored in two 
aliquots at -80°C till batch-wise measurement by ELISA: interleukin-1 (IL-1β), 
IL-1 receptor antagonist (IL-1Ra), tumour necrosis factor alpha (TNF-α) (all from 
R&D Systems, Minneapolis, MN), and IL-6, IL-10 and interferon-gamma (IFN-γ) 
(Sanquin, Amsterdam, the Netherlands). 
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Data analysis
Samples were excluded if they did not meet the technical minimum requirements. 
For flow cytometry, reasons to exclude were: CSF sample obtained after start of 
dexamethasone, or not resuspended in medium within 2.5 h, or inadequate 
fluorochrome staining or inadequate microparticle count in one of four panels. 
For ex-vivo stimulation exclusion criteria were: blood sample obtained after 
start of dexamethasone, or processed more than 24h after acquisition, or TNF-α 
above the detection limit of 90 pg/mL for the unstimulated control. 
Analyses were performed in R 3.2.2 (http://www.R-project.org). Non-parametric 
tests were used for all continuous variables. For principal component analysis 
(PCA), the covariance matrix was calculated on log-transformed, mean-centered, 
cytokine data for tuberculous meningitis patients using the R package prcomp. 
Only stimuli for which data were complete were included. Patients and controls 
scores were subsequently projected on the principal components using this 
covariance matrix. A correlation matrix was made using Spearman correlation 
on pair-wise complete data. Survival analysis was performed using Cox regression 
with the R packages survival and visualised with survminer. Other packages 
used were corrplot, dplyr, openxlsx, reshape2 and tableone, and graphs were 
visualised using ggplot2 enhanced by cowplot. 
Results
Patients and quality control
Of 160 patients with suspected tuberculous meningitis who were immuno-
phenotyped, 47 HIV-negative patients did not meet the tuberculous meningitis 
case definition, and 29 were HIV-positive. After exclusion of samples because of 
technical issues or because sampling had been performed after the first dose of 
dexamethasone, 67 HIV-negative tuberculous meningitis patients could be 
included in the final analysis (table 6.1). These 67 patients, 69.0% of whom had 
culture-confirmed tuberculous meningitis, presented with severe disease, 94.4 % 
with grade II or III. Tuberculous meningitis patients were slightly younger than 
pulmonary tuberculosis patients and healthy controls, while sex was similarly 
distributed (table 6.1). Clinical follow-up was complete for all but one tuberculous 
meningitis patient and 180-day mortality was 40% (supplementary table 6.1, 
supplementary figure 6.1B). Cell counts as measured by flow cytometry showed 
good correlation with routine cell counts (R2 0.45-0.65 in blood, 0.53-0.70 in CSF, 
supplementary figure 6.1C), although they were systematically lower. The ratio 
of cell counts using flow cytometry compared to routine counts was 0.73 for 
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blood neutrophils, 0.76 for blood lymphocytes, 0.42 for blood monocytes, 0.19 for 
CSF neutrophils and 0.46 for CSF mononuclear cells. These values were not 
influenced by time from lumbar puncture to resuspension in medium or time to 
flow cytometric analysis (data not shown). Fifteen patients were excluded from 
ex-vivo cytokine analysis as result of a batch of contaminated lithium-heparin 
tubes. 
Figure 6.1  Patient inclusion diagram.
Of the 26 patients with pulmonary tuberculosis, one had no ex-vivo cytokine response available. Of the 
27 healthy controls, one had no ex-vivo cytokine response and one had no flow cytometry results 
available. LP = lumbar puncture. 
148 | Chapter 6
Table 6.1   Comparison of tuberculous meningitis (TBM) patients versus  
pulmonary tuberculosis (PTB) patients and healthy controls (HC). 
Presented are the baseline characteristics of age and sex, routinely obtained cell counts and cell counts 
by flow cytometry. Comparisons are made by Mann-Whitney U for blood of tuberculous meningitis 
versus PTB and HC respectively.
TBM PTB HC comparison (p)
42 26 26 TBM  
vs PTB
TBM  
vs HC    CSF blood blood blood
sex N–% male 23 (55%) 12 (48%) 10 (39%) 0.660 0.290
age year 27 (20–36) 31 (24–43) 37 (24–52) 0.042 0.024
routine haematology counts
total leukocytes × 109 cells/L 0.216 (0.136–0.430) 10.1 (8.8–12.0) 9.1 (7.6–10.7) 6.9 (5.8–7.5) 0.088 <0.001
neutrophils × 109 cells/L 0.069 (0.026–0.162) 8.6 (7.1–10.2) 6.4 (5.2–8.2) 4.0 (3.3–4.8) <0.001 <0.001
lymphocytes × 109 cells/L 0.138 (0.087–0.251) 0.8 (0.4–1.2) 1.5 (1.3–1.8) 2.3 (1.8–2.6) 0.005 <0.001
monocytes × 109 cells/L * 0.7 (0.5–1.0) 0.6 (0.5–0.8) 0.4 (0.3–0.5) 0.705 <0.001
thrombocytes × 109 platelets/L n/a 267 (229–347) 396 (345–480) 285 (240–326) <0.001 0.562
flow cytometry results
total leukocytes × 106 cells/L 68.4 (33.6–146.9) 7217.5 (5608.5–9258.6) 6998.1 (5129.2–8629.9) 4052.1 (3757.1–5058.8) 0.276 <0.001
CD16+ neutrophils × 106 cells/L 12.0 (2.2–47.9) 6000.8 (4254.4–8167.5) 5011.3 (3434.9–6522.6) 2026.3 (1847.6–2874.9) 0.038 <0.001
CD16low neutrophils × 106 cells/L 0.5 (0.1–5.1) 113.5 (56.8–268.7) 140.7 (100.9–221.6) 237.7 (139.2–265.8) 0.684 0.101
CD14+CD16- monocytes × 106 cells/L 1.3 (0.3–3.0) 300.2 (179.7–395.1) 260.9 (181.1–353.0) 124.8 (94.3–168.2) 0.408 <0.001
CD14+CD16+ monocytes × 106 cells/L 0.2 (0.1–0.5) 7.3 (2.1–15.7) 17.9 (13.0–44.8) 11.1 (5.8–18.9) 0.001 0.118
CD14-CD16+ monocytes × 106 cells/L 0.1 (0.0–0.3) 1.2 (0.5–1.8) 6.9 (3.5–23.2) 10.2 (2.2–18.0) <0.001 <0.001
CD56- NK cells × 106 cells/L 0.8 (0.3–2.4) 5.8 (2.5–9.4) 8.3 (5.5–20.6) 21.8 (14.7–32.7) 0.011 <0.001
CD56+ NK cells × 106 cells/L 2.7 (1.2–7.6) 48.9 (33.7–86.5) 169.6 (94.8–198.8) 164.2 (120.9–198.1) <0.001 <0.001
CD56bright NK cells × 106 cells/L 0.5 (0.2–1.3) 1.8 (0.8–3.4) 4.9 (3.2–6.9) 5.4 (3.9–7.4) <0.001 <0.001
MAIT cells × 106 cells/L 0.2 (0.1–0.8) 11.2 (7.6–30.7) 37.6 (12.2–59.4) 85.7 (37.0–134.0) 0.016 <0.001
NKT cells × 106 cells/L 0.0 (0.0–0.1) 0.4 (0.1–0.8) 0.4 (0.1–1.1) 1.7 (1.3–3.4) 0.969 <0.001
Vδ2- γδT cells × 106 cells/L 0.2 (0.1–0.6) 6.0 (1.9–11.1) 9.0 (6.4–16.7) 15.2 (7.5–24.8) 0.014 <0.001
Vδ2+ γδT cells × 106 cells/L 0.4 (0.1–1.5) 6.7 (3.0–15.7) 16.7 (11.4–50.3) 29.5 (14.3–60.4) 0.002 <0.001
αβT cells × 106 cells/L 25.9 (17.9–44.4) 315.5 (160.7–689.7) 817.6 (705.8–1001.2) 1115.4 (950.2–1255.3) <0.001 <0.001
*  CSF mononuclear cells. Routine CSF leukocyte analysis by Sysmex does not differentiate lymphocytes  
and monocytes. Included in the number of CSF lymphocytes, which are categorized as  
“mononuclear cells” by Sysmex analysis of CSF.
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Table 6.1   Comparison of tuberculous meningitis (TBM) patients versus  
pulmonary tuberculosis (PTB) patients and healthy controls (HC). 
Presented are the baseline characteristics of age and sex, routinely obtained cell counts and cell counts 
by flow cytometry. Comparisons are made by Mann-Whitney U for blood of tuberculous meningitis 
versus PTB and HC respectively.
TBM PTB HC comparison (p)
42 26 26 TBM  
vs PTB
TBM  
vs HC    CSF blood blood blood
sex N–% male 23 (55%) 12 (48%) 10 (39%) 0.660 0.290
age year 27 (20–36) 31 (24–43) 37 (24–52) 0.042 0.024
routine haematology counts
total leukocytes × 109 cells/L 0.216 (0.136–0.430) 10.1 (8.8–12.0) 9.1 (7.6–10.7) 6.9 (5.8–7.5) 0.088 <0.001
neutrophils × 109 cells/L 0.069 (0.026–0.162) 8.6 (7.1–10.2) 6.4 (5.2–8.2) 4.0 (3.3–4.8) <0.001 <0.001
lymphocytes × 109 cells/L 0.138 (0.087–0.251) 0.8 (0.4–1.2) 1.5 (1.3–1.8) 2.3 (1.8–2.6) 0.005 <0.001
monocytes × 109 cells/L * 0.7 (0.5–1.0) 0.6 (0.5–0.8) 0.4 (0.3–0.5) 0.705 <0.001
thrombocytes × 109 platelets/L n/a 267 (229–347) 396 (345–480) 285 (240–326) <0.001 0.562
flow cytometry results
total leukocytes × 106 cells/L 68.4 (33.6–146.9) 7217.5 (5608.5–9258.6) 6998.1 (5129.2–8629.9) 4052.1 (3757.1–5058.8) 0.276 <0.001
CD16+ neutrophils × 106 cells/L 12.0 (2.2–47.9) 6000.8 (4254.4–8167.5) 5011.3 (3434.9–6522.6) 2026.3 (1847.6–2874.9) 0.038 <0.001
CD16low neutrophils × 106 cells/L 0.5 (0.1–5.1) 113.5 (56.8–268.7) 140.7 (100.9–221.6) 237.7 (139.2–265.8) 0.684 0.101
CD14+CD16- monocytes × 106 cells/L 1.3 (0.3–3.0) 300.2 (179.7–395.1) 260.9 (181.1–353.0) 124.8 (94.3–168.2) 0.408 <0.001
CD14+CD16+ monocytes × 106 cells/L 0.2 (0.1–0.5) 7.3 (2.1–15.7) 17.9 (13.0–44.8) 11.1 (5.8–18.9) 0.001 0.118
CD14-CD16+ monocytes × 106 cells/L 0.1 (0.0–0.3) 1.2 (0.5–1.8) 6.9 (3.5–23.2) 10.2 (2.2–18.0) <0.001 <0.001
CD56- NK cells × 106 cells/L 0.8 (0.3–2.4) 5.8 (2.5–9.4) 8.3 (5.5–20.6) 21.8 (14.7–32.7) 0.011 <0.001
CD56+ NK cells × 106 cells/L 2.7 (1.2–7.6) 48.9 (33.7–86.5) 169.6 (94.8–198.8) 164.2 (120.9–198.1) <0.001 <0.001
CD56bright NK cells × 106 cells/L 0.5 (0.2–1.3) 1.8 (0.8–3.4) 4.9 (3.2–6.9) 5.4 (3.9–7.4) <0.001 <0.001
MAIT cells × 106 cells/L 0.2 (0.1–0.8) 11.2 (7.6–30.7) 37.6 (12.2–59.4) 85.7 (37.0–134.0) 0.016 <0.001
NKT cells × 106 cells/L 0.0 (0.0–0.1) 0.4 (0.1–0.8) 0.4 (0.1–1.1) 1.7 (1.3–3.4) 0.969 <0.001
Vδ2- γδT cells × 106 cells/L 0.2 (0.1–0.6) 6.0 (1.9–11.1) 9.0 (6.4–16.7) 15.2 (7.5–24.8) 0.014 <0.001
Vδ2+ γδT cells × 106 cells/L 0.4 (0.1–1.5) 6.7 (3.0–15.7) 16.7 (11.4–50.3) 29.5 (14.3–60.4) 0.002 <0.001
αβT cells × 106 cells/L 25.9 (17.9–44.4) 315.5 (160.7–689.7) 817.6 (705.8–1001.2) 1115.4 (950.2–1255.3) <0.001 <0.001
*  CSF mononuclear cells. Routine CSF leukocyte analysis by Sysmex does not differentiate lymphocytes  
and monocytes. Included in the number of CSF lymphocytes, which are categorized as  
“mononuclear cells” by Sysmex analysis of CSF.
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Tuberculous meningitis is characterised by a predominance of 
myeloid cells in blood, and αβT cells in CSF
Individual variation was large (figure 6.2A), but blood of tuberculous meningitis 
and pulmonary tuberculosis patients showed a consistently stronger myeloid 
response compared to healthy controls (table 6.1), with increased numbers of 
mature (CD16+) neutrophils and classical (CD14+CD16-) monocytes. Intermediate 
(CD14+CD16+) and non-classical (CD14-CD16+) monocytes were lower in 
tuberculous meningitis compared to both control groups. The lymphoid 
response showed the opposite: counts of all lymphocyte subsets were lower in 
tuberculous meningitis patients compared to both pulmonary tuberculosis 
patients and healthy controls (figure 6.2B). In patients who survived past day 10, 
mature neutrophils showed a further increase while the number of classical 
monocytes decreased. The CSF cell count of tuberculous meningitis patients 
also showed a large variation, both in total cell number (median 68/μL, IQR 
34-147 as measured by flow cytometry) and in proportions of different cell 
populations (figure 6.2C). In the lymphoid compartment (median 49/μL, IQR 
25-85), αβT cells predominated (57%, IQR 43-73 of lymphocytes), with NK cells 
as the second largest group (13%, IQR 9-24), with most NK cells CD56+. γδT cells 
(1.5%, IQR 0.9-3.6) were predominantly Vδ2+, but Vδ2- cells were also present in 
all but one patient. Small, but well-defined populations of MAIT cells (0.4%, IQR 
0.3-0.8) and NKT cells (0.06%, IQR 0.03-0.12) were found in all but one and three 
patients, respectively. Monocytes only made up a small proportion (2%) of all 
CSF cells, but this could be an underestimation because of a larger loss of 
myeloid cells during sample preparation. Indeed, neutrophils made up 40% of 
CSF cells in the routine measurement and only 17% by flow cytometry. The large 
majority (95%) of neutrophils were of the mature (CD16+) phenotype (figure 
5.2D). Although variable between individuals, all blood lymphocyte subsets 
remained diminished during follow-up, while in CSF leukocyte counts had 
dropped by 59% at day 10, with αβT cells remaining the predominant cell type 
(supplementary figure 6.2).
CSF leukocytes are more activated than blood leukocytes
CD16+ neutrophils showed higher expression of the neutrophil activation 
marker CD69 in CSF compared to blood (MFI 4.3 versus 2.4, p<0.001), while 
there was no difference for the smaller CD16low neutrophil population. CSF 
monocytes showed higher HLA-DR expression in the classical (CD14+CD16-, 
MFI 21.3 versus 7.7, p<0.001) and intermediate (CD14+CD16+, MFI 24.4 versus 
17.7, p=0.043) subpopulations than in blood (figure 6.3A). The difference in 
activation was even more pronounced in the lymphoid component, with five-fold 
higher CD69 on NK cells in CSF compared to blood (MFI 10.4 versus 2.0, p<0.001) 
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and nine-fold higher CD69 on T cells (MFI 10.8 vs. 1.2, p<0.001, figure 6.3B). The 
most activated monocytes were non-classical (CD14-CD16+) and intermediate 
(CD14+CD16+) monocytes that were overrepresented among CSF monocytes 
compared to blood. Likewise, CD56bright NK cells had the largest proportional 
presence in CSF compared to blood among NK cells (supplementary figure 
6.3A-B). During follow-up, a gradual decrease in CSF activation was seen 
(supplementary figure 6.3C). 
Figure 6.2  Flow cytometry results. 
(A) blood flow cytometry results for 40 tuberculous meningitis patients showing concentrations of 
individual cell types as depicted in the legend. (B) median concentrations in 26 healthy controls, 26 
pulmonary tuberculosis and tuberculous meningitis patients for myeloid (left) and lymphoid (right) 
cell types. (C) CSF flow cytometry results for 41 individual tuberculous meningitis patients. Patients 
with > 200 leukocytes/μL are displayed in the left subplot and patients with ≤ 200 leukocytes /μL in 
the right subplot. (D) median CSF cell composition of all tuberculous meningitis patients combined. 
Note: CD3- lymphocytes without NK cell markers, most likely B cells (14%, IQR 11-43 of lymphocytes), 
were not included in the analysis because the flow cytometry panels lacked B-cell markers to 
formally confirm their phenotype.
A
C D
B
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Tuberculous meningitis patients show a broad range in  
ex-vivo cytokine responses
Overall, pulmonary tuberculosis patients had the highest cytokine responses 
but tuberculous meningitis patients showed the widest range in cytokine 
production (example for IL-1β in figure 6.4A, table 6.2). Principal component 
analysis on the responses to live BCG, M. tuberculosis and S. pneumoniae lysate 
for all six cytokines resulted in a first component (PC1, representing 45% of 
variation) that was largely determined by IL-1β, IL-6, IL-10 and TNF-α in 
response to all three stimuli (supplementary figure 6.4A). Tuberculous 
meningitis patients showed a much more heterogeneous response compared to 
pulmonary tuberculosis patients (p=0.002, Levene’s test for homogeneity) and 
healthy controls (p<0.001), as shown in figure 6.4B. The ex-vivo response of 
tuberculous meningitis patients showed a gradient in the monocyte-derived 
cytokines TNF-α, IL-1β, IL-6 and IL-10 after stimulation with the specific stimuli, 
Figure 6.3  Blood versus CSF leukocyte activation. 
Median fluorescence intensity of activation markers in blood (x-axis) versus CSF (y-axis) for myeloid 
(A) and lymphoid (B) cell types. These modified ‘bag plots’ show the 50% median data-points and can 
therefore be compared to a two-dimension box plot without whiskers.
A B
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Figure 6.4  Ex-vivo whole blood cytokine results. 
(A) IL-1β response after stimulation of whole blood with BCG, M. tuberculosis and S. pneumoniae for 
each of the three patient groups tuberculous meningitis (TBM), pulmonary tuberculosis (PTB) and 
healthy controls (HC). (B) Comparison of these patient groups on principal component (PC) 1 versus 
PC2 in principal component analysis of all six measured cytokines for the afore-mentioned stimuli 
for three patients groups. (C) Heatmap showing the combination of six cytokines and three stimuli 
(y-axis) for all 50 included tuberculous meningitis patients (x-axis) sorted on their score on PC1.
A
B
C
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Table 6.2   Whole blood ex-vivo cytokine results at baseline for tuberculous 
meningitis (TBM) versus pulmonary tuberculosis (PTB) and healthy 
controls (HC). 
  TBM PTB HC p
n 50 25 26
IFN-γ (pg/mL)
BCG 18 (10–22) 21 (13–26) 16 (11–29) 0.661
M. tuberculosis 16 (12–24) 16 (12–31) 14 (8–24) 0.403
S. pneumoniae 23 (16–35) 33 (16–47) 24 (15–35) 0.200
E. coli 15 (10–19) 14 (12–18) 16 (10–26) 0.674
C. albicans 12 (9–21) 24 (17–29) 20 (15–32) 0.005
TNF-α (pg/mL)
BCG 334 (142–847) 930 (538–1530) 252 (128–356) <0.001
M. tuberculosis 359 (97–803) 466 (215–1036) 83 (50–157) <0.001
S. pneumoniae 591 (136–1029) 1387 (1125–1668) 369 (202–647) <0.001
E. coli 365 (104–1242) 915 (333–1569) 391 (206–773) 0.047
C. albicans 122 (52–426) 139 (70–259) 153 (100–217) 0.984
IL-1β (pg/mL)
BCG 167 (79–393) 363 (204–761) 183 (106–382) 0.030
M. tuberculosis 200 (53–449) 335 (186–619) 178 (129–260) 0.070
S. pneumoniae 474 (134–968) 1477 (1055–1749) 721 (366–935) <0.001
E. coli 288 (42–473) 760 (486–1037) 667 (195–944) <0.001
C. albicans 95 (37–193) 106 (53–131) 104 (66–161) 0.723
IL-6 (pg/mL)
BCG 2838 (1056–5108) 6052 (4477–9882) 2888 (1731–4750) 0.001
M. tuberculosis 2281 (700–6104) 4000 (2986–7269) 1574 (850–2728) 0.001
S. pneumoniae 1635 (573–3114) 2183 (1667–3047) 1530 (971–2160) 0.078
E. coli 2068 (607–3284) 3331 (2379–5149) 2179 (1363–3024) 0.019
C. albicans 1151 (411–2436) 1192 (486–1630) 694 (318–1101) 0.198
IL-10 (pg/mL)
BCG 39 (12–81) 52 (44–84) 35 (24–53) 0.097
M. tuberculosis 21 (10–59) 36 (17–44) 14 (6–25) 0.023
S. pneumoniae 33 (15–54) 38 (21–55) 24 (13–40) 0.121
E. coli 38 (5–67) 51 (32–89) 61 (28–73) 0.206
C. albicans 6 (5–32) 5 (5–13) 6 (5–9) 0.612
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BCG and M. tuberculosis, but also with the non-mycobacterial stimulus 
S. pneumoniae (figure 6.4C). Data for C. albicans (not available for every patient) 
showed a similar gradient while E. coli (also incomplete) did not (data not shown).
 
During follow-up, cytokine responses showed a decrease from baseline to day 
10 (all but two patients had started on corticosteroids), and an increase again at 
day 60 and 180 (supplementary figure 6.4B). The response of tuberculous 
meningitis patients at day 180 was higher than that of healthy controls for 
cytokines induced by multiple stimuli: IFN-γ and IL-1RA induced by BCG; 
TNF-α, IFN-γ, IL-6, IL1-RA induced by M. tuberculosis; TNF- α, IFN-γ and IL-1RA 
induced by S. pneumoniae; and IL-1RA induced by C. albicans (p<0.05 for all, data 
not shown).
Immune responses correlate to clinical characteristics and survival 
Contrary to our hypothesis, we found a broad range in immune responses in 
tuberculous meningitis patients rather than clearly distinct immune phenotypes 
(‘high’ and ‘low’ responders). We therefore looked for correlations between cell 
distribution, cell activation and ex-vivo cytokine responses. Myeloid CSF cells 
correlated with other myeloid cells and lymphoid CSF cells with other lymphoid 
CSF cells, and the same was true for blood cells. Little or no correlation was seen 
between the CSF and blood markers (supplementary figure 6.5). 
We next examined the link between ex-vivo cytokine responses, blood flow 
cytometry and clinical characteristics. Activation of CD14+CD16- (classical) 
blood monocytes measured by HLA-DR showed a positive correlation with the 
Table 6.2   Continued. 
  TBM PTB HC p
n 50 25 26
IL-1RA (pg/mL)
BCG 3810 (2020–6132) 4833 (3210–6209) 1597 (1290–2269) <0.001
M. tuberculosis 3366 (1924–6719) 4651 (2677–5980) 1645 (1325–2067) <0.001
S. pneumoniae 3948 (1826–5861) 6083 (4499–10546) 1728 (956–2270) <0.001
E. coli 3902 (1647–6512) 6901 (3789–8459) 2830 (2329–3739) 0.001
C. albicans 1633 (1132–3071) 2334 (1751–3361) 908 (604–1578) <0.001
Kruskal-Wallis p-values for are shown (df = 2). Data were missing for one pulmonary tuberculosis 
patient and one healthy control. Data are 100% complete for BCG, M. tuberculosis and S. pneumoniae, 
87% for E. coli and 76% for C. albicans.
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first principal component of the ex-vivo cytokine response (Spearman rho=0.52, 
p=0.0089), and this was largely driven by the TNF-α, IL-6 and IL-10 responses 
across the range of stimuli. Not unexpectedly, the first principal component of 
the ex-vivo cytokine response also correlated positively to the following 
routinely collected clinical parameters: temperature (rho=0.33, p=0.0183), blood 
lymphocytes (rho=0.40, p=0.0048) and blood monocytes (rho=0.34, p=0.0171).
Finally we tested if immune markers predicted patient survival. Neither ex-vivo 
cytokine responses nor blood count markers showed an association with 
outcome, while higher levels of the main CSF lymphoid cell types (αβT and NK 
cells), were associated with better outcome (table 6.3).
Discussion
In this prospective cohort of carefully characterised patients in Indonesia, 
tuberculous meningitis patients showed a strong blood myeloid response 
compared to healthy controls and pulmonary tuberculosis patients. Within the 
group of tuberculous meningitis patients, CSF mostly showed a predominance 
of αβT cells, with highly variable proportions of NK cells and neutrophils, and 
higher expression of activation markers on CSF monocytes, neutrophils, NK 
cells and T cells than on these same cell types in blood. Whole blood ex-vivo 
cytokine responses showed a much wider range in tuberculous meningitis 
patients compared to pulmonary tuberculosis patients and controls. Rather 
than distinct immune phenotypes, a gradual scale in the immune response was 
seen with high cytokine responses correlating with other inflammatory markers. 
This study is the first to quantify innate cell population concentrations in blood 
and CSF of tuberculous meningitis patients in comparison to relevant control 
groups, adding to previous studies that reported low numbers of αβT cells in 
blood of tuberculous meningitis patients217 (probably due to compartmentalisa-
tion to CSF218), and the presence of γδT and NK cells in CSF33. In CSF, besides 
αβT cells the most abundant cell type were NK cells, an important source of 
IFN-γ and a critical CSF cytokine in tuberculous meningitis43. We also found 
NKT cells and MAIT cells in CSF, of which the latter have not been described in 
CSF before. Some patients showed a predominance of neutrophils in CSF, mostly 
mature, non-apoptotic neutrophils expressing CD16+219. Monocytes were found 
in low numbers in CSF, with proportionally more CD16+ (macrophage-like) 
subsets than in blood and with high expression of the activation marker 
HLA-DR. Leukocyte activation was much higher in CSF than blood, with very Ta
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little correlation between compartments, indicating that future studies cannot 
rely on blood flow cytometry or ex-vivo stimulation assays when aiming to 
characterise the cerebral immune response.
Whole blood cytokine responses showed a much wider range in tuberculous 
meningitis patients compared to the two control groups, ranging from non- 
responsiveness to hyper-responsiveness. This gradient in production of TNF-α, 
IL-1β, IL-6 and IL-10 was seen in response to the mycobacterial stimuli BCG and 
M. tuberculosis as well as to non-mycobacterial stimuli S. pneumonia and C. 
albicans. Ex-vivo cytokine responses showed a positive correlation with blood 
lymphocyte and monocyte counts and especially with HLA-DR expression on 
monocytes. Ex-vivo cytokine responses also correlated positively with body 
temperature, which predicted early mortality in our on routine inflammatory 
markers in 499 HIV-negative tuberculous meningitis patients presented in 
chapter 5. Other studies have shown that immunoparalytic sepsis patients with 
low cytokine responses have higher mortality later during the course of disease, 
possibly because of a higher rate of secondary infection220, but we could not 
confirm this in our present study. 
At 10 days post admission, a remarkable decrease in CSF myeloid cells and all 
lymphoid cells except αβT cells was seen. Different from a Vietnamese study 
analysing dexamethasone versus placebo that used comparable methodology33, 
ex-vivo cytokine responses were strongly down regulated in our patients at day 
10. We consider this to be the effect of corticosteroid treatment because the 
cytokine production was restored after cessation of steroids after 6 weeks (day 
60 and 180 measurements). At day 180, proinflammatory cytokine production 
were even higher than in healthy controls, both in response to mycobacterial 
stimuli as shown before221, as well as to unrelated stimuli C. albicans and S. 
pneumoniae. Our findings show similarities to HIV-associated cryptococcal 
meningitis with proportionally overrepresented CD56bright NK cells and 
CD14+CD16+ and CD14-CD16+ monocytes in CSF compared to blood222 and a 
subgroup of patients with low HLA-DR on monocytes and low ex-vivo TNF-α223.
Our study has several limitations. Although much larger than previous studies, 
caution is warranted in its interpretation because of the many comparisons 
relative to the number of included individuals. Our follow-up was 99% complete, 
but high early mortality compromised follow-up sampling. Also, CSF leukocytes, 
especially myeloid cells, show an almost 40% loss from 30 to 60 minutes after 
lumbar puncture224. To limit cell loss, we immediately resuspended CSF cells in 
culture medium. For the ex-vivo cytokine assay, we chose 24 hours incubation. 
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This is optimal for measuring for monocyte-derived cytokines170, but relatively 
short for IFN-γ. Cytokines in CSF were not measured in this study. The 
correlations of the ex-vivo cytokine response, require validation in a separate 
cohort given their number.
What is the clinical relevance of our findings? Besides better supportive care28 
and higher dose rifampicin29, immunomodulatory therapy may be a third 
strategy to improve treatment of tuberculous meningitis. In the sepsis field a 
one-size-fits-all approach has not been successful225. Our findings suggest that 
the same may be true for tuberculous meningitis. There could be a role additional 
anti-inflammatory therapy, i.e. with aspirin45(NCT02237365), or interleukin-1 
receptor antagonist for patients with a strong inflammatory response. At the 
same time, patients with a low response might have a better outcome without 
corticosteroid treatment, or might even benefit from adjuvant IFN-γ therapy to 
boost their immune response, as has been done successfully in a child with 
protracted tuberculous meningitis194. Preferably, future host-directed trials 
should include immune markers to allow for post-hoc identification of subgroups 
benefitting from the initiated therapy. Good candidates are blood monocyte 
HLD-DR expression, well generalizable to other settings, and ex-vivo cytokine 
responses. Because of the lack of correlation between blood and CSF compartments, 
we recommend to also include CSF markers when studying adjuvant therapies. 
In conclusion, tuberculous meningitis patients show a previously not appreciated 
strong myeloid blood response, and an unexpectedly large gradient in the immune 
response, with little correlation between blood and CSF compartments. We 
recommend integrating the assessment of the immune response in future randomised 
clinical trials evaluating host-directed therapy in tuberculous meningitis.
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Supplementary figures 
Supplementary figure 6.1 
(A) flow cytometry gating strategy. αβT cells are calculated by subtracting NKT cells, γδT cells and 
MAIT cells from the total number of CD3+ lymphocytes.
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Supplementary figure 6.1  Continued.
(B) Mortality in the first 180 days of follow-up. Outcome data were missing for one patient. Presumptive 
cause of death is depicted below the Kaplan-Meier graph in three categories: 1) tuberculous meningitis- 
related causes: 4 because of increased intracranial pressure, 2 because of a paradoxical reaction, 
2) pneumonia (8) or sepsis (4), and 3) miscellaneous: 3 aspiration pneumonia, 3 suspected cardiac 
arrest or pulmonary embolism, 1 head injury, 1 metabolic encephalopathy and 1 with unknown 
cause. (C) Regression lines with 95% confidence intervals for the correlation between cell counts as 
measured routinely (x-axis), and with flow cytometry (y-axis) for blood and CSF. Regression formulas 
and regression coefficients (R2) are printed on the graphs. Note: CSF cells are plotted on a 10log-axis 
and regression coefficients are 10log-transformed.
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Supplementary figure 6.2  
Flow cytometry follow-up results of tuberculous meningitis patients in the follow-up study who 
survived past day 10 (n = 15). Results show median (A) or median with interquartile range (B) for day 
0, 2 and 10 for myeloid and lymphoid cell types separately in blood (left) and CSF (right). Note the 
different y-axis limits. Data is ≥ 80% complete for all time-points for blood and is ≥ 87% complete 
for CSF.
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Supplementary figure 6.3
Flow cytometry results of proportions of monocyte (A) and NK cell (B) subtypes in blood versus CSF. 
*** p<0.001. (C) Activation marker expression by indicated cell populations during follow-up for 
tuberculous meningitis patients, all of whom survived past day 10 (n = 15). Data is ≥ 80% complete for 
all time-points for CSF and blood. Note: day 10 myeloid activation markers in CSF could not reliably 
be measured because of the low cell counts.
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Supplementary figure 6.4 
(A) Loadings for principal component analysis on ex-vivo cytokine data. B = BCG, M = M. tuberculosis 
and S = S. pneumoniae. (B) Ex-vivo whole blood cytokine results for tuberculous meningitis patients 
in the follow-up study who survived past day 180 (n = 15). Results show median with interquartile 
range for all five stimuli (ordered vertically) for all six measured cytokines (horizontally). Patients 
were selected who had complete data at day 0 and missed maximally one of the follow-up time-points. 
Data is 93% complete for day 10, 73% for day 60 and 53% for day 180. Missing data were due to 
technical errors.
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Supplementary figure 6.5
Correlation matrix for CSF and blood cell counts and activation markers, as well as blood ex-vivo 
whole blood response using Spearman correlation. Pair-wise complete data was included.
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Supplementary table 6.1  Clinical, cerebrospinal fluid and blood parameters 
of tuberculous meningitis patients.
Variable n/N or 
median
% or  
IQR
Clinical features
Sex 37/67 (56%)
Age 27 (21–38)
Duration of main complaint 4 (2–7)
Duration of the first neurological symptom 14 (7–21)
Tuberculous meningitis grade
I 2/67 (3%)
II 58/67 (87%)
III 7/67 (10%)
Temperature, °C 37.8 (37.0–38.2)
Glasgow Coma Scale score 13 (11–14)
Seizures present 1/66 (2%)
Motor abnormalities present 38/66 (57%)
Cranial nerve palsy present 51/66 (6%)
Abnormal chest radiograph findings 50/67 (75%)
Cerebrospinal fluid
CSF to blood glucose ratio 0.14 (0.09–0.20)
Protein, mg/dL 221 (150–386)
Culture, % positive 46/67 (69%)
Blood
Haemoglobin, g/dL 12.5 (10.5–13.8)
Thrombocytes, x 109/L 298 (234–379)
Outcomes
Length of hospital stay in days 21 (12,23)
Alive at discharge 51/66 (76%)
Outcome at day 180
Alive 39/71 (58%)
Deceased 27/67 (40%)
Lost to follow-up 1/67 (2%)
Continuous variables are presented as median with interquartile range and categorical variables as 
number and proportion. IQR = interquartile range. Additional routine inflammatory markers can be 
found in Table 6.1.
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Abstract
Rationale
Immunopathology contributes to the high mortality of tuberculous meningitis, 
but the biological pathways involved are mostly unknown. We aimed to compare 
cerebrospinal fluid (CSF) and serum metabolomes of patients with tuberculous 
meningitis with that of controls without tuberculous meningitis, and assess the 
link between metabolite concentrations and mortality.
Methods 
In this observational cohort study at the Hasan Sadikin Hospital (Bandung, 
Indonesia) we measured 425 metabolites using liquid chromatography-mass 
spectrometry in CSF and serum from 33 HIV-negative Indonesian patients with 
confirmed or probable tuberculous meningitis and 22 control participants with 
complete clinical data between March 12, 2009, and Oct 27, 2013. Associations of 
metabolite concentrations with survival were validated in a second cohort of 101 
patients from the same centre. Genome-wide single nucleotide polymorphism 
typing was used to identify tryptophan quantitative trait loci, which were used 
for survival analysis in a third cohort of 285 patients.
Findings 
Concentrations of 250 (70%) of 351 metabolites detected in CSF were higher in 
patients with tuberculous meningitis than in controls, especially in those who 
died during follow-up. Only five (1%) of the 390 metabolites detected in serum 
differed between patients with tuberculous meningitis and controls. CSF 
tryptophan concentrations showed a pattern different from most other CSF 
metabolites; concentrations were lower in patients who survived compared with 
patients who died (9-times) and to controls (31-times). The association of low CSF 
tryptophan with patient survival was confirmed in the validation cohort (hazard 
ratio 0.73; 95% CI 0.64–0.83; p<0.0001; per each halving). 11 genetic loci predictive 
for CSF tryptophan concentrations in tuberculous meningitis were identified 
(p<0.00001). These quantitative trait loci predicted survival in a third cohort of 
285 HIV-negative patients in a prognostic index including age and sex, also after 
correction for possible confounders (p=0.0083).
Interpretation 
Cerebral tryptophan metabolism, which is known to affect M. tuberculosis growth 
and central nervous system inflammation, is important for the outcome of tuber- 
culous meningitis. CSF tryptophan concentrations in tuberculous meningitis 
are under strong genetic influence, probably contributing to the variable outcomes 
of tuberculous meningitis. Interventions targeting tryptophan metabolism 
could improve outcomes of tuberculous meningitis.
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Introduction
Meningitis is the most severe manifestation of tuberculosis, resulting in death or 
neurological disability in more than 30% of adult patients (see chapter 5 and 16,25). 
The host immune system contributes to the poor outcome of tuberculous 
meningitis, either through inadequate killing of M. tuberculosis, or through an 
inappropriate inflammatory response leading to tissue damage (immuno-
pathology)16. Studying cellular metabolism can help to determine the function 
of immune cells, and analysis of cerebrospinal fluid (CSF) metabolites could 
help unravel underlying biological mechanisms or establish the prognosis of 
tuberculous meningitis.
Metabolic studies in tuberculosis have examined a small number of metabolites, 
and most have focused on identification of host or bacterial metabolites as diagnostic 
markers226-228. We aimed to compare CSF and serum metabolomes of patients 
with tuberculous meningitis with those of controls with negative M. tuberculosis 
culture, and assess the link between metabolite concentrations and mortality.
Methods
Study design and participants
This was a prospective observational cohort study done at the Hasan Sadikin 
Hospital (Bandung, Indonesia). Study participants were selected from a cohort 
of patients older than 14 years with suspected meningitis described in chapter 5. 
Eligible patients had definite tuberculous meningitis229, defined as positive CSF 
M. tuberculosis culture or PCR, or probable tuberculous meningitis, defined as 
clinically suspected disease with at least five leucocytes per μL of CSF, and a 
CSF to blood glucose ratio less than 0.5. HIV infection, which strongly affects 
host cellular responses and increases mortality of tuberculous meningitis, was 
an exclusion criterion for this study. Oral consent to be included in the study, for 
storage of surplus sample, and to obtain follow-up data was obtained from 
patients or close relatives of patients who were unconscious. Control participants 
were individuals who had a lumbar puncture because of suspected central 
nervous system infection or subarachnoid bleeding but who showed no 
abnormalities on routine CSF examination (<5 leucocytes per μL, glucose ratio 
≥0.5) and negative M. tuberculosis culture.
Ethical approval was obtained from the Ethical Committee of Hasan Sadikin 
Hospital, Faculty of Medicine of Universitas Padjadjaran, Bandung, Indonesia.
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Procedures
We determined the CSF and serum metabolome in a discovery cohort of 33 
patients with tuberculous meningitis, of whom 17 died while in hospital and 16 
survived during follow-up, and 22 controls without meningitis. Concentrations 
of metabolites were compared between patients and controls, and (among 
patients only) linked to survival. A second group of 101 patients with tuberculous 
meningitis and 17 controls was used for validation of the relationship between the 
CSF metabolome and survival. Genome-wide single nucleotide polymorphism 
(SNP) typing was done in 130 patients with tuberculous meningitis from the 
original discovery and validation cohorts to identify quantitative trait loci for 
individual CSF metabolites. Associations between identified genetic loci and 
patient survival were then validated in a third group of 285 tuberculous 
meningitis patients (the genetic validation cohort).
According to routine care, all patients with suspected meningitis underwent 
lumbar puncture before starting antimicrobial or corticosteroid treatment. 
Patients diagnosed with tuberculous meningitis underwent systematic clinical 
and CSF characterisation at the time of diagnosis, and survival was monitored 
prospectively for one year.
Gene Xpert MTB/RIF has only been used since 2015 and drug resistance testing 
was otherwise not routinely available in our study setting. Tuberculous meningitis 
was treated with a combination of rifampicin (unless otherwise indicated 450 
mg, corresponding to about 10 mg/kg), isoniazid (300 mg), ethambutol (750 mg), 
and pyrazinamide (1500 mg) for 6 months according to Indonesian guidelines. 
Patients were given adjunctive dexamethasone according to the internationally 
accepted 6-week tapering regimen, starting at 0.3 mg/kg for grade I and 0.4 mg/
kg for grade II or III tuberculous meningitis186; patients were switched to an 
equivalent dose of oral prednisolone in cases of early discharge.
CSF and serum metabolomics
CSF samples were centrifuged at 3000 rpm for 15 min and the supernatant was 
stored at −80°C. Serum was collected after centrifugation of peripheral blood at 
3000 rpm for 15 min. Samples were frozen and thawed once before metabolomics 
analysis. 425 metabolites were measured in serum and CSF using four liquid 
chromatography tandem mass spectrometry methods (see supplementary 
methods for more detail)230,231.
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Quantification of CSF tryptophan and CSF and serum albumin
CSF tryptophan in the original and validation cohorts was quantified by ultra- 
performance liquid chroma tography (see Supplementary Methods for more 
detail). The acquired ultra-performance liquid chromatography data showed 
good correlation with the original liquid chromatography-mass spectrometry 
data (Spearman’s rho=0.95, p<0.0001). CSF and serum albumin were measured 
to determine the CSF to serum albumin ratio (normal range 0.005–0.008 for 
individuals aged 15–60 years232; see Supplementary Methods for more detail). 
Metabolomic data analysis
Liquid chromatography-mass spectrometry and ultra-performance liquid 
chromatography data were analysed after log transformation. Values under the 
lower limit of detection of liquid chromatography-mass spectro metry were 
replaced with half of the metabolites’ lower limit of detection in the specific 
matrix (CSF or serum). Pathway analysis was done on log-transformed, 
mean-centred data for metabolites with less than 50% missing values using 
MetaboAnalyst version 3.0233, which performs topological analysis with relative 
betweenness centrality applying the GlobalTest algorithm234 to test for 
association of metabolite concentrations with diagnosis. Metabolites discovered 
in at least one sample were uploaded as a reference metabolome. 
All other analyses were done in R version 3.2.2. Visualisation was achieved by 
principal component analysis on centred unscaled data using the R package 
prcomp. Comparison of metabolites was done using the R package limma. 
Figure colour gradients are based on uncorrected p values and tables show false 
discovery rates after applying the Benjamini-Hochberg procedure to correct for 
multiple testing. Survival analyses were done using the R package survival and 
visualised with the R package survminer. Differences between tryptophan 
strata were evaluated using a log-rank test. Multivariate survival analysis was 
done using Cox regression after log transformation of skewed continuous 
variables as indicated. Other R packages used were openxlsx, dplyr, reshape2 
(for data handling), and tableone (for data representation), and all graphs were 
visualised using ggplot2 and enhanced by cowplot. Patients with negative CSF 
culture, who had received dexamethasone or antituberculosis drugs before 
lumbar puncture, who were infected with rifampicin-resistant strains, or who 
had received high-dose rifampicin were excluded from sensitivity analyses.
Transcriptional analyses
The tryptophan pathway was established based on the Kyoto Encyclopaedia of 
Genes and Genomes (map 00380) and the Small Molecule Pathway Database 
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(SMP00063), and all genes coding for enzymes in these reactions were included. 
For brain expression, data were available for five patients with tuberculous 
meningitis versus four patients deceased because of head injury (GSE23074), 
all from southern India235. Data were quantile-normalised, filtered for positive 
expression, log transformed, and analysed using the R package limma for 
association with patient group.
Tryptophan quantitative trait loci mapping and genotype-dependent 
survival analysis
Genotyping, quality control, and imputation was done as described in the 
supplementary methods. Log-transformed, normalised concentrations of tryptophan 
were then mapped to the 4,751,257 variants that passed quality control (R²>0.3 
and minor allele frequency ≥0.1) using a linear regression model corrected for 
age and sex. We defined a threshold for suggestive genome-wide significance 
(p<0.00001). We calculated a prognostic index236 using the linear component of 
the Cox model, as in prognostic index=β1x1 + β2x2 + … + βpxp, where x1 is the 
genotype data in dosages and β1 results from fitting the Cox proportional model. 
The genetic patient cohort was split into two groups according to the median of 
the prognostic index (low and high), and patients were evaluated for survival 
with a log-rank test. Finally, a prognostic index was used as a continuous covariate 
in multivariate Cox regression including possible confounders.
We used different approaches to examine the role of identified quantitative trait 
loci. First, identified quantitative trait loci were examined for possible effects 
on gene expression using the Gtex database. Second, genes neighbouring 
quantitative trait loci were extracted and expression was examined using Gene 
Set Enrichment Analysis in different human tissues and cell lines (deposited 
in the Human tissue compendium237). Finally, we used brain gene expression 
data235 to assess  the differential expression of genes near quantitative trait loci 
in patients with tuberculous meningitis compared with patients who had died 
from head injury.
Results
CSF and serum metabolome in tuberculous meningitis patients  
and controls
For the discovery metabolomics study, we included 33 patients with tuberculous 
meningitis with positive CSF culture between March 12, 2009, and Oct 27, 2013, 
including 16 who survived and 17 who died while in hospital. We also included 
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22 individuals with negative M. tuberculosis culture and normal routine CSF 
characteristics as controls (supplementary figure 7.1A).
Patients presented with severe disease, often with lowered consciousness, 
cranial nerve palsy, or paresis of one or more limbs (table 7.1). 425 metabolites 
were measured in serum and CSF. Quality and coverage of the metabolomics 
data was high, and routinely measured CSF glucose concentration was correlated 
with glucose concentration measured by liquid chromatography-mass 
spectrometry (Spearman’s rho=0.986; p<0.0001). The CSF sample of one patient 
with tuberculous meningitis with aberrant measurements on the hydrophilic 
interaction chromatography-positive platform was removed from subsequent 
analyses. Of 425 annotated metabolites, 348 (82%) were detected in CSF and 
serum, three (1%) in CSF only, and 42 (10%) in serum only (online supplement).
Patients with tuberculous meningitis had a distinct CSF metabolome compared 
with control participants, as shown by principal component analysis (figure 7.1). 
One patient with tuberculous meningitis and miliary tuberculosis who had no 
leucocytes in CSF clustered with the control group; we did not exclude this 
patient from the tuberculous meningitis group for the analysis as no technical 
anomaly was detected. Of 351 metabolites detected in CSF, 250 (71%) were higher 
and 18 (5%) were lower in patients with tuberculous meningitis than they were 
in controls (with a false discovery rate threshold of <0.05; figure 7.1). Metabolite 
concentrations showed large variation, but were on average 12-times higher in 
serum than in CSF (supplementary figure 7.1B). The median CSF to serum 
albumin ratio was 0.050 in patients with tuberculous meningitis, suggesting 
that the blood-CSF barrier was severely disrupted, compared with 0.0062 in 
controls (supplementary figure 7.1C). The difference in average relative 
abundance of metabolites between CSF and serum was smaller in patients 
(6.2-times) than in controls (32.2-times). CSF metabolites across the whole range 
of quantity and mass showed substantial differences between patients and 
controls (supplementary figure 7.1D), with 58 (97%) of 60 known metabolic 
pathways being affected (supplementary table 7.1). The serum metabolome 
showed more subtle differences between patients and controls, with only five 
(1%) of 397 metabolites being significant (false discovery rate <0.05; figure 7.1).
CSF metabolome as a predictor for patient survival 
We next compared metabolite profiles of patients with tuberculous meningitis 
who died while in hospital (n=17, median time to death 4 days [IQR 3–7]) and 
those who were discharged alive (n=15, after exclusion of the sample with 
aberrant measurements). Patients who survived were discharged after a median 
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Figure 7.1   CSF and serum metabolome in patients with tuberculous 
meningitis and controls. 
Principal component analysis for CSF (A) and serum (B) with proportion of variance per principal 
component indicated between brackets. Volcano plots for individual metabolites in CSF (C) and 
serum (D). Colours indicate strength of association. Metabolites that show no difference between 
groups (uncorrected p>0.05) are grey. PC = principal component.
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of 25 days (IQR 21–29), and one additional outpatient death was recorded at day 
89. None of the serum and CSF metabolites reached a false discovery rate 
threshold of less than 0.05 for comparison between survivors and non-survivors. 
At an ordinary significance level (p<0.05), 33 (8%) of 390 metabolites detected in 
serum differed between non-surviving and surviving patients with tuberculous 
meningitis (supplementary figure 7.2A), but only one of these (urate) also 
differed between patients and controls. At an ordinary significance level 
(p<0.05), 28 (8%) of 351 metabolites detected in CSF differed between non- 
survivors and surviving patients with tuberculous meningitis (figure 7.2A). 
25 (90%) of 28 metabolites were higher in non-surviving patients than in 
surviving patients with tuberculous meningitis. Of these 25 CSF metabolites, 
13 (52%) were higher in the original comparison of patients with tuberculous 
meningitis compared to controls. One of these 13 metabolites, the eicosanoid 
leukotriene B4—a downstream chemoattractant of Leukotriene A4 Hydrolase 
(LTA4H) that has been studied in relation to tuberculous meningitis survival—
was lowest in controls, 11-times higher in patients with tuberculous meningitis 
who survived, and 30-times higher in patients who died. Two metabolites, 
glucose and inositol, followed the reverse pattern. For example, glucose was 
highest in controls, 2.5-times lower in patients with tuberculous meningitis who 
survived, and 4-times lower in those who died. Three CSF metabolites 
(putrescence, cytidine, and tryptophan) followed a pattern in which survivors 
had lower concentrations than both controls and non-survivors. CSF tryptophan, 
which had the largest difference between groups, was 31-times lower in 
survivors than in controls, and 9-times lower in survivors than non-survivors 
(unadjusted p=0.00043).
Unlike many other metabolites, CSF tryptophan was not associated with CSF to 
serum albumin ratio (a marker of disruption to the blood–CSF barrier) (Pearson’s 
r²=0.015), CSF polymorphonuclear cell count (Pearson’s r²=0.058), or CSF 
mononuclear cell count (Pearson’s r²=0.019), suggesting that CSF tryptophan 
concentrations instead reflect metabolism in the brain itself (supplementary 
figure 7.2B; for correlations for all other metabolites see online supplement). 
Serum tryptophan concentrations were 1.3-times higher in patients who 
survived than they were in those who died (p=0.055; online supplement).
We tested the association between CSF tryptophan concentrations and patient 
survival in a separate group of 101 consecutively recruited patients with 
tuberculous meningitis (recruited between July 2, 2014, and April 6, 2016), 67 
(66%) of whom were culture-confirmed and 17 control participants (table 7.1). 
The concentration of CSF tryptophan, quantified using ultra-performance liquid 
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Table 7.1  Patient characteristics. 
Metabolomics  
discovery cohort
Tryptophan  
validation cohort
Genetic  
validation cohort
Controls 
(n=22)
Tuberculous  
meningitis survivors 
(n=15*)
Tuberculous  
meningitis non-survivors 
(n=17)
Controls  
(n=17)
Tuberculous  
meningitis  
(n=101)
Tuberculous  
meningitis  
(n=285)
Clinical features
Sex
Male 10 (45%) 11 (73%) 11 (65%) 9 (53%) 62 (61%) 153 (54%)
Female 12 (55%) 4 (27%) 6 (35%) 8 (47%) 39 (39%) 132 (46%)
Age, years 34 (22–25) 27 (25–34) 27 (22–30) 39 (22–39) 30 (21–38) 29 (22–37)
Tuberculous meningitis grade
I NA¶ 1 (7%) 0/16 NA 3/99 (3%) 30/258 (12%)
II NA¶ 13 (87%) 8/16 (50%) NA 82/99 (84%) 195/258 (76%)
III NA¶ 1 (7%) 8/16 (50%) NA 14/99 (14%) 33/258 (13%)
Temperature, °C 37.0 (36.7–37.5) 37.6 (36.9–38.2) 37.6 (37.2–37.9) 37.1 (36.8–37.5) 37.8 (37.0–38.3) 37.5 (36.8–38.0)
Glasgow Coma Scale 14 (13–15) 13 (12–14) 12 (11–13) 15 (14–15) 13 (11–14) 14 (12–15)
Seizures present 4 (18%) 0 2/16 (13%) 2 (12%) 5/98 (5%) 17/246 (7%)
Motor abnormalities present 14 (64%) 6 (40%) 9/16 (56%) 8 (47%) 59/99 (60%) 127/241 (53%)
Cranial nerve palsy present 13/21 (62%) 8 (53%) 14 (82%) 9 (53%) 69/100 (69%) 161/258 (62%)
Cerebrospinal fluid features
Leucocytes, cells per μL 2 (0–2) 99 (50–306) 54 (15–275) 2 (1–2) 236 (124–443) 138 (49–308)
Neutrophils, cells per μL 0 (0–1) 26 (14–66) 38 (6–171) 1 (0–1) 78 (25–186) 27 (8–89)
Mononuclear cells,  
cells per μL
1 (0–2) 84 (29–201) 47 (11–118) 1 (1–1) 136 (91–210) 74 (29–165)
Protein, mg/dL 34 (19–47) 291 (126–357) 216 (143–371) 27 (20–33) 173 (125–355) 190 (102–373)
CSF to blood glucose ratio 0.64 (0.56–0.70) 0.21 (0.13–0.29) 0.12 (0.08–0.17) 0.64 (0.56–0.68) 0.17 (0.10–0.25) 0.21 (0.12–0.33)
M. tuberculosis culture positive 0 15 (100%) 17 (100%) 0 67 (66%) 138/281 (49%)
Blood features
Haemoglobin, g/dL 12.0 (9.40–13.8) 11.9 (10.1–13.8) 12.4 (11.2–13.3) 11.0 (9.0–12.8) 12.4 (10.5–13.7) 12.1 (10.5–13.4)
Leucocytes, x 109/L 10.1 (7.6–12.6) 10.0 (8.8–11.3) 12.6 (8.5–15.8) 7.5 (5.2–8.7) 11.0 (8.8–13.7) 11.0 (7.9–14.3)
Thrombocytes, x 109/L 278 (136–416) 293 (192–351) 346 (301–400) 254 (168–305) 298 (227–378) 290 (216–377)
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Age, years 34 (22–25) 27 (25–34) 27 (22–30) 39 (22–39) 30 (21–38) 29 (22–37)
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I NA¶ 1 (7%) 0/16 NA 3/99 (3%) 30/258 (12%)
II NA¶ 13 (87%) 8/16 (50%) NA 82/99 (84%) 195/258 (76%)
III NA¶ 1 (7%) 8/16 (50%) NA 14/99 (14%) 33/258 (13%)
Temperature, °C 37.0 (36.7–37.5) 37.6 (36.9–38.2) 37.6 (37.2–37.9) 37.1 (36.8–37.5) 37.8 (37.0–38.3) 37.5 (36.8–38.0)
Glasgow Coma Scale 14 (13–15) 13 (12–14) 12 (11–13) 15 (14–15) 13 (11–14) 14 (12–15)
Seizures present 4 (18%) 0 2/16 (13%) 2 (12%) 5/98 (5%) 17/246 (7%)
Motor abnormalities present 14 (64%) 6 (40%) 9/16 (56%) 8 (47%) 59/99 (60%) 127/241 (53%)
Cranial nerve palsy present 13/21 (62%) 8 (53%) 14 (82%) 9 (53%) 69/100 (69%) 161/258 (62%)
Cerebrospinal fluid features
Leucocytes, cells per μL 2 (0–2) 99 (50–306) 54 (15–275) 2 (1–2) 236 (124–443) 138 (49–308)
Neutrophils, cells per μL 0 (0–1) 26 (14–66) 38 (6–171) 1 (0–1) 78 (25–186) 27 (8–89)
Mononuclear cells,  
cells per μL
1 (0–2) 84 (29–201) 47 (11–118) 1 (1–1) 136 (91–210) 74 (29–165)
Protein, mg/dL 34 (19–47) 291 (126–357) 216 (143–371) 27 (20–33) 173 (125–355) 190 (102–373)
CSF to blood glucose ratio 0.64 (0.56–0.70) 0.21 (0.13–0.29) 0.12 (0.08–0.17) 0.64 (0.56–0.68) 0.17 (0.10–0.25) 0.21 (0.12–0.33)
M. tuberculosis culture positive 0 15 (100%) 17 (100%) 0 67 (66%) 138/281 (49%)
Blood features
Haemoglobin, g/dL 12.0 (9.40–13.8) 11.9 (10.1–13.8) 12.4 (11.2–13.3) 11.0 (9.0–12.8) 12.4 (10.5–13.7) 12.1 (10.5–13.4)
Leucocytes, x 109/L 10.1 (7.6–12.6) 10.0 (8.8–11.3) 12.6 (8.5–15.8) 7.5 (5.2–8.7) 11.0 (8.8–13.7) 11.0 (7.9–14.3)
Thrombocytes, x 109/L 278 (136–416) 293 (192–351) 346 (301–400) 254 (168–305) 298 (227–378) 290 (216–377)
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chromatography, was 0.20 μM in survivors, 1.11 μM in non-survivors, and 2.08 
μM in controls (p<0.0001 for 30-day survival; supplementary figure 7.2C). Low 
CSF tryptophan concentration predicted survival in Cox regression (hazard 
ratio [HR] for mortality 0.73; 95% CI 0.64–0.83; p<0.0001, for each halving in CSF 
tryptophan concentration; figure 7.2B). The HR was not affected by correction 
for sex, age, Glasgow Coma Scale, CSF neutrophils, CSF mononuclear cells, and 
rs17525495 LTA4H promotor polymorphism43,191, either alone or in combination 
(table 7.2). This effect was not different in sensitivity analyses that excluded 
patients who were not culture-confirmed (n=33), patients who had received 
treatment before lumbar puncture (nine), patients who had received high-dose 
rifampicin (n=21), patients who had not received dexamethasone (four), and one 
patient with rifampicin-resistant tuberculous meningitis (data not shown).
Table 7.1  Continued. 
Metabolomics  
discovery cohort
Tryptophan  
validation cohort
Genetic  
validation cohort
Controls 
(n=22)
Tuberculous  
meningitis survivors 
(n=15*)
Tuberculous  
meningitis non-survivors 
(n=17)
Controls  
(n=17)
Tuberculous  
meningitis  
(n=101)
Tuberculous  
meningitis  
(n=285)
Outcomes
Length of hospital stay, days 16 (12–17) 25 (21–29) 4 (3–7) 11 (4–20) 20 (11–23) 16 (8–22)
Alive at discharge NA 15 (100%) 0 NA 72/100 (72%) 187/242 (77%)
Outcome at day 30
Alive NA 14 (93%) 0 NA 69 (68%) 199 (70%)
Deceased NA 0 17 (100%) NA 29 (29%) 74 (26%)
Lost to follow-up NA 1 (7%) 0 NA 3 (3%) 12 (4%)
Outcome at day 180
Alive NA 12 (80%) 0 NA 52 (51%) 153 (54%)
Deceased NA 1 (7%) 17 (100%) NA 40 (40%) 99 (35%)
Lost to follow-up NA 2 (13%) 0 NA 9 (9%) 33 (12%)
Data are n (%) or median (IQR). Quantitative trait loci were identified in the metabolomics discovery 
and tryptophan validation cohort combined (excluding three patients without genotype data). Data 
are missing for some patients, as indicated. NA = not applicable. *One patient was excluded from the 
analysis and table because of aberrant liquid chromatography-mass spectrometry results. ¶Eight 
control patients in the metabolomics discovery cohort were diagnosed with primary central nervous 
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CSF tryptophan metabolism in tuberculous meningitis
Based on the metabolomic data of the discovery cohort, cerebral tryptophan 
metabolism appeared to be one of the most upregulated pathways in patients 
with tuberculous meningitis compared with controls (false discovery rate 
<10-19). Although CSF tryptophan concentrations were lower in patients with 
tuberculous meningitis compared with controls, downstream metabolites in the 
kynurenine pathway were 4–60-times higher in CSF samples of patients with 
tuberculous meningitis than in controls, although none of the downstream 
metabolites showed a significant association with survival (supplementary 
figure 7.3A and online supplement). We analysed publicly available gene 
expression data from brain autopsies of five patients with tuberculous meningitis 
and four patients with traumatic brain injury for gene expression235. In the 
kynurenine pathway Indoleamine 2,3-dioxygenase (IDO1), which is expressed 
in astrocytes and neurons238 and codes for the rate-limiting enzyme that 
converts tryptophan to L-formylkynurenine, showed greater expression in 
Table 7.1  Continued. 
Metabolomics  
discovery cohort
Tryptophan  
validation cohort
Genetic  
validation cohort
Controls 
(n=22)
Tuberculous  
meningitis survivors 
(n=15*)
Tuberculous  
meningitis non-survivors 
(n=17)
Controls  
(n=17)
Tuberculous  
meningitis  
(n=101)
Tuberculous  
meningitis  
(n=285)
Outcomes
Length of hospital stay, days 16 (12–17) 25 (21–29) 4 (3–7) 11 (4–20) 20 (11–23) 16 (8–22)
Alive at discharge NA 15 (100%) 0 NA 72/100 (72%) 187/242 (77%)
Outcome at day 30
Alive NA 14 (93%) 0 NA 69 (68%) 199 (70%)
Deceased NA 0 17 (100%) NA 29 (29%) 74 (26%)
Lost to follow-up NA 1 (7%) 0 NA 3 (3%) 12 (4%)
Outcome at day 180
Alive NA 12 (80%) 0 NA 52 (51%) 153 (54%)
Deceased NA 1 (7%) 17 (100%) NA 40 (40%) 99 (35%)
Lost to follow-up NA 2 (13%) 0 NA 9 (9%) 33 (12%)
system disease (dementia, epilepsy, meningoencephalitis, neurolupus, space-occupying lesions, or 
stroke), 11 had central nervous system manifestations of systemic disease (active pulmonary or 
miliary tuberculosis, advanced heart or kidney disease, or metabolic encephalopathy), and three had 
no final diagnosis.
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patients with tuberculous meningitis than in patients with brain trauma (35-times 
upregulation, p=0.008; α = 0.05/10 for the ten genes tested; supplementary 
figure 7.3B), suggesting that increased tryptophan metabolism might lead to 
lower CSF tryptophan in tuberculous meningitis.
Figure 7.2   CSF metabolome as a determinant of survival in patients  
with tuberculous meningitis. 
(A) Individual metabolites in CSF with ratio between tuberculous meningitis survivors and 
non-survivors, and ratio between tuberculous meningitis survivors and controls. Colours indicate 
strength of association; metabolites that do not show differences between groups (uncorrected 
p>0.05) are grey. The three subplots show metabolite concentrations according to patient category. 
The y-axis shows the 2-log of the relative abundance of metabolite ions as chromatographic peaks 
(peak ion intensity). Leukotriene B4, glucose, and tryptophan were chosen as relevant metabolites 
representing three different quadrants of the plot. (B) Kaplan-Meier plot of patient survival in the 
tryptophan validation cohort, according to CSF tryptophan concentrations, as divided in the 
following tertiles: low (<0.18 μmol/L), intermediate (0.18–0.69 μmol/L), and high (>0.69 μmol/L). CSF 
= cerebrospinal fluid.
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The impact of genetic variation on CSF tryptophan levels and  
patient survival
We mapped quantitative trait loci for CSF tryptophan concentrations using 
genome-wide SNP genotype data (available for 130 [98%] of 133 patients with 
available CSF tryptophan concentrations from the discovery and validation 
cohorts; supplementary figure 7.1A) to assess whether host genetic variation 
plays a part in the regulation of the amount of tryptophan in CSF. No single SNP 
showed genome-wide significance for CSF tryptophan concentrations, but we 
identified 11 independent loci that showed suggestive associations with CSF 
tryptophan levels (p<0.00001; table 7.3).
Table 7.2   Multivariate Cox regression for 180-day mortality in the tryptophan 
validation cohort and independent genetic validation cohort.
 
Tryptophan  
validation cohort (n=100)
Genetic  
validation cohort (n=235)
HR (95% CI) p HR (95% CI) p 
Sex, male 0.86 (0.42–1.72) 0.669 NA* NA*
Age, per 10-year increase 1.06 (0.80–1.40) 0.691 NA* NA*
Glasgow Coma Scale,  
per point increase
0.76 (0.66–0.88) 0.00026 0.80 (0.72–0.88) <0.0001
CSF neutrophils,  
per 10-fold increase
1.70 (0.86–3.36) 0.127 1.53 (1.10–2.12) 0.011
CSF mononuclear cells,  
per 10-fold increase
0.32 (0.14–0.70) 0.0044 0.75 (0.50–1.15) 0.188
LTA4H rs17525495 genotype, 
CT vs CC
0.76 (0.36–1.59) 0.460 1.06 (0.65–1.71) 0.823
LTA4H rs17525495 genotype, 
TT vs CC
0.35 (0.07–1.62) 0.177 0.72 (0.30–1.69) 0.446
CSF tryptophan,  
per each halving
0.74 (0.63–0.87) 0.00033 NA NA
Prognostic index NA NA NA 0.0083
Patients with complete data were as follows: tryptophan validation cohort (n=100, with 39 events), 
genetic validation cohort (n=235, with 81 events); for multivariate analysis, one patient was excluded 
from the tryptophan validation cohort and 50 were excluded from the genetic validation cohort 
because of missing Glasgow Coma Scale or LTA4H genotype data. CSF cell counts were analysed 
after log10[x+1] transformation. Prognostic index was included as a continuous variable. HR = hazard 
ratio. NA = not applicable. CSF = cerebrospinal fluid. LTA4H = Leukotriene A4 Hydrolase. *Age and 
sex were included in the prognostic index together with the 11 tryptophan quantitative trait loci.
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These 11 identified quantitative trait loci, along with age and sex, were used to 
generate a composite prognostic index to predict survival among patients with 
tuberculous meningitis. As expected, this score strongly predicted survival 
among the 130 patients we used for identification of the quantitative trait loci 
(figure 7.3A). The relevance of the prognostic index was validated in a separate 
group of HIV-negative patients with tuberculous meningitis, for whom no 
CSF tryptophan concentrations were available (supplementary figure 7.1A). 
The prognostic index composed of the 11 tryptophan quantitative trait loci 
also strongly predicted patient survival in this independent cohort (p=0.023 on 
log-rank test for 180-day survival, n=285), and this predictive power was 
further improved by including age and sex in the model (p=0.0054; figure 7.3B), 
although age and sex alone did not predict survival (p=0.823). The prognostic 
index showed a similar effect in sensitivity analysis restricted to 166 bacterio-
logically confirmed cases (p=0.021), and after correction for possible confounders 
(included in the multivariate analysis presented in table 7.2).
Finally, we examined the possible biological relevance of the 11 tryptophan 
quantitative trait loci. Only one tryptophan quantitative trait locus was known 
to influence expression of a gene, WBP4, the expression of which was affected in 
skeletal muscle (p<0.0001) and tibial nerve (p=0.0006). As a second approach to 
prioritise causal genes at tryptophan quantitative trait loci, we extracted publicly 
available expression data for annotated genes located within a 1-Mb cis-window 
of the 11 tryptophan quantitative trait loci in different human tissues and cell 
lines. Unsupervised clustering analysis of the 54 (77%) of 70 annotated genes 
with data available showed that the tryptophan quantitative trait loci were 
mainly expressed in immune cells and brain tissues (supplementary figure 7.4). 
In brain autopsy data of patients with tuberculous meningitis235, 17 (24%) of 70 
annotated genes showed differential expression compared to patients who died 
of head injury (meeting a cut-off of p<0.05; table 7.3). Pathway analysis for these 
genes did not reveal enrichment for any one pathway (data not shown), but this 
selection emphasised the role of immune genes (TRIL, NAP1L1, and OSBPL8), 
metabolic enzymes (MAGI1), and brain-specific genes (WBP4, GAS7, and CHN2) 
in determining tryptophan concentrations in CSF of patients with tuberculous 
meningitis.
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Figure 7.3   Cerebrospinal fluid tryptophan quantitative trait loci in relation to 
survival of patients with tuberculous meningitis. 
(A) Manhattan plot for association of CSF tryptophan concentrations with single nucleotide 
polymorphisms on 22 somatic chromosomes. The horizontal line depicts the threshold chosen to call 
suggestive associations (p<10−5), with the accession number (rsID) of 11 independent single 
nucleotide polymorphisms associated with tryptophan concentrations. (B) Kaplan-Meier plots using 
prognostic index including these 11 tryptophan quantitative trait loci, age, and sex, predicting 
survival of patients with tuberculous meningitis in the genetic discovery cohort and genetic 
validation cohort. CSF = cerebrospinal fluid.
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Discussion
To our knowledge, this is the first study comparing the CSF and serum 
metabolome of patients with tuberculous meningitis and controls without 
meningitis, linking metabolite concentrations to patient mortality. CSF tryptophan 
concentration was identified as a strong predictor of mortality, and this finding 
was validated in a second patient cohort. Furthermore, by using genome-wide 
SNP data we identified 11 quantitative trait loci associated with CSF tryptophan 
concentrations, and found that these quantitative trait loci were predictive of 
patient survival in a third cohort of patients with tuberculous meningitis. 
Collectively, our data showed that cerebral tryptophan metabolism is important 
for the outcome of tuberculous meningitis.
We also believe this is the first study to examine the outcome of tuberculous 
meningitis using a combination of metabolomic and genomic approaches. In 
Table 7.3  Cerebrospinal fluid tryptophan quantitative trait loci in tuberculous meningitis
Chr. Position Reference  
allele (A)
Minor  
allele (a)
In tuberculous  
meningitis cohort
In tuberculous  
meningitis cohort
Association  
with CSF tryptophan 
concentration in 
tuberculous meningitis*
Biological plausibility
Minor allele 
frequency
AA Aa aa Imputation 
accuracy (R2)
p β Nearest 
gene
Genes indicated by  
differential expression analysis#
rs111552533 2 192 996 515 C T 0.42 47 63 20 0.87 3.21 × 10−6 1.26 TMEFF2 SDPR
rs62243769 3 65 949 227 C G 0.40 48 60 22 0.95 9.85 × 10−6 −1.14 MAGI1 MAGI1
rs13156386 5 123 017 888 A G 0.27 72 50 8 0.75 3.61 × 10−6 1.60 CSNK1G3 CEP120
rs141710116 7 80 867 056 T C 0.23 72 56 2 0.75 5.91 × 10−6 −1.94 SEMA3C HGF, SEMA3C
rs3815652 7 33 913 404 T C 0.32 58 63 9 0.66 1.31 × 10−7 1.83 BMPER BMPER, BBS9
rs2391754 7 29 403 188 T C 0.20 87 38 5 0.47 3.26 × 10−6 1.73 CHN2 TRIL
rs10998941 10 71 495 726 T G 0.44 39 65 26 0.87 6.89 × 10−6 1.22 COL13A1 TYSND1
rs12814611 12 76 384 849 T C 0.43 37 74 19 0.95 5.61 × 10−6 1.28 PHLDA1 OSBPL8, BBS10, NAP1L1, PHLDA1
rs11838725 13 41 671 085 T C 0.21 77 50 3 0.62 1.91 × 10−6 −1.89 WBP4 RGCC, WBP4, FOXO1
rs147182487 13 54 547 574 T C 0.13 36 94 0 0.47 2.56 × 10−6 2.35 LINC00558 ..
rs55854133 17 10 497 745 A G 0.15 98 29 3 0.70 4.75 × 10−6 1.87 MYHAS GAS7
AA, Aa, and aa genotypes are listed, where A represents the major allele and a the minor allele. 
SNP = single nucleotide polymorphism. *Linear regression analysis was used for quantitative trait loci 
mapping upon correcting for age and sex. #Based on differential expression analysis in tuberculous 
meningitis versus brain injury patients data (using data from Kumar and colleagues235), genes 
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accordance with earlier studies, we found lower CSF glucose and higher lactate 
concentrations195, and increased amounts of aminoacids239 in CSF of patients 
with tuberculous meningitis compared with controls. We confirmed that glucose 
was lowest in patients who subsequently died. We focused on tryptophan because 
of its distinct pattern and biological relevance for tuberculosis. The combination 
of lower CSF tryptophan concentrations, higher concentrations of downstream 
kynurenine metabolites, and upregulated IDO1 in brain autopsy mRNA expression 
profiles suggests that M. tuberculosis brain infection leads to increased cerebral 
tryptophan metabolism. Based on these findings, we concluded that an individual’s 
genetic makeup determines the response in tryptophan metabolism if M. tuberculosis 
invades the brain to cause meningitis, with lower CSF tryptophan associated 
with reduced mortality.
Low CSF tryptophan metabolite concentrations have previously been found in 
bacterial meningitis240, trypanosomiasis241, rabies242 and cerebral malaria243. 
Table 7.3  Cerebrospinal fluid tryptophan quantitative trait loci in tuberculous meningitis
Chr. Position Reference  
allele (A)
Minor  
allele (a)
In tuberculous  
meningitis cohort
In tuberculous  
meningitis cohort
Association  
with CSF tryptophan 
concentration in 
tuberculous meningitis*
Biological plausibility
Minor allele 
frequency
AA Aa aa Imputation 
accuracy (R2)
p β Nearest 
gene
Genes indicated by  
differential expression analysis#
rs111552533 2 192 996 515 C T 0.42 47 63 20 0.87 3.21 × 10−6 1.26 TMEFF2 SDPR
rs62243769 3 65 949 227 C G 0.40 48 60 22 0.95 9.85 × 10−6 −1.14 MAGI1 MAGI1
rs13156386 5 123 017 888 A G 0.27 72 50 8 0.75 3.61 × 10−6 1.60 CSNK1G3 CEP120
rs141710116 7 80 867 056 T C 0.23 72 56 2 0.75 5.91 × 10−6 −1.94 SEMA3C HGF, SEMA3C
rs3815652 7 33 913 404 T C 0.32 58 63 9 0.66 1.31 × 10−7 1.83 BMPER BMPER, BBS9
rs2391754 7 29 403 188 T C 0.20 87 38 5 0.47 3.26 × 10−6 1.73 CHN2 TRIL
rs10998941 10 71 495 726 T G 0.44 39 65 26 0.87 6.89 × 10−6 1.22 COL13A1 TYSND1
rs12814611 12 76 384 849 T C 0.43 37 74 19 0.95 5.61 × 10−6 1.28 PHLDA1 OSBPL8, BBS10, NAP1L1, PHLDA1
rs11838725 13 41 671 085 T C 0.21 77 50 3 0.62 1.91 × 10−6 −1.89 WBP4 RGCC, WBP4, FOXO1
rs147182487 13 54 547 574 T C 0.13 36 94 0 0.47 2.56 × 10−6 2.35 LINC00558 ..
rs55854133 17 10 497 745 A G 0.15 98 29 3 0.70 4.75 × 10−6 1.87 MYHAS GAS7
located within 1 Mb cis window of 11 tryptophan quantitative trait loci (n=70 for the 11 quantitative 
trait loci) that might contribute to tryptophan concentration in CSF of patients with tuberculous 
meningitis were identified. Chr = chromosome.
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However, to our knowledge, CSF tryptophan has never been reported in relation 
to survival of patients with central nervous system infection. Several possible 
explanations exist for how tryptophan and kynurenine metabolism might affect 
the outcome of tuberculous meningitis. First, activated macrophages could 
inhibit M. tuberculosis growth through activation of IDO1, with depletion of 
tryptophan as an energy source for mycobacteria244. Second, tryptophan and its 
downstream metabolites affect T-cell responses and inflammation. For instance, 
kynurenine is sensed by the aryl hydrocarbon receptor245, which is engaged in 
M. tuberculosis-infected macrophages and crucial for several innate immune 
responses246. Finally, certain kynurenine metabolites, such as kynurenic acid 
and quinolinic acid, are involved in neuroprotective and neurodamaging 
responses238. Therefore, the relative abundance and balance of tryptophan and 
kynurenine metabolites is likely to affect the outcome of tuberculous meningitis. 
Notably, compared to tryptophan, individual downstream metabolites showed 
smaller differences between survivors and non-survivors, probably because 
tryptophan is metabolised via different pathways.
We found a genetic correlate of CSF tryptophan concentration in tuberculous 
meningitis that predicted survival in an independent cohort, which suggested 
the intrinsic ability to upregulate tryptophan metabolism in response to M. 
tuberculosis infection affects the balance between bacterial clearance and immu-
nopathology in tuberculous meningitis. As there are no Indonesian specific SNP 
reference panels available for imputation we should be cautious about inferring 
causality of identified variants. Nevertheless, further analysis of CSF tryptophan 
quantitative trait loci identified several candidate genes with immune, metabolic, 
or brain-specific functions, which could be targets for further study (e.g., in 
experimental models). Tryptophan metabolism is an attractive target for adjunctive 
therapy. Treatment with interferon-α successfully increased peripheral blood 
but not CSF kynurenine concentrations247, and ingestion of a 15-aminoacid, 
tryptophan-free mixture strongly reduced CSF tryptophan concentrations248.
Strengths of our study are the careful description and prospective follow-up of 
patients, the combination of metabolomics and genetics, and the validation of 
findings in two separate patient groups. Limitations of the metabolomic 
approach include the large but still restricted number of annotated metabolites, 
which form a fraction of the incompletely characterised human metabolome. 
Therefore, metabolites other than tryptophan that are not yet annotated could 
be better predictors for survival. Moreover, the discovery cohort included a 
relatively small number of culture-confirmed, HIV-negative patients, so further 
study is needed to discover metabolites with smaller effect sizes and to expand 
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our findings to HIV-positive patients. We showed a genetic association with 
tryptophan concentration and mortality, but the observational nature of our 
study precludes statements on the causative mechanism. Further study is 
therefore needed to identify specific metabolic steps in cerebral tryptophan 
metabolism that are linked to immunopathology and patient survival. Also, 
confirmation of our results in a cohort with a different genetic background could 
validate the ability of specific quantitative trait loci in their ability to predict 
CSF tryptophan concentration and survival. Intervention studies should help 
establish if tryptophan metabolism can be used as a target for adjuvant treatment 
in tuberculous meningitis.
In summary, a low CSF tryptophan concentration strongly predicted patient 
survival, and no association was found between serum tryptophan and mortality. 
CSF tryptophan concentrations in patients with tuberculous meningitis were 
under genetic influence, and genetic loci correlating with CSF tryptophan 
concentrations also predicted survival in an independent patient group. 
Collectively, these data suggest that cerebral tryptophan metabolism is crucial 
for survival of tuberculous meningitis. Our findings provide possible new 
strategies for host-directed therapy (e.g., pharmacological induction of tryptophan 
metabolism) for tuberculous meningitis. Our integrative approach of combining 
CSF metabolomics and genetics with routine patient characteristics and survival 
also holds promise for identification of other relevant biological pathways and 
targets for adjuvant therapy, both in tuberculous meningitis and in other central 
nervous system infections.
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Supplementary Methods
CSF and serum metabolomics
For the hydrophilic interaction chromatography negative ion method, serum 
and plasma samples were precipitated in 80% methanol containing inosine-15N4, 
thymine-d4, and glycocholate-d4 internal standards (Cambridge Isotope 
Laboratories; Andover, MA, USA). Samples were cleared by centrifugation and 
supernatants injected onto a 150 mm × 2 mm Luna NH2 column (Phenomenex; 
Torrance, CA, USA). 
For the hydrophilic interaction chromatography positive ion method, samples 
were precipitated with nine volumes of 74.9% acetonitrile, 24.9% methanol, and 
0.2% formic acid, by volume containing stable isotope-labelled internal standards 
(valine-d8; Isotec, Sigma-Aldrich; St Louis, MI, USA; and phenylalanine-d; 
Cambridge Isotope Laboratories). After centrifugation, supernatants were 
injected onto a 150 mm × 2 mm Atlantis hydrophilic interaction chromatography 
column (Waters; Milford, MA, USA)230.
 For measuring compounds of intermediate polarity, serum and plasma samples 
were extracted in methanol containing PGE2-d4 as an internal standard 
(Cayman Chemical Company, Ann Arbor, MI, USA), and supernatants of 
samples were cleared by centrifugation. Extracted CSF samples underwent solid 
phase extraction with an Oasis HLB Cartridges column (Waters) before injection 
onto a 150 mm × 2 mm ACQUITY T3 column (Waters). Finally, polar and 
non-polar lipids were obtained by extracting samples in isopropanol containing 
1-dodecanoyl-2-tridecanoyl-sn-glycero-3-phosphocholine as an internal standard 
(Avanti Polar Lipids; Alabaster, AL, USA). After centrifugation, supernatants 
were injected directly onto a 100 mm × 2.1 mm ACQUITY BEH C8 column 
(1.7 μm; Waters)231. 
Targeted data were analysed using MultiQuant software (version 1.1; AB SCIEX, 
Foster City, CA, USA) for automated peak integration and manual review for 
quality of integration. Metabolites analysed using non-targeted measurements 
were manually integrated and inspected using TraceFinder software (version 
3.1, Thermo Fisher Scientific; Waltham, MA, USA) and their identities validated 
by matching measured retention times and masses to mixtures of reference 
metabolites.
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CSF samples were diluted three times with formic acid (0.05%) before injection 
(25 μL) onto a reverse phase column (ACQUITY UPLC R HSS T3 [1.8 μm, 2.1 × 
100 mm]; Waters). The mobile phase (0.3 mL/min) consisted of ammonium 
acetate buffer (pH 5.4), containing 0.38% methanol. Fluorescence was used for 
detection (excitation at 278 nm and emission at 325 nm) during a 15 min run. 
CSF and serum albumin was measured using routine nephelometry in CSF 
(Immage; Beckman Coulter, Brea, CA, USA) and photometrically in serum 
(cobas 6000; Roche Diagnostics, Indianapolis, IN, USA).
Genotyping, quality control and imputation
DNA samples were genotyped using a commercially available SNP chip 
(Human OmniExpressExome-8 v1.0; Illumina; San Diego, CA, USA). Genotype 
calling was performed using Opticall 0.7.0249 using the default settings. Samples 
with a call rate less than 0.99 were excluded, as were variants with a Hardy- 
Weinberg equilibrium p<0.0001, and minor allele frequency less than 0.001. 
No genetic outliers were detected by visualizing the cohort using multi- 
dimensional scaling plots. Strands of the remaining 259, 335 variants were 
aligned and identified against the 1000 Genome reference panel with Genotype 
Harmonizer.250 We imputed the samples on the Michigan imputation server,251 
using the Asian population in human reference consortium as reference panel,252 
and then selected variants with an R2 of at least 0.3253. The rs17525495 LTA4H 
promotor polymorphism was genotyped using the TaqMan C__25593629_10 assay 
on a 7300 ABI real-time PCR system (Applied Biosystems, Foster City, CA, USA). 
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Supplementary figures
Supplementary figure 7.1 
(A) Overview of patients in different parts of the study. All tuberculous meningitis patients (100%) in 
the metabolomics discovery cohort had a positive CSF culture, and the same was true for 60% of 
patients in the tryptophan validation cohort and 57% in the genetic validation cohort. (B) Comparison 
of serum and CSF metabolite concentrations. Correlation between LC-MS obtained values for serum 
versus CSF. Dotted line: x = y. (C) Differences between patients and controls across the range of 
metabolites. Serum versus CSF albumin concentration (left) and CSF/serum ratio (right). 
Mann-Whitney U test for diagnosis (control versus patients): p<0.001. Mann-Whitney U test for 
outcome (survivor versus non-survivor): p=0.58. Dotted lines indicate the normal range (0.005 to 
0.008).232 (D) Differences between patients and controls across the range of metabolites. Relationship 
between metabolite m/z and abundance (mean intensity) in CSF and serum. Colours indicate fold 
difference (margins indicated in the coloured bar) between patients and controls based on 
uncorrected p-values (as in main text figure 7.1C and 7.1D).
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Supplementary figure 7.1  Continued.
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Supplementary figure 7.2  Comparison of CSF and serum metabolites according 
to survival status. 
(A) Volcano plot for individual metabolites in CSF (upper plot) and serum (lower plot), with fold 
difference between tuberculous meningitis survivors and nonsurvivors (x-axis), and unadjusted 
p-value (y-axis). The plot on the lower right features the same x-axis, but contrasts against fold 
difference between tuberculous meningitis survivors and controls (y-axis). Colours indicate strength 
of association and metabolites without an association (uncorrected p>0.05) are coloured grey. 
The black circle indicates tryptophan. (B) Correlation of CSF metabolites with CSF neutrophils (left), 
CSF mononuclear cells (middle) and blood-CSF barrier disruption as measured by CSF-serum 
albumin gradient in tuberculous meningitis patients. Colours correspond to fold difference between 
survivors and nonsurvivors. Metabolites without an association (uncorrected p>0.05) are coloured 
grey (as in Figure 7.2A). The black circle indicates tryptophan. (C) CSF tryptophan measured by 
 ultra-performance liquid chromatography in the discovery and the validation cohort. P-value by 
Mann-Whitney test for outcome of tuberculous meningitis patients at discharge (discovery cohort) 
and at 30 days after admission (validation cohort).
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Supplementary figure 7.2  Continued.
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Supplementary figure 7.3 
(A) Pathway based on Kyoto Encyclopedia of Genes and Genomes (map 00380; http://www.genome.
jp/kegg/pathway/), Virtual Metabolic Human; http://vmh.uni.lu) and the Small Molecule Pathway 
Database (SMP00063, http://smpdb.ca). Gene symbols: AADAT: aminoadipate aminotransferase; ACMSD: 
aminocarboxymuconate semialdehyde decarboxylase; AFMID: arylformamidase; DDC: DOPA decarbo - 
xylase (aromatic L-amino acid decarboxylase); IDO1 and IDO2: indolamine 2,3-dioxygenase 1 and 2; 
HAAO: 3-hydroxyanthranilate 3,4-dioxygenase; KMO: kynurenine 3-monooxygenase; KYAT1 and 
KYAT3: kynurenine aminotransferase 1 and 3; KYNU: Kynureninase. TDO2: tryptophan 2,3-dioxy-
genase. TPH1 and TPH2: tryptophan hydroxylase 1/2; WARS1/2: tryptophanyl-tRNA synthetase. 
Other abbreviations: ALDH: an aldehyde dehydrogenase; MAO: a monoamine oxidase, i.e. MAOA or 
MAOB. 5-HIAA: 5-hydroxy-indolacetate. Inlay: mean tryptophan pathway metabolite levels in 
serum versus CSF for controls (green), tuberculous meningitis survivors (blue) and nonsurvivors 
(red). (B) Volcano plot of brain autopsy mRNA expression with fold difference between five 
tuberculous meningitis patients and four patients deceased of head-injury (x-axis) with unadjusted 
p-values (y-axis). Genes involved in the tryptophan pathway are indicated by black circles, against 
grey circles for all other genes tested by Kumar et al. Differentially expressed genes (p<0.05) in the 
tryptophan pathway are named. Data made publicly available by Kumar et al235 (GSE23074).
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Abstract
Introduction 
Tuberculous meningitis is the most severe form of tuberculosis. Damaging and/or 
ineffective host immune responses contribute to the high mortality of tuberculous 
meningitis, but the underlying mechanisms remain largely unknown. 
Methods 
We included patients with confirmed or probable tuberculous meningitis in a 
prospective cohort at the Hasan Sadikin Hospital (Bandung, Indonesia). Using a 
multiplex immunoassay, 94 inflammation-related proteins were measured in 
cerebrospinal fluid (CSF) samples of 131 tuberculous meningitis patients and 45 
control patients without meningitis. Next, genome-wide single nucleotide 
polymorphism typing was used to identify genetic loci correlating to CSF 
protein levels. These quantitative trait loci (QTLs) were analysed in a survival 
analysis in an independent cohort of 299 tuberculous meningitis patients.
Findings
Overall, 77 of 94 proteins detected in at least 25% of the samples were included 
in the analysis; 69 (92%) of these were significantly different between the 
tuberculous meningitis patients and the control group (FDR < 0.05), and 66 of 
69 markers were higher in tuberculous meningitis patients compared to controls. 
Four CSF proteins significantly predicted 180-day mortality, including vascular 
endothelial growth factor (VEGF). Six QTLs for CSF VEGF were identified, 
including one genome-wide significant QTL (rs3019146; p=2.17 x 10-8). A prognostic 
index based on these QTLs significantly predicted survival in the discovery 
cohort (p=0.0088) and an independent validation cohort (p=0.0018). 
Interpretation
High CSF concentrations of VEGF show a strong association with increased 
mortality of tuberculous meningitis, possibly because of its effects on vascular 
permeability, dysfunction of tight junction proteins, and brain oedema. CSF 
VEGF concentrations in tuberculous meningitis have a genetic correlate, likely 
contributing to the variable outcome of tuberculous meningitis. 
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Introduction
On a global scale, tuberculosis remains a leading cause of death, and approximately 
one fourth of the world’s population is infected with M. tuberculosis1. Tuberculous 
meningitis is the most devastating manifestation of tuberculosis, which results 
in death or severe disability in roughly half of all tuberculous meningitis cases27. 
Understanding and identifying factors that affect mortality is crucial to improve 
therapeutic strategies.
The host immune system contributes to the poor outcome of tuberculous 
meningitis, either through inadequate killing of M. tuberculosis, or through an 
inappropriate inflammatory response leading to tissue damage (immunopa-
thology)16. Previous studies have identified a low proportion of cerebrospinal 
fluid (CSF) lymphocytes (chapter 5) or a low overall number of CSF leukocytes43 
associated with mortality. Reports on individual inflammatory mediators have 
not been consistent. For example, in a recent study high CSF IFN-γ was associated 
with good outcome in HIV-negative patients, but not HIV-positive patients43, 
while in an older study IFN-γ was protective only in HIV-positive patients255. 
Therefore, the aim of this study was to obtain a broader characterization of the 
inflammatory response in CSF in tuberculous meningitis using an unbiased 
approach, and to link this to mortality. To this purpose we measured a large 
panel of inflammatory proteins in CSF and linked their concentrations to 
survival in a prospective cohort of tuberculous meningitis patients. We then 
searched for single nucleotide polymorphisms (SNPs) that act as quantitative 
trait loci (QTLs) for CSF proteins associated with survival, and examined whether 
these QTLs also predicted survival in an independent cohort of tuberculous 
meningitis patients. 
Methods
Study design and participants
Study participants with suspected meningitis were included in a prospective 
cohort from the Hasan Sadikin Hospital (Bandung, Indonesia) from 31st October 
2006 to 16th June 2016 as described in chapter 5. HIV co-infection, which strongly 
affects the immune response and mortality of tuberculous meningitis, was an 
exclusion criterion for this study. Routine clinical and CSF characterization were 
performed at the time of diagnosis, and survival was monitored for one year. For 
the proteomic and genetic analyses, 131 tuberculous meningitis patients and 45 
controls were selected from this prospective cohort, and another 299 tuberculous 
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meningitis patients were selected for genetic validation. Patients were included 
under the project “Optimization of Diagnosis of Meningitis,” approved by the 
Ethical Committee of Hasan Sadikin Hospital/Faculty of Medicine of Universitas 
Padjadjaran, Bandung, Indonesia (449/UN6.C1.3.3/KEPK/PN/2015).
Protein analysis
CSF samples were centrifuged for 15 minutes at 3000 x g and the supernatant 
was stored at -80°C.  The commercially available ProSeek Multiplex Inflammation 
I panel (Olink Proteomics, Uppsala, Sweden) was used to measure a panel of 92 
inflammation-related proteins in CSF. The procedure of the multiplex proximity 
extension assay was performed as previously described256. Briefly, proteins are 
recognized by pairs of antibodies coupled to cDNA strands. These cDNA strands 
bind when they are in close proximity, after which they extend by a polymerase 
reaction. After detection and normalization, this results in normalized protein 
expression values, measured on a log2-scale. Proteins were excluded from the 
analysis when the target protein was detected in less than 25% of the samples. 
Additionally, levels of neuron-specific enolase (NSE), calprotectin (S100A8/A9), 
and IL-1Ra were measured in these CSF samples using enzyme-linked 
immunosorbent assays (ELISAs) and were performed according to the 
manufacturer’s protocol (R&D Systems, Minneapolis, Minnesota, USA). ELISA 
data were log-transformed before analysis. Serum and CSF albumin were 
measured in a subgroup of patients as described in chapter 7.
Protein data analysis and statistics
Data analysis of this study included protein, survival and QTL analysis. All 
computational analyses were performed in R 3.3.3. Protein levels were compared 
between tuberculous meningitis patients and controls using two-sample Wilcoxon 
tests. A false discovery rates (FDR) based on Benjamini-Hochberg procedure of 
less than 0.05 was considered significant. Proteins levels were then correlated 
using Spearman’s Rank-Order correlation and clustered using average hierarchical 
clustering using a maximum distance between proteins of 0.3, visualized using 
the R package ‘corrplot’. Each cluster was represented by the protein with the 
lowest distance to the other proteins in that cluster. Due to high correlation 
between markers and to avoid the burden of multiple testing corrections, only 
the representatives were included in further analysis, which enabled us to 
analyse groups of proteins rather than all markers individually. The protein 
cluster representatives were correlated to relevant measures of inflammation or 
brain damage using Spearman correlation, and analysed for survival using Cox 
regression with R packages survival and survminer. The Bonferroni method 
was used to correct for multiple testing.
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Genome-wide quantitative trait loci mapping
Genotyping and imputation was performed as described in chapter 7. Quantitative 
trait loci (QTLs), genetic variants association with protein levels, were identified 
using log2-transformed CSF protein expression values with a threshold for 
genome-wide significance was of p<5 x 10-8, while p<1 x 10-5 was considered 
a suggestive association. Finally, to test whether clinical parameters were 
confounding VEGF or our prognostic index, we performed a multivariate Cox 
regression including gender, age, Glasgow Coma Scale, and polymorpho nuclear 
and mononuclear cell counts in the CSF.
Results
Inflammation-related proteins in CSF of tuberculous  
meningitis patients 
For the proteomic analysis, 131 tuberculous meningitis patients and 45 controls 
were included. Of those 131 patients, 97 (74%) had definite tuberculous 
meningitis, as confirmed by CSF culture or PCR. The patient characteristics of 
the cohort are summarized in table 8.1. Including the proteins measured by 
ELISA, 94 proteins were measured in CSF (online supplement). The quality of 
the measurement was high, and 99% of the samples passed quality control. 
Patients with tuberculous meningitis had a distinct CSF proteome compared to 
controls. Overall, 77 of the 94 (82%) were detected in at least 25% of the 
tuberculous meningitis patients’ CSF samples and therefore included in the 
analysis. Of these 77 proteins, 71 (92%) differed significantly between the 
controls and the tuberculous meningitis group, 68 were higher and 3 were lower 
in tuberculous meningitis patients compared to controls (figure 8.1).
Subsequently, we analysed global correlation patterns for CSF proteins in 
tuberculous meningitis patients. Using Spearman correlations and average 
hierarchical clustering, we identified 30 clusters of proteins, each represented by 
one protein with the lowest relative distance to the other proteins in the cluster 
(figure 8.2). 
The majority of the protein pairs showed positive correlations, although a 
number of proteins including CXCL9, CXCL10, and FGF5 mainly showed inverse 
correlations with the other proteins. None of the CSF protein concentrations 
correlated well (Spearman’s rho>0.5) with CSF mononuclear cell count, and only 
four (13%) out of 31 correlated with polymorphonuclear cell counts (figure 8.3), 
indicating that CSF leukocytes are not the main source of these proteins. Seven 
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(23%) protein cluster representatives correlated well with neuron-specific 
enolase (NSE), a well-established marker for neuronal damage257. Correlations 
were especially high for CSF total protein (11 representatives with rho >0.5). CSF 
total protein is used as a proxy for blood-CSF barrier disruption, showing an 
excellent correlation CSF-serum albumin gradient (Pearson r = 0.95, p<0.0001). 
CSF vascular endothelial growth factor concentrations strongly 
predict patient survival
Among 130 (99%) of the tuberculous meningitis patients with complete follow-up till 
six months, mortality was 44%. Four protein cluster representatives significantly 
predicted survival after correction for multiple testing in Cox regression 
(α=0.05/30 clusters of proteins = 0.0017), all with a hazard ratio above 1, indicating 
that higher CSF protein concentrations are associated with a higher mortality 
rate (table 8.2). One of the four identified CSF markers was vascular endothelial 
growth factor (VEGF). Because of its plausible biological role in tuberculous 
meningitis, we restricted further analysis to VEGF. CSF VEGF levels also 
Figure 8.1   Protein levels show large differences between patients and  
controls in CSF. 
Volcano plot for individual proteins in CSF with log-transformed fold change between tuberculous 
meningitis patients and controls (x-axis), and log-transformed false discovery rate (FDR, y-axis). 
Proteins significantly different between tuberculous meningitis and controls (FDR < 0.05) are 
coloured blue. 
tuberculous meningitis : controls
FD
R
0.001 0.01 0.1 1 10 100 1000
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correlated with CSF total protein (Spearman’s rho=0.57, p=1.03 x 10-12) and CSF 
NSE (rho=0.51, p=4.50 x 10-8), and to a lesser extent to CSF polymorphonuclear 
cell counts (Spearman’s rho=0.24, p=0.0069). A two-fold increase in VEGF was 
associated with a hazard ratio (HR) of 1.57 for 180-day mortality (95% CI 
1.24–1.99, p=1.6 x 10-4, figure 8.4). This relationship was unchanged in a 
sensitivity analysis restricted to culture-positive cases (HR 1.54, 95% CI 1.18–2.01) 
and in multivariate analysis including known risk factors (HR 1.55, 95% CI 
1.19–2.01, p=1.2 x 10-3, table 8.3). 
Figure 8.2  High overall correlation between inflammatory proteins. 
Correlation matrix with Spearman correlations, in which the proteins are ordered by average 
hierarchical clustering. The squares define 30 clusters (maximum distance between proteins in the 
same cluster is 0.3), and the proteins in blue are the representatives for a cluster (the lowest distance 
to the other proteins in the cluster).
212 | Chapter 8
Fi
g
u
re
 8
.3
   C
SF
 p
ro
tei
ns
 (i
nc
lu
di
ng
 V
EG
F)
 co
rre
lat
e w
ith
 ba
rri
er
 d
isr
up
tio
n m
ar
ke
rs,
 bu
t p
oo
rly
 w
ith
 C
SF
 le
uk
oc
yt
e c
ou
nt
s. 
Sp
ea
rm
an
 c
or
re
la
ti
on
 c
oe
ffi
ci
en
ts
 (x
-a
xe
s)
 o
f 
th
e 
p
ro
te
in
 c
lu
st
er
 r
ep
re
se
nt
at
iv
es
 w
it
h
, C
SF
 t
ot
al
 p
ro
te
in
, n
eu
ro
n-
sp
ec
ifi
c 
en
ol
as
e 
(N
SE
), 
m
on
on
u
cl
ea
r 
ce
ll
 c
ou
nt
,  
po
ly
m
or
ph
on
uc
lea
r c
ell
 co
un
ts.
To
ta
l p
ro
te
in
 
N
S
E
 
M
on
on
uc
le
ar
 c
el
ls
P
ol
ym
or
hp
on
uc
le
ar
 c
el
ls
Vascular endothelial growth factor in tuberculous meningitis | 213
Genetic variation associated with CSF inflammatory proteins is an 
independent factor associated with patient survival
To identify a genetic basis for the regulation of CSF VEGF in tuberculous 
meningitis patients, quantitative trait loci for VEGF were mapped using 
genome-wide SNP genotype data (figure 8.5A). One locus on chromosome 8 
(rs3019146 in RAD54B) showed a genome-wide significant association with 
VEGF levels (p=2.18 x 10-8, figure 8.5B-C). This SNP has a known function in 
influencing the expression of RAD54B, which is involved in DNA repair and 
mitotic recombination. Five other loci showed a suggestive association with 
VEGF levels (p<1 x 10-5, table 8.4).
These six identified quantitative loci were used to generate a prognostic index, 
and study participants were divided into two groups, low and high risk, based 
on the median of the prognostic index. As expected, this predicted survival in 
the 128 (98%) tuberculous meningitis patients used for QTL mapping (log-rank 
test for 180-days survival, p=0.0088, figure 8.5D). This finding was validated in 
a second group of 299 tuberculous meningitis patients (49% culture-confirmed) 
with complete six-month follow-up for 171 (91%) with 106 (35%) recorded deaths 
(table 8.1). Similar to the discovery cohort, the prognostic index including QTLs 
Table 8.2   Cox regression for 180-day mortality for the 30 protein  
cluster representatives
Representative Hazard ratio + 95% CI p Proteins  
in the same cluster
IL-24 2.35 (1.59–3.48) 2.00 x 10-5* -
TWEAK 1.93 (1.37–2.72) 1.55 x 10-4* -
VEGF 1.57 (1.24–1.99) 1.62 x 10-4* -
OPG 1.49 (1.18–1.88) 6.85 x 10-4* -
IL-7 1.60 (1.16–2.21) 3.92 x 10-3 -
MMP-10 1.31 (1.08–1.60) 6.11 x 10-3 -
Beta-NGF 1.91 (1.09–3.33) 2.30 x 10-2 HGF, SCF, FGF19
CCL11 1.39 (1.05–1.86) 2.36 x 10-2 CCL25
MCP-4 1.28 (1.03–1.59) 2.51 x 10-2 CCL23
IL-12B 0.86 (0.74–0.99) 3.55 x 10-2 -
AXIN1 2.22 (1.05–4.73) 3.80 x 10-2 -
The hazard ratio is expressed per two-fold increase. The * represents proteins associated with survival 
after Bonferroni correction (α = 0.05; 0.05 / 30 = 0.0017). N = 130; 57 events.
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for CSF VEGF predicted survival in this second group of 299 tuberculous 
meningitis patients (p=0.0018, figure 8.5E), also in multivariate analysis correcting 
for possible confounders (table 8.3). 
Figure 8.4  CSF VEGF concentrations predict survival in tuberculous meningitis. 
Kaplan-Meier graph with survival table for patients (n=130) based on CSF VEGF concentrations 
divided in tertiles. The VEGF concentrations are expressed as normalized protein expression (NPX) 
and groups were defined by the following cut-offs:  low (NPX < 9.80), middle (NPX 9.80 – 10.87) and 
high (NPX > 10.87).
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Figure 8.5   Genetic traits predict VEGF levels in CSF from tuberculous 
meningitis patients. 
(A) Manhattan plot showing the genome-wide QTL mapping results for CSF VEGF levels in tuber- 
culous meningitis patients. Horizontal dashed lines correspond to p<5 × 10−7 and p<1 × 10−5.  (B) Boxplot 
showing the VEGF levels distributed across the three genotypes of the genome-wide QTL rs2291439. 
(C) Regional plot for genome-wide QTL rs2291439. (D) Kaplan-Meier graph of prognostic index 
predicting survival in 128 individuals with available genetic and follow-up data from the discovery 
cohort. (E) Kaplan-Meier graph of prognostic index predicting survival in 299 individuals with 
available genetic and follow-up data from the validation cohort.
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Discussion
Damaging or ineffective host immune responses contribute to the high mortality 
of tuberculous meningitis, but the underlying mechanisms remain largely 
unknown. We studied the inflammatory proteome in CSF of tuberculous 
meningitis patients and its correlation to CSF leukocytes and markers of damage 
to the brain and blood-CSF barrier. Four proteins showed an independent 
association with mortality, including vascular endothelial growth factor (VEGF). 
We identified six genetic loci associated with CSF VEGF concentrations in 
tuberculous meningitis patients, including one locus with genome-wide 
significance. A prognostic index based on these loci predicted survival in an 
independent validation cohort. 
VEGF induces a potent angiogenic response, but is also known as a vascular 
permeability factor, based on its ability to induce vascular leakage258. One of the 
most critical triggers of angiogenesis is hypoxia, which activates hypoxia-induc-
ible factor (HIF) proteins, HIF-1 and HIF-2, leading to an increased VEGF release. 
Although hypoxia is considered to be the main driver of angiogenesis, 
inflammation also makes important contributions to this process, e.g. TNF-α is 
also able to induce VEGF production259. Due to cerebral vasculitis and stroke, 
both cerebral hypoxia and inflammation are often present in tuberculous 
meningitis patients. 
Figure 8.5   Continued. 
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To our knowledge, this study is the first to link VEGF levels in CSF to survival 
in tuberculous meningitis patients and to describe a genetic basis for VEGF 
levels in CSF in tuberculous meningitis. In a pulmonary tuberculosis rabbit 
model, anti-VEGF treatment reduced the formation of immature and 
hyperpermeable vessels and hypoxia in tuberculous granuloma’s, thereby 
increasing anti-tuberculous drug efficacy260. Increased VEGF could also play 
a causal role in tuberculous meningitis immunopathology, in which case 
anti-VEGF treatment might reduce this ‘collateral damage’. Tuberculous 
meningitis is characterized by disruption of the blood-brain barrier, cerebral 
oedema and increased intracranial pressure16. As mentioned, VEGF is a potent 
vascular permeability factor, which induces dysfunction of tight junction 
proteins, and is a mediator of brain oedema261. Therefore, targeting this pathway 
may help to reduce the dysfunction of tight junctions, which is characteristic 
of tuberculous meningitis disease, and improve outcome. 
This is not the first study showing VEGF is increased in tuberculous meningitis. 
Children with tuberculous meningitis, who all received anti-tuberculous and 
adjuvant corticosteroid therapy, had significantly higher CSF VEGF concentrations 
compared to controls262. Compared to bacterial, fungal, and viral meningitis, 
tuberculous meningitis patients had higher serum and CSF VEGF levels, 
especially in those with hydrocephalus263. In adult tuberculous meningitis 
patients in India, higher serum VEGF was associated with infarction on MRI264. 
It has not yet been established whether CSF VEGF originates from the 
inflammatory infiltrate or the brain parenchyma. In HIV-associated cryptococcal 
meningitis, VEGF was thought to result from local production based on CSF- 
serum indices265. In an immunohistochemical brain autopsy study in bacterial 
meningitis, VEGF was found in the neutrophil and monocyte infiltrate, as well 
in brain endothelium and epithelium266. In paediatric tuberculous meningitis, 
CSF VEGF correlated with CSF-serum barrier disruption262. We found that CSF 
VEGF correlated with NSE, as a marker of neuronal damage, as with CSF total 
protein concentration used as a proxy for blood-CSF barrier disruption. 
Our study has several limitations. We did not include serum measurements in 
our study, as in our previous metabolomic study in chapter 7 the CSF metabolome 
was much more informative than the plasma metabolome. Also, we could not 
examine brain tissue to establish the source of detrimental VEGF production, 
because brain autopsy is not performed in Indonesia. In addition, examining 
HIV-infected patients could give further insights, noting that previous studies 
have found associations between serum VEGF and immune reconstitution 
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syndrome in HIV-associated cryptococcal meningitis267. Although we validated 
our genetic risk factors findings in a second cohort, no validation of proteomic 
data or QTLs was done in patients from a different setting or genetic background. 
Finally, although the genetic correlate suggests a causal role for VEGF in 
tuberculous meningitis immunopathogenesis, it is also possible that it is a 
bystander effect of hypoxia caused by another pathway.
In conclusion, CSF concentrations of VEGF show a strong association with 
increased mortality of tuberculous meningitis, possibly because of its effects on 
vascular permeability, dysfunction of tight junction proteins, and brain oedema. 
CSF VEGF concentrations in tuberculous meningitis are under strong genetic 
influence, likely contributing to the variable outcome of tuberculous meningitis. 
Future studies should examine if monoclonal antibodies against VEGF improve 
outcome of tuberculous meningitis patients. Combined with timely diagnosis, 
appropriate supportive treatment28, and intensified antibiotic treatment29,30, 
such strategies to limit immunopathology or boost host defence against M. 
tuberculosis may help improve outcome of this most deadly manifestation of 
tuberculosis.
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Summary and general discussion
Much has been learned on human immunology in the past decades, but so far 
this has hardly led to better tools to prevent or treat tuberculosis. One reason 
may be that we need to study the immunology of tuberculosis in its specific 
context, as much as possible linking epidemiology, clinical manifestations and 
laboratory sciences. That is what I have aimed for in this thesis, combining 
patient studies with genetics and in-vitro experimental models, in order to 
improve understanding of factors determining tuberculosis susceptibility, 
transmission and outcome (graphically summarised in figure 9.1). 
Summary of research findings
Tuberculosis susceptibility and transmission
The first part of this thesis focussed on susceptibility to tuberculosis and on 
transmission of M. tuberculosis. 
Since the C-type lectin receptor CLEC4D was recently shown to recognize 
components of M. tuberculosis, we investigated its role in the development of 
active disease in chapter 2. We showed that mice without functioning Clec4d 
have higher pulmonary bacterial burden and higher mortality upon infection 
with M. tuberculosis. In humans, we found increased CLEC4D expression in 
pulmonary tuberculosis in five publicly available gene expression data sets. This 
is most outspoken in monocytes and granulocytes and reverses with successful 
treatment. We then found that one allele of a nonsynynomous CLEC4D 
polymorphism is more common in pulmonary tuberculosis patients than 
controls. CLEC4D is therefore likely to play a role in the development of active 
pulmonary tuberculosis.
Hypothesising that the early immune response to different M. tuberculosis 
strains partly explains their widely varying prevalence, we studied the immune 
response evoked by different M. tuberculosis strains in blood monocytes, 
lymphocytes and neutrophils of healthy volunteers in chapter 3 and 4. In 
chapter 3 it was shown that strains of the evolutionary successful modern 
Beijing genotype family evoke a less profound proinflammatory cytokine 
response compared to ancient Beijing strains. Variation between strains was 
large also within the modern strains, but on average they induced lower amounts 
of IL-1β, IFN-γ and IL-22 in leukocytes of healthy volunteers. 
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In chapter 4 we used a more refined starting point for the selection of strains: 
the ability of individual strains to cause secondary cases. Based on the Dutch 
tuberculosis database, which includes >13,000 M. tuberculosis strains, we selected 
isolates with contrasting abilities in causing secondary cases. Strains that 
clustered among cases without risk factors for transmission, i.e. among elderly 
female patients, were considered to be highly transmissible. Strains that did not 
cause a secondary case, even though they were isolated from a patient with 
many risk factors for clustering, i.e. a homeless young male, were considered to 
be minimally transmissible. Through whole-genome sequencing of 100 of these 
strains, variation in five mycobacterial genes was associated with clustering. 
Four of these genes were confirmed in a second dataset of 143 isolates from a 
different geographical background. We then selected 19 representative M. 
tuberculosis strains that did or did not carry a mutation in these five genes and 
linked different cytokine responses to the presence or absence of mutations in 
three of these genes. One of these genes was associated with a difference in 
Figure 9.1  Summary of the main findings of this thesis.
CLEC4D is linked to human 
TB susceptibility (chapter 2) 
Prevalent Beijing M. tuberculosis strains    
induce low IL-1β, IFN-γ and IL-22 (chapter 3)  
Mycobacterial transmissibility genes show differential effects 
on human immune response mediated by TNF-α, IL-10, IFN-γ 
and neutrophil reactive oxygen species (chapter 4)  
Tuberculous meningitis
mortality is related to:
• Neurological severity,
 age, fever, inflammatory
 markers and bacterial load
 (chapter 5)
• CSF αβT cells and
 NK cells (chapter 6)
• Cerebral tryptophan
 metabolism (chapter 7)
• CSF vascular endothelial
 growth factor (chapter 8)    
Pulmonary 
tuberculosis 
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neutrophil responses, important in of the first line of defence against M. 
tuberculosis. Together, chapter 3 and 4 provide evidence for interaction between 
M. tuberculosis genotype and the human immune response in establishing 
transmission and disease. 
Outcome of tuberculous meningitis
The second part of this thesis focussed on tuberculous meningitis and more 
specifically on factors determining the poor prognosis of this manifestation of 
tuberculosis. 
To identify patient groups in highest need of adjunctive treatment, we identified 
routine prognostic factors for outcome of tuberculous meningitis in a large 
prospective cohort in Indonesia in chapter 5. In line with other studies we 
identified HIV co-infection, low Glasgow Coma Scale (indicating severe disease), 
and a low cerebrospinal fluid (CSF)-blood glucose ratio as important predictors 
for mortality. Additional clinical parameters predictive for mortality were high 
body temperature and paresis of extremities, inflammatory markers including 
high CSF and blood neutrophil counts, and high CSF protein and a positive CSF 
M. tuberculosis culture as a marker for bacterial load. 
New host-directed therapies are proposed as adjunct to antibiotics to improve 
the prognosis of tuberculous meningitis. The immune response in tuberculous 
meningitis shows large variation between patients in terms of body temperature, 
inflammation on neuroimaging, or CSF inflammatory markers. Therefore, some 
patients might need strong immunosuppressive therapy, while others are more 
likely to benefit from immune stimulatory therapy. In chapter 6 we therefore 
explored the immune response in tuberculous meningitis in detail. We found a 
strong myeloid immune response in blood compared to pulmonary tuberculosis 
patients and healthy controls, while lymphocytes, including the innate γδT cells, 
MAIT cells, NKT cells and NK cells, were decreased in number. In contrast, 
lymphoid cells dominated CSF in 70% of patients, again with all innate subsets 
present. The cytokine response that was determined ex vivo by stimulating 
blood with specific (BCG, M. tuberculosis) and aspecific (S. pneumoniae, C. albicans) 
stimuli, showed a much broader range in tuberculous meningitis than in 
pulmonary tuberculosis patients and controls. A high ex-vivo blood cytokine 
response correlated to fever, higher blood lymphocyte counts and higher 
monocyte activation. Low CSF αβT and γδT cells were associated with increased 
mortality. In future trials investigating immunomodulatory therapy, adequate 
immunophenotyping will be important to identify patient groups benefitting 
from the studied intervention. 
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Since metabolism is important for an efficient immune response, we measured 
over 400 metabolites in both CSF and serum of both patients and controls from 
the same cohort in Indonesia in chapter 7. Low CSF tryptophan was a strong 
predictor for survival of tuberculous meningitis. CSF tryptophan was lower in 
patients than controls, something that is known from other cerebral infections, 
but especially low in patients who survived. The ability to modulate tryptophan 
concentrations is partially genetically determined, and polymorphisms that 
predicted CSF tryptophan, also predicted survival in another group of tuberculous 
meningitis patients. Cerebral tryptophan metabolism could affect outcome of 
tuberculous meningitis through food-deprivation of M. tuberculosis, or because 
of the immunomodulatory properties of downstream tryptophan metabolites.
Studies on individual cytokines have shown a high and sustained cytokine 
response in tuberculous meningitis, but without clear relation to patient 
outcome. In chapter 8 we choose a more comprehensive approach examining 
almost examining almost 100 cytokines and other inflammatory proteins. Most 
of the 100 studied leukocyte or brain-derived inflammatory messenger molecules 
showed a strong increase in CSF of tuberculosis meningitis patients compared 
to controls. These proteins showed strong clustering and 4 of 30 clusters 
correlated to increased mortality. Vascular endothelial growth factor (VEGF) 
showed a strong relation with mortality. It correlated with measures of neuronal 
damage and blood-CSF barrier disruption. The VEGF concentrations had a 
genetic correlate, which predicted survival in a second group of tuberculous 
meningitis patients. 
Together, chapters 5 to 8 identified an important and partially genetically 
determined role for the immune response in the outcome of tuberculous 
meningitis. These findings strengthen the basis for rational host-directed 
therapy in the treatment of tuberculous meningitis.
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General discussion
The two parts of this thesis are discussed separately, followed by a discussion of 
the employed integrative approach and how this can be used in the improvement 
host-directed therapy of tuberculosis.
Susceptibility and transmission
Susceptibility to tuberculosis can be viewed only in relationship to particular 
tuberculosis phenotypes. In other words, biological mechanisms responsible for 
establishing infection may be different from those causing progression to active 
pulmonary tuberculosis or tuberculous meningitis. The first part of this thesis 
shows that precise patient phenotyping and M. tuberculosis strains classification 
helps advancing insight in susceptibility and transmission.
The estimated extent to which tuberculosis susceptibility is heritable is high, 
based on old twin studies that find much higher concordance rate for 
monozygotic twins (32-65%) than dizygotic twins (13-25%)268. In contrast, the 
yield of present-day genetic association studies is relatively modest: few loci 
have been identified, each only linked to a relatively small proportions of 
increased risk (odds ratio) for pulmonary disease compared to controls. The two 
largest studies so far found an odds ratio of 1.19 (95% CI 1.13–1.27, n=7,501) in 
18q11.2269 and 1.10–1.30 (overall p=2.57 x 10-11, n=13,859) in 11p1323 respectively, 
and our study on the CLEC4D polymorphism in chapter 2 found a similar effect 
with an odds ratio of 1.33 (95% CI 1.02–1.73). In contrast to twins, who grew up 
in very homogenous circumstances and were exposed to the same M. tuberculosis 
strains and in the same amount, present-day genetic studies are performed in 
large cohorts of unrelated individuals. Of our present-day ‘healthy controls’, we 
do not know their exposure level or infection status (figure 9.2). This means that 
in our case, the rs4304840 in variant in CLEC4D confers increased susceptibility 
to 1) infection; 2) primary progression to active tuberculosis; 3) secondary 
progression to active tuberculosis; 4) to a combination of each of these; or 5) - 
theoretically - is protective at one stage and harmful at another. A positive 
example of a study employing sophisticated phenotyping is the INFECT study 
in Bandung12 that follows exposed individuals overtime and records infection 
later on. INFECT will increase our knowledge on the susceptibility to infection 
itself, but will also provide well-phenotyped control groups for studying 
susceptibility to pulmonary tuberculosis.
Imprecise phenotyping probably contributes to the lack of successful replication 
studies in other populations. Other problems involved are a lower frequency 
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of causative genetic variants, or differences in prevalence of different poly- 
morphisms and linkage disequilibrium between populations: an identified 
polymorphism is linked to the causative – unknown – polymorphism in one, 
but not another population. Additionally, the M. tuberculosis strains in the 
replication area might be different, decreasing statistical power in these studies.
Including mycobacterial genotyping may increase power to find human 
susceptibility loci for pulmonary tuberculosis, as shown in three previous 
studies. An ALOX5 polymorphism was linked to increased susceptibility 
especially for patients infected with M. africanum270 and a Toll-like receptor 2 
(TLR2) variant was especially linked to tuberculosis caused by Beijing strains85. 
Like a third study, linking an NRAMP1 polymorphism to Beijing strains271, 
these associations were found under ‘optimal conditions’: large proportions (≥ 
29%) of the mycobacterial genotype that showed an association; few human 
polymorphisms (2-3) tested or reported; and all with reasonably high minor 
allele frequencies (8% or higher). Even these studies, published 8-10 years ago, 
with odd ratios of 1.7-2.5, still await replication. To decipher the meaning of the 
SNP identified in chapter 2, we would ideally first compare uninfected controls, 
infected individuals and patients with active tuberculosis disease in a replication 
Figure 9.2   Imprecise patient and control phenotyping decrease the power  
of genetic association studies.
which infecting strain? 
? exposed? infected? 
Controls 
Patients 
different linkage disequilibrium 
between causative and marker 
polymorphism 
replication 
study 
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tuberculosis 
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study in the same geographical area. This can help define the association as 
important for either infection, or progression to active disease, possibly restricted 
to one specific mycobacterial lineage. More precisely establishing the role of the 
genetic variation would significantly increase the chances of successful 
replication in other populations.
Also in immunological association studies, more detailed M. tuberculosis 
genotyping is important. In chapter 3 we found a lower induction of proinflam-
matory cytokines (i.e. IL-1β) in four out of seven modern Beijing strains included. 
Another group replicated our findings with 13 out of 20 modern Beijing strains 
they selected168. This shows that more precise genotyping than ‘modern’ versus 
‘ancient’ is necessary to identify the driving genetic difference because not all 
modern Beijing strains behave in the same way. Further accuracy can also be 
gained by more precise phenotypic definition of relevant mycobacterial strains, 
like in chapter 4 that took the ability to cause secondary cases as starting point, 
before identifying relevant mycobacterial genetics and immunological 
consequences. This study however also shows that the sheer number of identified 
genetic variants becomes larger than the statistical power of immunological 
studies allows. We therefore aggregated these mycobacterial loci at a gene level 
and analysed host responses at the level of cell types instead of cytokines. This 
increases the robustness of the findings at the expense of the level of detail. At a 
methodological level, it would be good to test whether our identified associations 
can be confirmed in an experimental model with live mycobacteria.
Based on the studies in this thesis and those of others, I think we can only 
increase our understanding of tuberculosis susceptibility and transmission by 
precise characterisation of human subjects, and by including mycobacterial 
genotypes into the equation. An important methodological challenge is to 
decide about the optimal resolution to use when comparing different ‘phenotypes’ 
given the vast amount data. As some associations identified will be a result of 
trial-and-error with multiple testing issues, solid confirmatory studies will 
be needed, ultimately in settings with a different human and mycobacterial 
genotype distribution. 
Outcome of tuberculous meningitis
The second part of this thesis focuses on outcome of tuberculous meningitis. 
Its extremely high mortality is associated to severe disease at the moment 
of presentation in the hospital, which is often late. This leaves time for 
M. tuberculosis, but also for the immune response, to cause damage. 
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Strategies to improve patient outcome once in the hospital include better 
supportive care28, which is not yet studied systematically, and better antibiotic- 
delivery to the brain. Interesting in this regard, intrathecal injection has been 
used in individual cases from 1946 272 to 2017 273. Larger studies have been 
performed with increased dosing of the cornerstone drug rifampicin, administered 
either orally26 or intravenously, of which the latter strategy has shown promising 
results in a phase IIb-study29. Other possible strategies, improving blood-brain 
penetration or inhibiting drug efflux pumps274, have not yet been applied 
clinically. Given the strong influence of the immune response on outcome of 
tuberculous meningitis as exemplified in chapter 5 to 8, alternative strategies 
can be formulated, involving modulation of the host immune response, some of 
which have been tried (table 9.1).
Studying the local immune response in tuberculous meningitis is facilitated by 
the access to lumbar or even ventricular275 CSF, which contains waste products 
of the brain and is therefore indicative of local metabolism and inflammation. 
As summarised in the General introduction (table 1.1 and 1.2), data on the 
immune response in tuberculous meningitis are limited and sometimes 
contradictory. For example, in a recent study a higher IFN-γ and other Th1 as 
well as Th2 cytokines were protective in HIV-negative patients but not 
HIV-positive patients43, while a in an older study IFN-γ was protective in 
HIV-positive but not HIV-negative patients255 and also in our study in chapter 8, 
CSF IFN-γ did not predict mortality in HIV-negative patients. 
Table 9.1  Possible intervention strategies in tuberculous meningitis.
Example (mechanism) Clinical 
study
N Success Comment
Dexamethasone 
(immune suppression)
RCTs 337 Yes RR 0.75 (0.65-0.87)  
in the first two years44
Thalidomide 
(immune suppression)
RCT 47 No Increased mortality  
when applied at 24mg/kg/day  
in children193
Aspirin 
(immune suppression 
and platelet inhibition)
RCTs 60 Yes Unblinded Indian study  
showed reduced mortality  
with 150mg aspirin daily45
120 Result 
pending
Vietnamese pilot study underway 
evaluating  
81 and 1000mg aspirin 
(NCT02237365)
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We identified CSF VEGF as an important determinant for tuberculous meningitis 
mortality in chapter 8 and this moves the focus to hypoxia as a possible, and 
potentially modifiable, pathway. The interpretation of levels of cytokines and 
other circulating mediators remains challenging. We infer the meaning of 
signals from other in-vitro models or other diseases, like pulmonary tuberculosis, 
and it is hard to interpret the origins of the signals considering that either the 
CSF leukocytes or brain astrocytes or microglia as producers of these molecules. 
The brain is likely to play an active role in the immunopathogenesis of 
tuberculous meningitis, as brain cells of deceased tuberculous meningitis 
patients have shown, with >1,000 genes at least two-fold upregulated compared 
to patients who died of an accident235. A similar study using CSF leukocytes 
would be very interesting, but is technically difficult because of the small 
amount of RNA involved, and the difference in CSF cell number and composition 
in control subjects. Including CSF metabolites in the analysis has the advantage 
of the elaborate existing knowledge on their interdependence and (enzymatic) 
regulation. Moreover, host genetics can be added to further pinpoint regulatory 
mechanisms. 
It is yet unknown what immunomodulatory treatment is most promising, and 
for whom. Chapter 7 showed that a low CSF tryptophan is associated with better 
survival, and it should be investigated whether this has therapeutic potential. 
Decreasing CSF tryptophan supply is possible within a day by a tryptophan- 
depleted diet248, but given the brain-protecting effects of some downstream 
tryptophan metabolites a strategy that increases CSF tryptophan metabolism, 
for example by employing IFN-γ, may be preferred247. This is most likely to be 
effective in the group of patients that naturally have the least active tryptophan 
metabolism (i.e. the tertile with the highest CSF tryptophan levels in figure 6.4), 
while the patients with the lowest CSF tryptophan already have such a low 
6-month mortality (5%) in our study that side effects might outweigh benefits. 
Another selection criterion for immunomodulatory therapy could be the 
immune response as studied in chapter 6. Patients with a high ex-vivo response 
and more activated monocytes might benefit from extra immunosuppressive 
therapy such as IL-1 receptor antagonist (anakinra). The group with low 
responses however, might benefit from other interventions including adjunctive 
IFN-γ therapy, or simply withholding corticosteroids that are now routinely 
administered276. A genotype-based trial (NCT03100786) currently randomises 
patients with CC or CT LTA4H rs1725495 genotypes to dexamethasone or 
placebo. Even if the primary outcome is not met, this study can improve our 
understanding of the disease.
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In the field of sepsis, over 100 phase II and III trials have been performed testing 
different adjuvant strategies, all without success225. We should learn from this 
experience. Future host-directed trials in tuberculous meningitis could be 
improved by adhering to the following criteria: 1) the proposed intervention 
should be expected to be beneficial to a larger number of patients than it is 
expected to harm; and 2) the design should allow answering pathophysiological 
questions through collection of genetic and immune phenotypic data for 
post-hoc identification of patient subgroups for whom the intervention showed 
benefit, no effect or harm. For example, when studying adjunctive IFN-γ, it will 
be key to assess downstream tryptophan metabolites, but also the number and 
activation of regulatory T cells in CSF, as well as mycobacterial counts. Ideally, 
readily available markers will be included that will allow upfront stratification 
in a follow-up trial. It is challenging to perform these immunological measures 
in low- or middle-income countries, but the studies in this thesis and others33 
have shown its feasibility.
I think that a major remaining question is how the different clinical, metabolic, 
inflammatory prognostic factors should be integrated, not just to better predict 
outcome, but especially to improve our understanding of the processes involved. 
Future perspectives, using an integrative approach
Tuberculosis is an old foe, and continues to be a challenging disease. Vaccine 
development is hampered by the absence of known immunological correlates of 
protection against infection277 and even natural immunity only partially 
protects from active disease278. Common genetic variations conferring high 
level of protection against tuberculosis, like sickle cell trait protects against 
malaria279, would have been detected by conducted genome-wide association 
studies269 by now already. A ‘vector-based approach’, like targeting the Aedes 
mosquito in dengue, will not be feasible because of the rare, but severe 
side-effects in the treatment of latent tuberculosis combined with the large pool 
(1.7 billion people!) of latently infected individuals1. 
Will there be ‘Mountains beyond Mountains’280 in the quest for better treatment 
of tuberculosis? Possibly, but there is reason for optimism when it comes to 
better understanding of the disease. Promising, and increasingly affordable, 
techniques now include live functional imaging in both pre-clinical191 and 
clinical281 models. Also, RNA-sequencing techniques requiring small RNA 
concentrations282 allows transcriptomics of tissues closer to the infection than 
blood, like CSF leukocytes or lung or brain tissue obtained by biopsy. Lastly, the 
combination of genetics with other platforms is a powerful way to identify the 
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effect of polymorphisms on a quantitative measurement such as gene expression 
in a certain condition. These response quantitative trait loci (QTLs)21,283 were 
determined in vitro and need to be confirmed in patient studies. As an example, 
the difference in metabolites before and after dexamethasone administration is 
likely to depend on certain genetic traits that can next be used to predict which 
patients benefit most from this intervention. 
Another reason for optimism is the increasing power of computational biology 
integrating different data sources. ‘Systems biology’ cannot be expected to 
produce new biological insights just by itself284, but it can help identifying new 
biological concepts. This thesis propagates an integrative approach, most often 
starting with a clinical observation (figure 9.3), such as higher mortality in 
patients with fever and a higher proportion of CSF neutrophils. Rather than 
performing large studies using one modality, such as genetics, that need 
confirmation by even larger studies, we combined analytical platforms with 
high-quality patient phenotyping in relatively small cohorts. The tuberculous 
meningitis patient data itself is rich and layered, so that genetic polymorphisms 
can be searched to predict the patient phenotype, but also the associated gene 
expression, metabolite or protein levels. We next used publicly available data 
(table 9.2) to sharpen hypotheses. 
This requires the definition of certain ‘keys’: a genetic polymorphism (SNP), or a 
gene or metabolite name. Additionally, hypotheses arising from this approach 
can be further refined using mycobacterial data. If for example a certain 
metabolite is identified as important, mycobacterial genetics focussing on the 
specific pathway can be associated to patient outcomes. This thesis shows that 
the starting-points can be an association between mycobacterial genotype and 
transmission or human immune response (chapter 3 and 4), or a gene identified 
in an animal model (chapter 2), or an association between a metabolite or protein 
level and patient outcome (chapter 7 and 8). The association between clinical 
parameters or immune response and survival (chapter 5 and 6), asks for further 
exploration to other levels of this model. 
Because these types of studies are exploratory in nature, external validation is 
needed. A biologically driven and specific hypothesis, supported by multiple 
data sources, can be confirmed by testing specific metabolites or genetic loci in 
relatively small patient cohorts of hundreds. We think that the limited funds 
available for tuberculosis research (0.7 billion US$ annually)2 ask for an integrative, 
iterative approach to answer clinical questions using new technologies  as close 
as possible to the side of disease. I think that intervention studies will be needed to 
move from correlation to causation. The power to identify meaningful differences 
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might be increased by careful serial clinical and immunological phenotyping, 
which could be aided by studying brain biopsies or using functional brain 
imaging in the case of tuberculous meningitis. 
Tuberculosis is a devastating disease with a fascinating immunopathogenesis. 
I hope that this thesis will contribute to identification of effective host-directed 
therapy to brighten the outlook for future patients.
Table 9.2  Publicly available data relevant to tuberculosis research.
Subject Example
Mycobacterial 
Genetics TB Database
Proteomics Peptide Atlas
Human genetics
Function NCBI 
SNP prevalence 1000 genomes
SNP linkage Broad institute
Gene expression
Comparing disease status Expression in blood of pulmonary tuberculosis 
patients versus controls72; expression in brain 
of tuberculous meningitis patients versus head-
injury controls235
Comparing human issues BioGPS; GTEx portal
Quantitative trait loci
Comparing gene expression depending on 
the presence of a SNP
GTEx portal
Comparing gene expression  
in response to in-vitro manipulation  
in response to a SNP
Stimulation of dendritic cells 
by M. tuberculosis283
Pathway analysis 
Gene expression WebGestalt, DAVID
Metabolites MetaboAnalyst
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Abbreviations
BCG = M. bovis Bacille Calmette-Guérin 
CFU = colony forming units
CI = confidence interval
CLR = C-type lectin receptor
CSF = cerebrospinal fluid
CPP = cluster propensity to propagate
GFP = green fluorescent protein
HR = hazard ratio
IL = interleukin
IFN = interferon
LTA4H = Leukotriene A4 Hydrolase
MN = mononuclear cell
PBMC = peripheral blood mononuclear cells 
PC = principal component
PMN = polymorphonuclear cell
QTL = quantitative trait locus
SNP = single nucleotide polymorphism
TDM = trehalose- 6,6-dimycolate 
TIM = target of independent mutation
TNF = tumour necrosis factor
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Tuberculose
Een hoestende tuberculosepatiënt verspreidt Mycobacterium tuberculosis door de 
lucht. Als iemand anders deze bacterie vervolgens inademt, zijn er verschillende 
uitkomsten mogelijk: een vooralsnog onbekend deel van de blootgestelde 
individuen ruimt M. tuberculosis op, nog voordat het afweersysteem geheugen 
opbouwt. Een kleine minderheid wordt direct en vaak ernstig ziek, terwijl  de 
meerderheid niets van de besmetting merkt omdat de infectie beperkt blijft tot 
een klein stukje van de long. Als in de loop van het leven het afweersysteem 
verzwakt, kan zich alsnog actieve tuberculose ontwikkelen. Dat gebeurt bij 
ongeveer een op de tien besmette personen. Actieve tuberculose manifesteert 
zich doorgaans in de long maar het kan ook in de botten, in de lymfeklieren, in 
de organen van de buik en zelfs in de hersenen voorkomen. 
Deel 1: tuberculose gevoeligheid en transmissie
Tuberculose is een oeroude ziekte. Naar schatting 70.000 jaar geleden evolueerde 
M. tuberculosis uit het geslacht van Mycobacteriae, bacteriën die ook nu nog in de 
bodem gevonden worden. Mensen leefden toen in kleine, geïsoleerde 
gemeenschappen, geen ideale omstandigheden voor een besmettelijke ziekte. 
M. tuberculosis kon tóch persisteren door de combinatie van een lange incubatie-
periode die jaren kan duren, een lange periode waarin iemand besmettelijk is en 
het feit dat slechts een deel van de besmette individuen op jonge leeftijd overlijdt. 
De bacterie is vervolgens met de mens mee gemigreerd vanuit Afrika, door het 
Arabisch Schiereiland naar Europa en Azië, en door kolonisatie verder over de 
wereld verspreid. Doordat de populatiedichtheid van de mens toenam, kregen 
ook modernere, epidemische ziektekiemen zoals de pest of Zika een kans. Deze 
leiden vrijwel direct tot ziekte in een groot deel van de besmette personen, met 
een hoge sterfte tot gevolg. Toch is de ‘strategie’ van tuberculose nog steeds 
succesvol te noemen: naar schatting zijn 1,7 biljoen wereldburgers besmet met 
M. tuberculosis en krijgen jaarlijks 10,4 miljoen patiënten actieve tuberculose, met 
1,7 miljoen sterfgevallen tot gevolg. 
In hoofdstuk 2 onderzoeken we een aspect van de menselijke gevoeligheid voor 
tuberculose. Het slijmvlies van onze luchtwegen en de macrofagen die daar 
aanwezig zijn vormen de eerste afweer tegen zwevende ziektekiemen. Deze 
macrofagen en andere witte bloedcellen gebruiken ‘receptoren’ (eiwitten op 
hun oppervlakte) om typische bacteriële structuren te herkennen. Deze 
receptoren vallen in een aantal groepen uiteen en een daarvan is de groep van 
de ‘C-type lectins’ (CLECs). Van receptor CLEC subtype 4D was bekend dat het 
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M. tuberculosis kon herkennen. In dit hoofdstuk toonden we aan dat muizen die 
deze receptor missen, een hevige ontsteking krijgen als ze besmet worden met 
M. tuberculosis. De sterfte aan de infectie is hoger dan bij muizen mét de receptor. 
We gebruikten vervolgens gepubliceerde studies met openbare data om te 
onderzoeken wat er bij de mens gebeurt gedurende het ziekteproces. Het blijkt 
dat het gen dat codeert voor de receptor CLEC4D veel sterker tot expressie wordt 
gebracht bij zieke patiënten met longtuberculose dan bij gezonde individuen. 
Deze expressie neemt weer af gedurende de behandeling. Vervolgens onder- 
zochten we of genetische variatie in de code van dit gen geassocieerd is met de 
kans op het krijgen van longtuberculose. In het DNA van meer dan duizend 
longtuberculosepatiënten uit het Hasan Sadikin ziekenhuis in Bandung in 
Indonesië hebben we gekeken naar drie plaatsen in het gen CLEC4D waarvan 
bekend is dat er in Azië verschil is tussen individuen. Op een van de drie locaties 
kwam een bepaalde variant vaker voor bij patiënten dan gezonde invidiuen. 
Dit vormt een aanwijzing dat CLEC4D van belang is bij de ontwikkeling van 
longtuberculose. Een makke bij veel genetische associatiestudies, waaronder 
de onze, is dat we van deze ‘controles’ niet weten in welke mate zij óók zijn 
blootgesteld aan tuberculose, en of ze besmet zijn geraakt. We weten daarom 
nog niet of deze genetische variatie slechts een verhoogd risico geeft op 
besmetting of ook op het daadwerkelijk ziek worden. Daarnaast is vooralsnog 
onduidelijk of de bevindingen ook van toepassing zijn op patiënten met een 
andere genetische achtergrond.
Hoofdstuk 3 gaat in op de Beijing ‘familie’ van M. tuberculosis binnen de 
Oost-Aziatische hoofdgroep van de bacterie. Binnen de Beijing familie komen 
de modernere stammen steeds vaker voor dan hun oudere familieleden. 
Mogelijk zijn ze beter overdraagbaar, of hebben ze zich beter aangepast aan de 
huidige hoge populatiedichtheid door sneller tot ziekte te leiden. We gebruikten 
een extract van zeven moderne en zeven oude Beijing M. tuberculosis-stammen 
om witte bloedcellen van gezonde vrijwilligers mee te stimuleren. Nadat deze 
witte bloedcellen de bacterie herkenden, maakten ze in de daaropvolgende 
dagen zoals verwacht signaalstoffen aan. Enkele van deze zogeheten cytokines 
die helpen de afweerreactie op gang te brengen en te houden, kwamen na 
stimulatie met de moderne stammen in lagere concentratie voor dan na 
stimulatie met hun evolutionair oudere verwanten. Dit wijst op een minder 
efficiënte herkenning door de witte bloedcellen en dit kan mogelijk bijdragen 
aan het succes van de moderne Beijing M. tuberculosis stammen.
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In hoofdstuk 4 gebruikten we ook de afweerreactie van witte bloedcellen van 
gezonde vrijwilligers om het succes van M. tuberculosis stammen mee te 
verklaren, maar de selectie van de  stammen was gebaseerd op hun bewezen 
vermogen om nieuwe gevallen van tuberculose te veroorzaken. Het Rijksinstituut 
voor de Volksgezondheid en Milieu weet van meer dan 10.000 tuberculosepati-
enten uit de periode 1993-2014 in Nederland door welke stam ze besmet zijn 
geraakt (inmiddels is het aantal tuberculosegevallen in Nederland gedaald tot 
<1000/jaar). We zochten eerst stammen die voorkwamen in een cluster mensen 
die door dezelfde bron besmet geraakt waren. We zochten daarbij specifiek naar 
clusters van mensen die a-priori een laag risico hadden om tot een cluster te 
behoren, dat zijn bijvoorbeeld oudere vrouwen die gebruikelijk met name 
tuberculose krijgen door reactivatie van stammen opgelopen in het verleden. 
Als stammen in deze groep tóch veel nieuwe gevallen veroorzaken, zijn het 
blijkbaar wel erg goed overdraagbare stammen, zo redeneerden we. Daarna 
zochten we naar stammen die voorkwamen bij individuen die juist veel risico 
hadden om tot een cluster te behoren, zoals jonge dakloze mannen die alcohol 
en drugs gebruikten. Door de hoge mate van blootstelling, en een verzwakte 
afweerrespons, worden zij juist relatief vaak snel ziek na een besmetting. Als 
een stam slechts in één individu met deze kenmerken ziekte had veroorzaakt, 
was het blijkbaar een weinig besmettelijke stam. Van 100 patiënten uit deze twee 
groepen vergeleken we vervolgens het complete genoom. We konden daarmee 
vijf M. tuberculosis genen identificeren die geassocieerd waren met het 
veroorzaken van nieuwe gevallen. De variatie in drie van die genen leidde ook 
daadwerkelijk tot een andere afweerrespons in de witte bloedcellen van gezonde 
vrijwilligers. Dit vormt een extra bevestiging van het belang van de 
afweerrespons in het verklaren van het succes van sommige tuberculosestam-
men ten opzichte van andere stammen.
Deel 2: de uitkomst van tuberculeuze meningitis
Het tweede deel van dit proefschrift behandelt hersenvliesontsteking 
(meningitis) als specifieke verschijningsvorm van tuberculose. Deze ziekte 
kenmerkt zich door een langzaam progressief beloop, waarin patiënten 
aanvankelijk aspecifieke symptomen hebben zoals hoofdpijn. Tuberculeuze 
meningitis wordt dan meestal nog niet als zodanig herkend. In de dagen of 
meestal weken die volgen, kan het bewustzijn afnemen en kunnen uitvalsver-
schijnselen optreden. Zo kunnen herseninfarcten of  beklemming van 
hersenzenuwen in een dikke laag pus verlamming van ledematen of uitval van 
gelaatsfuncties veroorzaken. Jonge kinderen en met HIV geïnfecteerde patiënten 
hebben de grootste kans op uitgezaaide tuberculose. Meningitis is hiervan de 
ernstigste verschijningsvorm en leidt bij 30-50% van de aangedane patiënten tot 
264 | Appendix
invaliditeit of de dood. We denken dat deze percentages verkleind kunnen 
worden door snellere herkenning van de ziekte, betere ondersteunende therapie 
zoals bloeddrukregulatie en zuurstoftoediening en toediening van hogere doses 
van antibiotica zodat die beter in het hersenvocht doordringen. Momenteel 
krijgen alle patiënten met tuberculeuze meningitis behalve antibiotica ook 
afweerremmende medicijnen (corticosteroïden) en dit verlaagt de sterfte 
enigszins, maar alleen bij de minst zieke patiënten. Het is onbekend hoe de ont-
stekingsmechanismen in tuberculeuze meningitis precies werken en daarop 
gaat dit tweede deel in.
In hoofdstuk 5 geven we een overzicht van voorspellers van sterfte door 
tuberculeuze meningitis. We gebruikten hiervoor de data die in het Hasan 
Sadikin ziekenhuis in Bandung, Indonesië vanaf 2006 systematisch verzameld 
zijn samen met het Radboud Universitair Medisch Centrum. Het Hasan Sadikin 
is een tertiair verwijzingscentrum met een afferentiegebied voor 43 miljoen 
mensen uit West-Java. We konden bevestigen dat HIV-infectie een sterke 
voorspeller is van sterfte door meningitis en beperkten vervolgens de analyse 
tot de 499 HIV-negatieve patiënten. Hieruit kwamen verschillende onafhankelijke 
klinische voorspellers van een hogere mortaliteit één jaar na diagnose: ernstige 
ziekte-ernst, hogere leeftijd, verlamming van een of meer ledematen, en ook een 
hogere temperatuur bij binnenkomst. Dit laatste wijst al op een rol voor ontste-
kingscellen, die ook de lichaamstemperatuur beïnvloeden. Voor de diagnostiek 
van tuberculeuze meningitis wordt het hersenvocht, de liquor cerebrospinalis, 
middels een lumbaalpunctie afgetapt. Metingen aan de liquor lieten zien dat de 
verhouding tussen neutrofiele en lymfoïde witte bloedcellen een belangrijke 
voorspeller is van sterfte. Neutrofiele witte bloedcellen kunnen potentieel M. 
tuberculosis doden, maar kunnen door de vorming van vrije zuurstofradicalen 
ook veel schade veroorzaken. Ook in bloed waren hogere neutrofielen 
geassocieerd met hogere sterfte. We deden in dit cohort verder een replicatiestu-
die van genetische variatie die in Vietnamees onderzoek voorspellend bleek te 
zijn voor sterfte. Deze associatie konden we  niet bevestigen voor de Indonesische 
patiënten met tuberculeuze meningitis.
Hoofdstuk 6 gaat dieper in op de ontsteking in zowel liquor cerebrospinalis als 
het bloed. We categoriseerden de subtypen van witte bloedcellen preciezer door 
antistoffen te gebruiken die zich binden verschillende eiwitten op het 
oppervlakte van de witte bloedcellen. In het bloed van patiënten met 
tuberculeuze meningitis waren meer neutrofielen en monocyten maar minder 
lymfocyten dan bij longtuberculosepatiënten en gezonde controles. In de liquor 
cerebrospinalis van patiënten met tuberculeuze meningitis vonden we deze 
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lymfocyten weer terug en deze bleken niet alleen te bestaan uit de eerder 
beschreven αβT-cellen van het adaptieve deel van het immuunsysteem, maar 
ook uit meerdere type witte bloedcellen van het aangeboren immuunsysteem: 
γδT-cellen, NKT-cellen, NK-cellen en MAIT-cellen. Deze cellen waren bijna 
zonder uitzondering veel sterker geactiveerd in liquor dan in bloed. Het bloed 
van de patiënten hebben we daarnaast in het laboratorium gestimuleerd met 
verschillende bacteriën om te zien welke cytokines deze aanmaakten, analoog 
aan de methode van hoofdstuk 3 en 4. De witte bloedcellen van patiënten met 
tuberculeuze meningitis lieten een groot bereik zien in hun reactievermogen. 
Dit liep van lager dan de gezonde controles, tot aan hoger dan de longtubercu-
losepatiënten. De patiënten met de meeste cytokinerespons, hadden daarbij ook 
de hoogste lichaamstemperatuur. Bij het optimaliseren van de afweerbeïnvloe-
dende therapie bij tuberculose meningitis, lijkt het dan ook waarschijnlijk dat 
rekening gehouden moet worden met de individuele immuunrespons.
In hoofdstuk 7 bestudeerden we het metabolisme (de stofwisseling) in bloed en 
liquor cerebrospinalis van patiënten met tuberculeuze meningitis. We gebruikten 
hierbij vloeistofchromatografie gecombineerd met massaspectrometrie waardoor 
het mogelijk was om in zeer kleine volumes toch meer dan 400 metabolieten te 
onderscheiden. We vonden grote verschillen in liquor tussen de 32 patiënten en 
22 controles, maar niet in bloed. Binnen de patiëntengroep verschilden enkele 
metabolieten in liquor ook tussen hen die het overleefden en hen die al in het 
ziekenhuis overleden. De laatste groep had vaak een meer uitgesproken respons: 
de metabolieten die hoger waren bij patiënten dan controles, waren bij hen extra 
hoog en vice versa. Tryptofaan liet als enige metaboliet een uitgesproken 
afwijkende  respons zien: het was lager in patiënten dan controles, en bijzonder 
laag in hen die het overleefden. Tryptofaan is een essentieel aminozuur voor de 
mens, dat wil zeggen dat we het alleen door voeding tot ons kunnen nemen. We 
kunnen van tryptofaan wel andere metabolieten maken. De waardes hiervan 
waren juist hoger in patiënten, wat wijst op actieve omzetting van tryptofaan. In 
een grotere groep van 101 patiënten konden we de relatie van tryptofaan met 
overleving bevestigen. Vervolgens zochten we naar genetische variatie die 
samenhing met de tryptofaanrespons en we vonden 11 plaatsen in het DNA die 
hiervoor goed voorspellend waren. Gecombineerd voorspelde deze genetische 
informatie zoals verwacht ook de overleving van deze patiënten. Interessant is 
dat het ook de overleving voorspelde in een derde groep van 285 tuberculeuze 
meningitis patiënten. Het is dus goed mogelijk dat individuen verschillen in 
hun aanleg om tryptofaan te metaboliseren als ze tuberculeuze meningitis 
krijgen. Vervolgonderzoek kan uitwijzen hoe een gunstige omzetting van 
tryptofaan gestimuleerd zou kunnen worden.
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In hoofdstuk 8 onderzoeken we de cytokinerespons in tuberculeuze meningitis. 
We gebruikten hiervoor een techniek die in een kleine hoeveelheid liquor cere-
brospinalis bijna honderd signaalstoffen (cytokines) kan meten. Zoals verwacht, 
waren de concentraties van bijna alle cytokines hoger in patiënten dan in 
controles. Veel cytokines vertoonden een hoge mate van correlatie, dat wil 
zeggen dat als ze in één patiënt omhoog gingen, ze dat ook in een tweede patiënt 
deden. We verdeelden de cytokines in 30 clusters op basis van hun onderlinge 
correlatie en testten van elk cluster één cytokine op relatie met overleving. Vijf 
clusters waren sterk voorspellend voor overleving tot na 180 dagen. Een hiervan 
is ‘vascular endothelial growth factor’ (VEGF), een eiwit dat vaatgroei stimuleert. 
Dit kan gebeuren in respons op zuurstofgebrek. Het verbreekt daarbij mogelijk 
ook de verbindingen van de bloed-hersenbarrière en de bloed-liquorbarrière. 
Analoog aan hoofdstuk 7 zochten we naar genetische variatie die de VEGF 
respons voorspelde. Zes plaatsen in het DNA van de patiënten bleken hiermee 
geassocieerd. Samen voorspelden deze de overleving van patiënten in zowel het 
oorspronkelijke cohort als in 299 patiënten uit een tweede groep patiënten.
Slot: onderzoeksaanpak van complexe ziekten
Tuberculose is een oeroude, fascinerende en verwoestende ziekte. De complexiteit 
van het ziektebeeld noopt tot het combineren van verschillende methoden om 
haar te onderzoeken. Gezien het grote aantal variabelen dat tegelijkertijd 
gemeten wordt bij moderne meetmethoden, zijn er volgens de maatstaven van 
klassieke statistiek heel grote patiëntenaantallen nodig om robuuste verschillen 
te vinden. De beperkte middelen en infrastructuur in de landen waar de 
meerderheid van de patiënten zich bevindt, staan deze grote aantallen echter 
niet toe. Dit proefschrift laat zien dat door integratie van verschillende methoden 
in patiëntencohorten van slechts honderden patiënten toch betekenisvolle 
resultaten gevonden kunnen worden. Dit zal hopelijk bijdragen aan het 
identificeren van effectieve aanvullende behandeling en het verbeteren van de 
overlevingskansen van toekomstige tuberculosepatiënten.
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ontwikkeling op gang gekomen. Dat heeft in Nijmegen, maar ook in Bandung 
veel moois tot stand gebracht. Mihai Netea’s inspiratie door de biologie neemt 
jonge onderzoekers mee en zijn bescheidenheid is voor mij een voorbeeld. Jullie 
heetten me hartelijk welkom en vervolgens was er veel ruimte binnen het lab en 
nog meer ruimte om naar buiten te treden. Aan ideeën en ook uitvoerbare 
plannen nooit een gebrek. Ik had geen idee dat dit proefschrift het resultaat zou 
zijn. Jullie waarschijnlijk ook niet. Dank voor het vertrouwen vanaf de start en 
nu nog steeds.
Dank aan Robert Sauerwein, Irma Joosten en Jaap van Dissel die als manuscript-
commissie dit proefschrift kritisch hebben bezien. 
Anderen gingen mijn promoteren als mentor vooraf: Kees van Gastel was altijd 
stimulerend als het ging om wetenschap en geneeskunde. Anne Wensing nam 
me enthousiast onder haar hoede in het Utrechtse HIV-onderzoek. Joep Lange 
gaf me de mogelijkheid om voor PharmAccess naar Tanzania te gaan. Teresa 
Lambe was an excellent mentor in the animal and immunological labs of the 
Jenner Institute and showed how good science, a good laugh and holding the 
door open for others go hand in hand. 
Wetenschap is soms een eenzaam bedrijf, maar brengt ook een hoop plezier 
door samenwerking. Het lab van de Experimentele Interne Geneeskunde is 
daarvoor een fijne uitvalsbasis. Leo Joosten neemt je mee in het plezier van het 
bedrijven en organiseren van wetenschap, met als gevolg een fijne samenwerking 
op het lab. Jos van der Meer, dank voor het delen van inzichten en ervaring op 
verschillende momenten. Tegen de tijdsgeest in zou ik graag pleiten voor meer 
analisten in vaste dienst, want het collectief geheugen van Anneke Hijmans, Cor 
Jacobs, Heidi Lemmers, Helga Toenhake, Ineke Verschueren, Kiki Schraa, 
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Liesbeth Jacobs en Trees Jansen is van onschatbare waarde, net als de getalenteerde 
post-docs uit wiens kennis ik mocht putten:  Bas Heijnhuis, James Cheng, Janna 
van Diepen, Jessica Quintin, Marije Oosting, Mark Gresnigt, Richard Notebaart, 
Rinke Stienstra, Sanne Smeekens en Theo Plantinga. Veel dank aan het steeds 
veranderende, uitdijende en blijvend leuke team van medepromovendi, voor de 
gezelligheid en het heel fijne samenwerken: Ajeng Tunjungputri, Andreea Mirea, 
Anne Ammerdorfer, Anne Jansen, Anouk Jansen, Bas Blok, Berenice Rösler, 
Charlotte de Bree, Charlotte de Bruijn, Charlotte van der Heijden, Diana 
RosentulAmram, Daniela Ifrim, Duby Ballak, Floor Aleva, Hanne Rooijackers, 
Hedwig Vrijmouth, Hinta Meierink, Inge van den Munckhof, Jaap ten Oever, 
Jacqueline Ratter, Jessica Dos Santos, Johanneke Kleinnijenhuis, Jorge 
Dominguez Andres, Katharina Gößling, Kathrin Buffen, Kathrin Thiem, Khutso 
Mothapo, Laszlo Groh, Lilly Boutens, Lisa van de Wijer, Maartje Cleophas, 
Mariska Kerstholt, Mark Stappers, Marlies Noz, Martin Jäger, Meta Michels, 
Michelle Damen, Monique Stoffels, Rob Arts, Rob ter Horst, Ruud Raijmakers, 
Simone Moorlag, Siroon Bekkering, Tania Crisan, Teske Schoffelen, Thalijn 
Wolters, Vesla Kullaya, Wouter van der Heijden en Yvette Sloot.
Valerie Koeken was als student en later als collega een schot in de roos, met een 
combinatie van inzet en relativeringsvermogen, enthousiasme en nuchterheid. 
It has also been a big pleasure and an honour to work with the other fellow 
tuberculosis PhD students Anca Riza, Carolien Ruesen, Ekta Lachmandas, 
Lidya Chaidir, Lindsey te Brake and Sofiati Dian. Van de ijver, humor en inzet 
van de Nijmeegse club internist-infectiologen heb ik al een fijn voorproefje 
gehad. Ook bij hen loopt niets soepel zonder de secretariële ondersteuning van 
Mieke Daalderop en Jeanine van der Wijst, die niet alleen voor de internationale 
studenten maar ook voor ons een baken van licht en gezelligheid zijn. 
More than a quarter of my PhD time was spent in Bandung, were all the work 
in the TB-HIV working group starts with the laugh and twinkling eyes of 
Dr Bachti Alisjahbana. He takes pride in extending good care to everyone in 
his study team, whom he enables to excel in the studies performed. Terima kasih 
untuk semua teman2 kantor, untuk keramahan, kesabaran dan kebaikan Anda. Senang 
sekali bekerja bersama Anda semua. Thanks to my roommates Alit Koesoemadinata, 
Misheilla Maryam, Resvi Livia, Sue McAllister and Sofia Imaculata for all the 
good company, and lunches at Sederhana and Sederhana baru. Shared 
experiences made it so nice to chat with the other PhD students Annissa 
Rahmalia, Merrin Rutherford, Meta Michels, Silvita Riswari and Vycke Yunivita. 
A great place to be and work was Dr Agnes Indrati’s lab immuno, where Emira 
Diandini, Fitria Utami, Suharyani, Dwi Febni Ratnaningsih, Inas Kathina, 
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Nana Rasnawati and Yusandi Sastra Atmaja, worked with great optimism and 
dedication. It was a great joy to do the Immunology Classes with you. I’m very 
glad to have met Intan Mauli there, who pursues her own passion, while 
remaining understanding to others. I’m happy to have you as my paranimf on 
the side, and our whole family is glad that you brought Edwin and Fadlan to 
the Netherlands.
The tuberculous meningitis clinical team took care of excellent clinical 
phenotyping, led by Dr Ahmad Rizal Ganiem with whom one can discuss TBM, 
photography and history. Dr Sofiati Dian was in the daily lead, stood up for her 
team and was in for a good laugh. She is a hard worker who has given so much 
of herself in the research in Bandung, and abroad. It was a big pleasure to work 
with Ela Hayati, Feby Purnama, Tiara Pramaesya, Sofia Imaculata, Sri Margi, 
Rani Trisnawati and Shehika Shulda. Thanks also to Witri Indrasari and Dr Leni 
Lismayanti of the clinical chemistry lab team for arranging a flow for quick 
blood and cerebrospinal fluid processing out-of-office hours that would have 
been impossible in many other settings. All of the clinical work would have 
been of lesser quality without the mycobacterial lab in Bandung. Lidya Chaidir 
has put tremendous effort not only in techniques and machines but also in her 
colleagues who provide high-quality diagnostics. Jessi Annisa worked tirelessly 
in overseeing the big sample flows and other managerial tasks. Arlisa Alisjahbana 
is always keen to learn new techniques, just as the rest of the team that does a 
tremendous job. Prof Rovina Ruslami has been not only a welcoming host, but 
also as counterpart and sparring partner from the first time in Bandung. Prof 
Philip Hill, thank you for showing your ways of performing excellent research 
in Bandung and enabling others to shine (and for a joke or two). Ayesha Verrall 
thanks for the discussions we had from the first moment onwards and the 
optimistic long-term collaboration, and to you and Alice for your hospitality. 
Lika Apriani and INFECT-team, your efforts reaching out to the household are 
tremendous, and thanks to part of the team and others for the nice evenings of 
indoor soccer. Rudi Wisaksana and Yovita Hartantri welcomed me on the 
instructive Friday morning clinical rounds. Like everywhere, nothing in the 
TB-HIV working group starts without the help of the secretarial team of Ria 
Windyani and her team, which took care of guests, packages, forms, reminders 
and a smile. We would not have been able to give the best of ourselves without 
the support of Ibu Zaimah and Pak Dudu at our home in Cipaku. Thanks to our 
biking friends for their help in keeping body and mind healthy too. 
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I’m very grateful for the welcome I received at other places where the research 
took me: thanks to Arnout Mulder, Jessica de Beer, Miramda Kamst, Petra de 
Haas and Tridia van der Laan for the selection and culturing of many strains at 
the RIVM; thanks to Jakko van Ingen, Melanie Wattenberg and Nicole Aalders 
for not only discussing mycobacteria, but also showing how to handle them; 
to Tom Otterhof and Esther van der Vosse in Leiden for showing the first steps 
in genetics; for the friendly welcome by Adrian Hill and Vivek Naranbhai, 
who patiently guided me through basic computational genetics in Oxford. 
Many thanks for the enthusiastic discussions with Vinod Kumar in Groningen 
and the reception by Mathieu Plateel and the collaboration with Yang Li, Isis 
Ricaño-Ponce and Raúl Aguirre-Gamboa. A big thank you for the hospitality of 
Julian Avila-Pacheco, and the science-pursuing open mindedness of Clary Clish 
who has a great team of co-workers Amy Deik, Kerry Pierce, Kevin Bullock, and 
Justin Scott at the Broad Institute in Boston. 
I have enjoyed meeting inspiring co-workers and colleagues some of whom are 
co-writers of the manuscripts in this thesis or who were keen to discussing 
tuberculosis in all its aspects: Ayesha Verrall, Darma Imram, Dick van Soolingen, 
Gillian Wilson, Gordon Brown, Guy Thwaites, Hanna Guimaraes, James Ussher, 
Jelle Goeman, Jeroen de Keijzer, Megan Murray, Philip Hill and Suzaan Marais. 
Lucas Kaaij’s ultimate enthusiasm for science has been inspirational. Dank aan 
prof. dr. Daan den Hengst en dr. Joost van Neer, voor het verhelderen van de 
oorsprong van de citaten van respectievelijk Gilbert Cousin en Augustinus. 
Ook veel dank aan mijn voormalige collega’s uit het Rijnstate voor de gezelligheid 
op de fiets en in de trein, en de onwijs fijne sfeer tijdens het werk. 
Lieve vrienden, jullie zijn een bijzonder stel. Dank voor alle gezelligheid en 
warmte, en voor het brengen van relativering door jullie onbegrip voor medische 
streberigheid. Bas, Coen en paranimf Jornt hebben hierin een hoofdrol gehad. 
Lieve vrienden die toevallig ook nog dokter zijn, voor jullie geldt hetzelfde, min 
dat stuk over de streberigheid dan. Afstand speelt nauwelijks een rol, en we zien 
jullie overal, zelfs in Nijmegen. Het is een genoegen ook daar fijne mensen te 
ontdekken. Dank ook aan de lieve mensen die ik eerder tegen ben gekomen en 
een positieve rol in mijn ontwikkeling hebben gehad, in het bijzonder Willemijn 
en familie. Siebren en familie, heel fijn om je ook na drieëndertig jaar er weer bij 
te hebben. 
Dank aan mijn lieve schoonfamilie Yvonne & Harry, Chris & Doreen, Alice & Lynn, 
voor de gezelligheid, discussies, en onophoudelijke stroom leestips en grappen.
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Ik ben blij met mijn warme en diverse familie in bredere zin en ben in het 
bijzonder dankbaar voor de voorbeelden die mijn vier grootouders zijn geweest, 
met elk hun eigen eigenschappen: interesse in de mens, liefde voor onderwijs en 
het helpen van anderen, verzet en sociale betrokkenheid, bedachtzaamheid en 
reflectie, leeslust, reislust en levenslust. 
Mijn lieve ouders hebben Marlou, Kasper en mij alle ruimte en veiligheid 
geboden om wat te brouwen van de mix van eigenschappen die we van ze 
hebben gekregen. Deze thuishaven blijft een fijne plek, en fijner nog door coole 
kant Jibbe. Zonder jullie was dit proefschrift er zeker niet geweest, was ik niet 
geweest wie ik ben en had ik me zeker nooit door zo’n prachtige vrouw kunnen 
laten schaken. Lieve Suzanne, de zeven heerlijk vette jaren die we achter ons 
liggen doen me enorm verheugen op de rest.
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Tuberculosis has plagued humankind since prehistoric 
times. Coughing tuberculosis patients disperse the bacterium 
Mycobacterium tuberculosis through the air. Inhalation of 
this bacterium does not always lead to an infection, and only 
one in ten infected individuals becomes ill. In most cases, 
tuberculosis is contained to the lungs, but the infection 
can also spread to lymph nodes, bones and even the brain. 
Over the last century, higher standards of living and the 
development of antibiotics have significantly reduced 
the disease burden but still, each year, 1.7 million people die 
because of tuberculosis globally.
 
This thesis examines the role of the human immune system in 
tuberculosis. The first part assesses tuberculosis susceptibility 
and transmission by studying the interaction between white 
blood cells and various tuberculosis strains. The second part 
focuses on the high mortality rates associated with tuberculous 
meningitis by studying cells, proteins and metabolites in blood 
and cerebrospinal fluid of infected patients. The research in 
this thesis aims to advance a customized and more effective 
treatment for this ancient, but still highly relevant disease.
